<SEC-DOCUMENT>0001010549-17-000167.txt : 20170511
<SEC-HEADER>0001010549-17-000167.hdr.sgml : 20170511
<ACCEPTANCE-DATETIME>20170511170252
ACCESSION NUMBER:		0001010549-17-000167
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20170331
FILED AS OF DATE:		20170511
DATE AS OF CHANGE:		20170511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHINA PHARMA HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001106644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				731564807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34471
		FILM NUMBER:		17835258

	BUSINESS ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216
		BUSINESS PHONE:		8689866811730

	MAIL ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TS ELECTRONICS INC
		DATE OF NAME CHANGE:	20030818

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC
		DATE OF NAME CHANGE:	20030128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC /DE/
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cphi10q033117.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 14pt/15.95pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt/15.95pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 14pt/18.25pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>(Mark One)</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD STYLE="width: 8%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="width: 92%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUARTERLY
    REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the quarterly period ended <U>March
31, 2017</U></B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD STYLE="width: 8%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 92%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the transition period from ____________
to ____________</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Commission File Number 001-34471</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt/22.8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>CHINA PHARMA HOLDINGS, INC.</U></B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD STYLE="width: 50%; text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Nevada</U></FONT></TD>
    <TD STYLE="width: 50%; text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>75-1564807</U></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction
    of</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incorporation or
    organization)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Second Floor, No. 17, Jinpan Road</U></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Haikou, Hainan Province, China 570216</U></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>+86- 898-6681-1730 (China)</U></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Issuer's telephone number, including
area code)</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">No </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">No </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate by check
mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act. (Check One):</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Do not check if a smaller reporting company)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting
    company </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #FEFEFE">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth
    company </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/11.4pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;</FONT></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Arial, Helvetica, Sans-Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9744;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">No </FONT><FONT STYLE="font-family: Segoe UI Symbol,sans-serif">&#9746;</FONT></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center">APPLICABLE ONLY TO CORPORATE ISSUERS:</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Indicate the number
of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 43,579,557 shares of
Common Stock, $.001 par value, were outstanding as of May 9, 2017.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 481.5pt"><B>Page</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>PART I FINANCIAL INFORMATION</B></P>
        <P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 14%">&nbsp;</TD>
    <TD STYLE="width: 82%">&nbsp;</TD>
    <TD STYLE="width: 4%; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
    Consolidated Balance Sheets as of March 31, 2017 (Unaudtied) and December 31, 2016 (Audited)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Consolidated Statements of Operations
    and Comprehensive Income (Loss) for the Three Months Ended March 31, 2017 and 2016 (Unaudited)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 2.05pt; text-indent: -2.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
    Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2017 and 2016 (Unaudited)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Condensed Consolidated Financial Statements (Unaudited)</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management's Discussion and Analysis of Financial
    Condition and Results of Operations</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures about
    Market Risk</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART II OTHER INFORMATION</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART I - FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>Item 1. Financial Statements</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The accompanying unaudited condensed
consolidated balance sheets, statements of operations and comprehensive income, and statements of cash flows and the related notes
thereto, have been prepared in accordance with generally accepted accounting principles in the United States of America (&quot;U.S.
GAAP&quot;) for interim financial information and in conjunction with the rules and regulations of the Securities and Exchange
Commission. Accordingly, they do not include all of the disclosures required by U.S. GAAP for complete financial statements. The
financial statements reflect all adjustments, consisting only of normal, recurring adjustments, which are, in the opinion of management,
necessary for a fair presentation for the interim periods.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The accompanying financial statements
should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the
year ended December 31, 2016.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The results of operations for the three-month
period ended March 31, 2017 are not necessarily indicative of the results to be expected for the entire fiscal year or any other
period.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CHINA PHARMA HOLDINGS, INC.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CONDENSED CONSOLIDATED BALANCE SHEETS</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(Unaudited)</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left; padding-left: 12px">Cash and cash equivalents</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,523,541</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,665,802</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,718,823</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,088,879</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Banker's acceptances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,513</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Trade accounts receivable, less allowance for doubtful</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">accounts of $16,161,252 and $15,664,496, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,703,593</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,999,809</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Other receivables, less allowance for doubtful</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">accounts of $56,157 and $71,548, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">272,097</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">224,373</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Advances to suppliers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,036,758</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,003,792</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,985,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,310,939</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Prepaid expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">205,293</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">226,357</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total Current Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,460,583</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,519,951</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Advances for purchases of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,771,976</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,498,059</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Property and equipment, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,422,373</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,967,448</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Intangible assets, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">488,044</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">534,682</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">78,142,976</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">78,520,140</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Trade accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,877,412</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,060,374</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,232</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">139,830</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Other payables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,355,365</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,502,694</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Advances from customers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">703,915</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">811,232</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Other payables - related parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,354,567</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,354,567</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Current portion of construction loan facility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,440,154</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,440,154</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Bankers' acceptance notes payable</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,718,823</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,088,879</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Total Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,540,468</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,397,730</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Non-current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Construction loan facility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,573,590</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,640,927</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Deferred tax liability</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">607,090</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">572,349</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,721,148</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,611,006</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders' Equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Preferred stock, $0.001 par value; 5,000,000 shares authorized;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">no shares issued or outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Common stock, $0.001 par value; 95,000,000 shares authorized;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">43,579,557 shares and 43,579,557 shares outstanding, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,590,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,590,204</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Retained earnings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,790,476</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,757,374</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Accumulated other comprehensive income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,997,568</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,517,976</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Stockholders' Equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">58,421,828</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">58,909,134</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">78,142,976</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">78,520,140</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral
part of these condensed consolidated financial statements.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CHINA PHARMA HOLDINGS, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">AND COMPREHENSIVE INCOME (LOSS)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center">For the Three Months</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Ended March 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left">Revenue</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,285,203</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">3,640,494</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cost of revenue</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,567,350</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,999,675</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Gross profit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">717,853</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">640,819</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Selling expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">717,637</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">968,507</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">General and administrative expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">416,726</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">318,930</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,060</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93,433</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Bad debt expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">360,063</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">581,300</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,520,486</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,962,170</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Loss from operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(802,633</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,321,351</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,033</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,592</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Interest expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(138,964</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(242,309</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net other expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(133,931</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(208,717</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss before income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(936,564</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,530,068</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Income tax&nbsp;&nbsp;expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(30,334</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(22,828</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(966,898</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,552,896</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other comprehensive income - foreign currency</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">translation adjustment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">479,592</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">480,430</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(487,306</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,072,466</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Loss per share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Basic and diluted</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.04</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Weighted average shares outstanding</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,579,557</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">43,579,557</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral
part of these condensed consolidated financial statements.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CHINA PHARMA HOLDINGS, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="font-weight: bold; text-align: center">(Unaudited)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center">For the Three Months</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Ended March 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows from Operating Activities:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left; padding-left: 12px">Net loss</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(966,898</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(1,552,896</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">815,394</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">857,195</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Bad debt expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">360,063</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">581,300</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Deferred income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,334</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,828</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">Changes in assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Trade accounts and other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(261,377</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(61,069</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Advances to suppliers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,509</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(92,039</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">549,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">215,496</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Trade accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(206,599</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">888,212</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Accrued taxes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(71,575</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(53,955</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Other payables and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(130,772</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,514</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 24px">Advances from customers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(113,615</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">328,354</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 24px">Prepaid expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22,818</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">144,262</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Provided by Operating Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9,764</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,303,202</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows from Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Purchases of property and equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26,628</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(39,248</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used in Investing Activities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26,628</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(39,248</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows from Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Payments of construction term loan</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(145,176</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(305,835</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net Cash Used in Financing Activity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(145,176</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(305,835</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Effect of Exchange Rate Changes on Cash</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,779</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">54,898</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net (Decrease) Increase in Cash and Cash Equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(142,261</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,013,017</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash and Cash Equivalents at Beginning of Period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,665,802</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,248,760</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and Cash Equivalents at End of Period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,523,541</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,261,777</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 12px">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental Cash Flow Information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 12px">Cash paid for interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">138,964</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">242,309</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental Noncash Investing and Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of banker's acceptances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">621,753</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts receivable collected with banker's acceptances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">182,499</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">517,770</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Inventory purchased with banker's acceptances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">167,981</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">403,081</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral
part of these consolidated financial statements.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;CHINA
PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THREE MONTHS ENDED MARCH 31, 2017
AND 2016 (UNAUDITED)</B></P>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 1 &ndash; ORGANIZATION AND SIGNIFICANT ACCOUNTING
POLICIES</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Organization and Nature of Operations
&ndash; </I></B>China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin
Islands corporation, which owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under
the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein
as the Company.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">On
December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation
from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&nbsp;&nbsp;The
reincorporation merger was approved by stockholders holding the majority of the Company&rsquo;s outstanding shares of common stock
on December 21, 2012.</FONT></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">The
Foreign Investment Industrial Catalogue<I>&nbsp;</I>(the &ldquo;Catalogue&rdquo;) jointly issued by China&rsquo;s Ministry of
Commerce and the National Development and Reform Commission (the latest version is the 2012 version, effective January 30, 2012)
classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted
to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three
categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership
restriction in the pharmaceutical industry is that a foreign investment enterprise (the &ldquo;FIE&rdquo;) shall not have the
whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes
a variety of brands in those franchise stores, which is not the case for the Company&rsquo;s business.</FONT></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Helpson
manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and
private retailers located throughout the PRC. The Company believes Helpson&rsquo;s business is not subject to any ownership restrictions
prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer
Agreement with Helpson&rsquo;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province
on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the
PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</FONT></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has acquired and continues
to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Consolidation and Basis of Presentation
</I></B>&ndash; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements
include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and
transactions have been eliminated in the consolidation.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Helpson&rsquo;s functional currency
is the Chinese Renminbi. Helpson&rsquo;s revenue and expenses are translated into United States dollars at the average exchange
rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or
losses from translating Helpson&rsquo;s financial statements are included in accumulated other comprehensive income, which is
a component of stockholders&rsquo; equity. Gains and losses arising from transactions denominated in a currency other than the
functional currency of the entity that is party to the transaction are included in the results of operations.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Accounting Estimates </I>- </B>The
methodology used to prepare for the Company&rsquo;s financial statements is in conformity with the accounting principles generally
accepted in the United States of America, which requires the management of the Company (&ldquo;Management&rdquo;) to make estimates
and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities
at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore,
actual results could differ from those estimates.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Cash and Cash Equivalents </I></B>&ndash;
Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term
banker&rsquo;s acceptances purchased with maturities of three months or less.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Restricted Cash</I>&nbsp;</B>&ndash;<B>&nbsp;</B>Restricted
cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker's acceptance notes issued
by the Company as discussed in Note 7.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Trade Accounts Receivable and
Allowance for Doubtful Accounts &ndash; </I></B>Trade accounts receivables are carried at the original invoiced amounts less an
allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual
customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews
a customer's credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate,
resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made
against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $360,063
and $581,300 for the three months ended March 31, 2017 and 2016, respectively.&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THREE MONTHS ENDED MARCH 31, 2017
AND 2016 (UNAUDITED)</B></P>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable that have
been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is
made. The Company charged off uncollectable trade accounts receivable balances in the amount of $0 against the allowance for both
the three months ended March 31, 2017 and 2016, respectively. It is common practice in the pharmaceutical industry in the PRC
for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate
when calculating the allowance for doubtful accounts.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Advances to Suppliers and Advances
from Customers</I></B> &ndash; Common practice in the pharmaceutical industry in the PRC is to make advances to suppliers for
materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable
when the materials are received. Advances received from customers are applied against trade accounts receivable when finished
products are sold. The Company reviews a supplier's credit history and background information before advancing a payment. If the
financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide
services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected. The Company
recognized no bad debt expense for the three months ended March 31, 2017 and 2016, respectively.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Inventories&nbsp;&ndash;</I></B>
Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or market. Cost is
determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct
labor and an allocated portion of the Company&rsquo;s production overhead. The Company writes down excess and obsolete inventory
to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and
work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary
course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory
item is written down to its estimated net realizable value. Market for raw materials is based on replacement cost. Provisions
for inventory write-downs are included in cost of revenues in the consolidated statements of operations. Once written down, inventories
are carried at this lower cost basis until sold or scrapped.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Valuation of Long-Lived Assets
</I></B>&ndash; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in
circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted
cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections
indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value
over the projected discounted cash flows estimated to be generated by the asset. There was no impairment adjustment required for
the three months ended March 31, 2017 and 2016.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Property and Equipment</I></B>
&ndash; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements
are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition.
Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was
included in cost of revenue.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Revenue Recognition</I></B> &ndash;
Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of
the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery
does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer
acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria
specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable
until all contingencies related to the sale have been resolved. Revenue is deferred when collectability is not considered to be
reasonably assured.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Cost of Revenues</I></B> &ndash;
Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture
and delivery of products.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and Development</I></B>
&ndash; Research and development expenditures are recorded as expenses in the period in which they occur.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Basic and Diluted Loss per Common
Share </I>- </B>Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding
during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares. There were
no potential dilutive common shares outstanding during the three months ended March 31, 2017 and 2016, respectively.&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Credit Risk</I></B> &ndash; The
carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation
to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing
credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances
in the aggregate have not exceeded Management's estimates.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THREE MONTHS ENDED MARCH 31, 2017
AND 2016 (UNAUDITED)</B></P>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has its cash in bank deposits
primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy
of protecting depositors&rsquo; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&nbsp;1, 2007,
which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws
are enacted for banks in the PRC, the Company&rsquo;s deposits may be at a higher risk of loss.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Interest Rate Risk</I></B> &ndash;
The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing
debts and viability of securing future debt instruments within the PRC.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Recent Accounting Pronouncements</I></B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU 2014-09,&nbsp;<I>&quot;Revenue
from Contracts with Customers&quot;</I>&nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when
a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to
customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods
and services. &nbsp;In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the
new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will
be permitted, but no earlier than 2017 for calendar year-end entities.&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The standard allows for two transition
methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially
applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are
evaluating the impact that this guidance will have on our financial statements.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU
No. 2016-02,&nbsp;<I>Leases</I>, a new standard on accounting for leases. The ASU introduces a lessee model that brings most leases
on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the
current accounting guidance as well as the FASB's new revenue recognition standard. However, the ASU eliminates the use of bright-line
tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures
along with specific quantitative disclosures to better enable users of financial statements to assess the amount, timing, and
uncertainty of cash flows arising from leases. The pronouncement is effective for annual reporting periods beginning after December
15, 2018, including interim periods within that reporting period, using a modified retrospective approach. Early adoption is permitted.
The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements
and related disclosures.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the FASB issued Accounting
Standards Update 2016-13,&nbsp;<I>Financial Instruments &ndash; Credit Losses (Topic 326)</I>, which introduces new guidance for
the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses
to estimate credit losses on certain types of financial instruments. It also modifies the impairment model for available-for-sale
(AFS) debt securities and provides for a simplified accounting model for purchased financial assets with credit deterioration
since their origination.&nbsp;The pronouncement will be effective for Public business entities that are SEC filers in fiscal years
beginning after&nbsp;December 15, 2019, including interim periods within those fiscal years.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Early application of the guidance will
be permitted for all entities for fiscal years beginning after&nbsp;December 15, 2018, including interim periods within those
fiscal years. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial
statements and related disclosures.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2016, the FASB issued ASU
No. 2016-15,&nbsp;<I>Classification of Certain Cash Receipts and Cash Payments</I>. The standard addresses the classification
and presentation of eight specific cash flow issues that currently result in diverse practices. This pronouncement is effective
for annual reporting periods beginning after December 15, 2017. The amendments in this ASU should be applied using a retrospective
approach.&nbsp; The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial
statements and related disclosures, but does not expect the impact to be material.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, the FASB issued ASU
2016-18,&nbsp;<I>Statement of Cash Flows (Topic 230): Restricted Cash (&ldquo;ASU 2016-18&rdquo;)</I>. The ASU requires an entity
to explain the changes in the total of cash, cash equivalents, restricted cash, and restricted cash equivalents on the statement
of cash flows and to provide a reconciliation of the totals in that statement to the related captions in the balance sheet when
the cash, cash equivalents, restricted cash, and restricted cash equivalents are presented in more than one line item on the balance
sheet. This ASU is effective for annual and interim periods beginning after December 15, 2017, and is required to be adopted using
a retrospective approach, with early adoption permitted. The Company is currently evaluating the potential impact that the adoption
of ASU 2016-18 may have on its consolidated financial statements.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THREE MONTHS ENDED MARCH 31, 2017
AND 2016 (UNAUDITED)</B></P>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Other
accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect
on the Company&rsquo;s financial position, result of operations or cash flows.&nbsp;</FONT></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 2 &ndash; INVENTORY</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">Inventory consisted of the following:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left">Raw materials</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">10,796,239</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">11,562,388</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in process</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">692,827</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">360,550</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Finished goods</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,397,514</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,530,641</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,886,580</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,453,579</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Obsolescence reserve</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,900,615</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,142,640</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 12px">Total Inventory</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,985,965</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,310,939</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 3 - PROPERTY AND EQUIPMENT</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">Property and equipment consisted of the following:</P>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left">Permit of land use</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">408,775</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">405,645</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Building</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,492,387</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,419,700</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Plant, machinery and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,379,439</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,151,029</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Motor vehicle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312,167</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">309,777</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Office equipment</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">184,128</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">182,718</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 12px">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,776,896</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,468,869</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,354,523</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,501,421</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Property and Equipment, net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24,422,373</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">24,967,448</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 9pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">Depreciation is computed on a straight-line basis over the
estimated useful lives of the assets as follows:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: center; width: 71%">Asset</TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: center; width: 27%">&nbsp;Life - years&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Permit of land use</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">40 - 70</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Building</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">20 - 49</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Plant, machinery and equipment</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">5 - 10</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Motor vehicle</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">5 - 10</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Office equipment</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: center">3-5</TD></TR>
</TABLE>


<P STYLE="font: 9pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation relating to office equipment
was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the three
months ended March 31, 2017 and 2016, depreciation expense was $764,614 and $790,254, respectively.&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 4 - INTANGIBLE ASSETS</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets represent the cost
of medical formulas approved for production by the China Food and Drug Administration (&ldquo;CFDA&rdquo;). The Company did not
obtain CFDA production approval for any medical formula during the three months ended March 31, 2017 and 2016 and no costs were
reclassified from advances to intangible assets during the three months ended March 31, 2017 and 2016, respectively.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Approved medical formulas are amortized
from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen
years.&nbsp;&nbsp;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could
occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization
expense relating to intangible assets was $50,780 and $66,941 for the three months ended March 31, 2017 and 2016, respectively,
and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end
of their amortization period.&nbsp;&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THREE MONTHS ENDED MARCH 31, 2017
AND 2016 (UNAUDITED)</B></P>


<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates each approved
medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each
financial statement. The Company&rsquo;s evaluation is based on an estimated undiscounted net cash flow model, considering currently
available market data for the related drug and the Company&rsquo;s estimated market share. If the carrying value of the medical
formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over
the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss
was recognized during the three months ended March 31, 2017 and 2016.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Intangible assets consisted solely of
CFDA approved medical formulas as follows:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">March 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center">December 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left">Gross carrying amount</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">4,899,281</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">4,861,766</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,411,237</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,327,084</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net carrying amount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">488,044</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">534,682</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 5 &ndash; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to expand the number of medicines
the Company manufactured and marketed, it has entered into contracts with independent laboratories and others for the purchase
of medical formulas. Although CFDA approval had not been obtained for these medical formulas at the dates of the respective contracts,
the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is
completed. The Company received the titles to two patents that relate to medical formulas currently in the CFDA approval process
for the year end December 31, 2013. These patents have not expired.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to entering into contracts with
the Company, laboratories typically are required to complete all&nbsp;research and development to determine the content of the
medical formula and the method to produce the generic medicine. The application to the CFDA for production approval must be made
by the production facility that will produce the related product. As a result, a contract typically provides that the Company
buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining
the production approval from the CFDA.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A typical CFDA approval process for
the production of a generic medical product involves a number of steps that generally require three to five years to complete.
If the medical formula is purchased at the point when the generic medical product receives the CFDA&rsquo;s approval for a clinical
study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years
to complete. After completing the clinical study, the results are submitted to the CFDA and a production approval application
is filed with the CFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval
application and obtain CFDA approval. Upon approving the generic medical product, the CFDA issues a production certificate and
the Company can commence the production and sales of the generic medical product. As a result of this process, CFDA approval is
expected to be received in approximately two to five years from the date&nbsp;the Company signs the medical formula contracts.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the contracts, the
laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management
monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately
under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if
the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the
full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments
to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an
approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as
advances for purchases of intangible assets. During the fiscal year of 2016, with CFDA's new regulations on scrutiny procedures
in connection with its review of production applications and based on the Company's monitoring and assessment process, the Company
determined five advanced payments to five independent laboratories were impaired. As a result, the Company recognized an impairment
loss for the advances made to these laboratories in the amount of $3,962,141.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2017, the Company was
obligated to pay laboratories and others approximately $4,400,000 upon the completion of various phases of contracts to obtain
CFDA production approval of medical formulas.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CHINA PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THREE MONTHS ENDED MARCH 31, 2017
AND 2016 (UNAUDITED)</B></P>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 6 &ndash; RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A member of the Company&rsquo;s board
of directors (the &ldquo;Board&rdquo;) had previously advanced the Company an aggregate amount of $1,354,567 as of March 31, 2017
and December 31, 2016 which are recorded as Other payables &ndash; related parties on the accompanying consolidated balance sheets.
The advances bear interest at a rate of 1.0% per year.&nbsp;&nbsp;Total interest expense of $3,386 was recognized for each of
the three months ended March 31, 2017 and 2016.&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 7 &ndash; BANKER'S ACCEPTANCE
NOTES PAYABLE</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2016, the Company entered into
a Banker's Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company can issue banker's acceptance
notes (the &quot;Banker's Notes&quot;) to any third party as payment of amounts owing to that third party. The Company is required
to deposit with the bank an amount equal to the amounts represented by the Banker's Notes issued to the third parties. The amount
of these deposited balances is shown as &quot;Restricted cash&quot; on the accompanying balance sheets as of March 31, 2017 and
December 31, 2016. The maximum amount that the Company can issue under this agreement is limited to the lesser of RMB30,000,000
(approximately $4.5 million) or the amount of cash available to deposit against the Banker's Notes. In addition, the agreement
calls for the payment of fees equal to 0.05% of the note amount to the bank. At March 31, 2017 and December 31 2016, the Company
had outstanding Banker's Acceptance Notes in the amount of $1,718,823 and $1,088,879, respectively.</P>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 8 &ndash; CONSTRUCTION LOAN
FACILITY</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company obtained a construction
loan facility in the amount of RMB 80,000,000 (approximately $13 million) from a construction loan facility dated June 21, 2013.
The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date and is from the same
bank that currently provides the line of credit as discussed in Note 7.&nbsp;&nbsp;The proceeds of the loan were used for and
are collateralized by the construction of the Company&rsquo;s new production facility and the included production line equipment
and machinery. The loan currently bears weighted interest at 5.73%, based upon 110% of the PRC government&rsquo;s eight-year term
rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type
of loan on the anniversary from the draw-down date and its subsequent anniversary dates. On July 10, 2015 the interest rate was
adjusted to 5.94% and on July 10, 2016 the rate was further adjusted to 5.39%. &nbsp;The loan required interest only payments
for the first two years. Beginning July 11, 2015, the balance of the principal is due in at least two (2) annual installments
with the first annual payment being due within the six-month period after July 10, 2015 and the second annual payment being due
July 10, 2016 and each following year over the next five years through July 11, 2022 on the identical terms as described above
for 2015. During the first quarter of 2017, the Company made a principal payment in the amount of approximately $145,000 (RMB1,000,000)
with the remaining annual principal payment of approximately $1,306,000 (9,000,000 RMB) being due in July 2017. As of March 31,
2017, the Company had no additional amounts available to it under this facility.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Principal payments required for the
next five years as of March 31, 2017 are as follows:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 43%; text-align: left">2017</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 43%; text-align: right">1,306,140</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">2018</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,176,901</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">2019</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,176,901</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">2020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,176,901</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: left">2021</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,176,901</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">$10,013,744</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Fair Value of Construction Loan
Facility</I></B> &ndash; Based on the borrowing rates currently available to the Company for bank loans with similar terms and
maturities, the carrying amounts of the construction loan facility outstanding as of March 31, 2017 and December 31, 2016 approximated
its fair value because the underlying instrument bears an interest rate that approximated current market rates.&nbsp;&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 9 - INCOME TAXES</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred income tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected
to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in
income in the period that includes the enactment date.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<B>CHINA
PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THREE MONTHS ENDED MARCH 31, 2017
AND 2016 (UNAUDITED)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Undistributed
                                         earnings of Helpson, the Company&rsquo;s foreign subsidiary, since its acquisition, amounted
                                         to approximately $30.5 million as of March 31, 2017. Those earnings, as well as the investment
                                         in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested
                                         and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon
                                         distribution of those earnings in the form of dividends or otherwise, the Company would
                                         be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax
                                         credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized
                                         deferred U.S. income tax liability is not practical because of the complexities associated
                                         with its hypothetical calculation; however, unrecognized foreign tax credits may be available
                                         to reduce a portion of the U.S. tax liability.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Liabilities are established for uncertain
tax positions expected to be taken in income tax return when such positions are judged to meet the &ldquo;more-likely-than-not&rdquo;
threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions
are included as a component of other expenses. Through March 31, 2017, the Company has not identified any uncertain tax positions
that it has taken. U.S. income tax returns for the years ended December 31, 2013 through December 31, 2016 and the Chinese income
tax return for the year ended December 31, 2016 are open for possible examination.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 16, 2007, the National People&rsquo;s
Congress of China passed the Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the
Implementation Regulations for the EIT Law which took effect on January&nbsp;1, 2008. The EIT Law and Implementation Regulations
Rules impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify
under certain limited exceptions.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is located in a special
region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate
income tax rate in the special region. The Company transitioned to the new 25% tax rate over a five year period which began on
January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due
to its status in the PRC as a high technology enterprise. In 2013, the Company again applied for and received the same favorable
tax rate for 2014 to 2016.&nbsp;The recent&nbsp;net losses put the Company in an unfavorable position for the potential renewal
of&nbsp;&quot;National High-Tech Enterprise&quot; status for 2017. After evaluating the feasibility of the renewal in 2016, the
Company has decided not to renew this status.&nbsp;&nbsp;Under the current tax law in the PRC, the Company is and will be subject
to the following enterprise income tax rates:</P>



<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; width: 39%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 10%">&nbsp;</TD>
    <TD ROWSPAN="2" STYLE="font-weight: bold; border-bottom: black 0.5pt solid; text-align: center; width: 51%"><P STYLE="margin-top: 0; margin-bottom: 0">Enterprise
                                         Income</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Tax
                                         Rate</P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 0.5pt solid; text-align: center">Year</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">2016</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">15%</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">2017</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25%</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">Thereafter</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">25%</TD></TR>
</TABLE>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The provision for income taxes consisted
of the following:</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; padding-bottom: 1pt">Deferred</TD><TD STYLE="width: 8%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">30,334</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">22,828</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total income tax expense</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,334</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22,828</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2017, the Company had
net operating loss carryforwards for PRC tax purposes of approximately $52.2 million which are available to offset any future
taxable income through 2022. These carryforwards begin to expire in 2018. The Company also has net operating losses for United
States federal income tax purposes of approximately $4.6 million which are available to offset future taxable income, if any,
through 2037.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In assessing the realizability of deferred
tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not
be realized.&nbsp;&nbsp;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income
during the periods in which those differences become deductible or tax loss carry forwards are utilized.&nbsp;&nbsp;Management
considers projected future taxable income and tax planning strategies in making this assessment.&nbsp;&nbsp;Based upon an assessment
of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax
assets are deductible or can be utilized, Management believes it is not likely for the Company to realize all benefits of the
deferred tax assets as of March 31, 2017 and December 31, 2016.&nbsp;&nbsp;Therefore, the Company provided for a valuation allowance
against its deferred tax assets of $21,963,335 and $21,452,802 as of March 31, 2017 and December 31, 2016, respectively.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also incurred various other
taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any
unpaid amounts are reflected on the balance sheets as accrued taxes payable.&nbsp;<B>&nbsp;</B></P>




<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 9pt/normal Sans-Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>&nbsp;CHINA
PHARMA HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THREE MONTHS ENDED MARCH 31, 2017
AND 2016 (UNAUDITED)</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<P STYLE="font: 10pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>NOTE
                                         10 &ndash; FAIR VALUE MEASUREMENTS</B></P>

<P STYLE="font: 10pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 9pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Fair value
is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs
and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and
liabilities as follows: Level 1 &ndash; Quoted prices in active markets for identical assets or liabilities. Level 2 &ndash; Observable
inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or
other observable inputs that can be corroborated by observable market data. Level 3 &ndash; Unobservable inputs supported by little
or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies,
or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment
or estimation.</P>

<P STYLE="font: 10pt/10.25pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/10.25pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company
uses fair value to measure the derivative warrant liability on a recurring basis because fair value is the primary measure for
accounting. The Company also uses fair value to measure the value of the banker's acceptance notes it holds.&nbsp;&nbsp;The Company
values its derivative warrants using a valuation method explained above.&nbsp;&nbsp;The banker's acceptance notes are recorded
at cost which approximates fair value.&nbsp;&nbsp;As of December 31, 2016, the Company had no banker's acceptance notes to be
recorded at fair value.&nbsp; The Company held the following assets and liabilities recorded at fair value as of March 31, 2017:&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center">Fair Value Measurements at</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Reporting
                                         Date Using</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Description</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March
                                         31, 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">Level
                                         1</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">Level
                                         2</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">Level
                                         3</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1pt">Banker's acceptance notes</TD><TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">14,513</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">14,513</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 3%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Total</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,513</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,513</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR></TABLE>


<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0"><B>NOTE 11 - STOCKHOLDERS' EQUITY</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is authorized to issue 95,000,000
shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be
issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely
by the Company&rsquo;s Board.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>Employee Stock Options</U></B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>2010 Incentive Plan</I></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 12, 2010, the Company&rsquo;s
Board adopted the Company&rsquo;s 2010 Incentive Plan (the &ldquo;Plan&rdquo;), which was then approved by stockholders on December
22, 2010. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance
units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company
and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through March
31, 2017, there were 175,000 shares of restricted stock granted and outstanding under the Plan.&nbsp; No options were outstanding
as of March 31, 2017 under the Plan.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;There were no securities issued from the Plan during
each of the three months ended March 31, 2017 and 2016.&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized no compensation
expense related to the awards of common shares and the grants and modifications of stock options during each of the three months
ended March 31, 2017 and 2016.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option award
is estimated on the date of grant using the Black-Scholes Option Pricing Model. Expected volatility is based on the historical
volatility of the Company&rsquo;s common stock prices. The Company uses historical data to estimate employee termination rates.
The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term.
The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which
to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury
yield curve in effect at the time of grant.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2017, there was no remaining
unrecognized compensation expense related to stock options or restricted stock grants.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 12 &ndash; COMMITMENTS AND CONTINGENCIES</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Economic environment </I>- </B>Substantially
all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant
risks not typically associated with companies operating in the United States of America. These risks include, among others, the
political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from
operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental
policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates
and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect
the Company&rsquo;s operations.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, all of the Company's revenue
is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of
the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of
the PRC government.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOTE 13 &ndash; CONCENTRATIONS</B></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31,
2017, no customer accounted for more than 10% of sales and two customers accounted for 46.2% and 15% of accounts receivable.&nbsp;Four
suppliers accounted for 23.7%, 17.3%, 13.6% and 12.7% of raw material purchases.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31,
2016, no customer accounted for more than 10% of sales and&nbsp;three customers accounted for 28.5%, 11.4% and 11.0%&nbsp;of accounts
receivable, respectively.&nbsp;No supplier accounted for greater than 10% of raw material purchases.</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>ITEM 7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">The statements contained in this report
with respect to our financial condition, results of operations and business that are not historical facts are forward-looking
statements. Forward-looking statements can be identified by the use of forward-looking terminology, such as &quot;anticipate&quot;,
&quot;believe&quot;, &quot;expect&quot;, &quot;plan&quot;, &quot;intend&quot;, &quot;seek&quot;, &quot;estimate&quot;, &quot;project&quot;,
&quot;could&quot;, &quot;may&quot; or the negative thereof or other variations thereon, or by discussions of strategy that involve
risks and uncertainties. Management wishes to caution the readers of the forward-looking statements that any such statements that
are contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties
and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general
business factors affecting our operations, markets, growth, services, products, licenses and other factors, some of which are
described in this report including in &ldquo;Risk Factors&rdquo; in Item 1A and some of which are discussed in our other filings
with the Securities and Exchange Commission. These forward-looking statements are only estimates or predictions. No assurances
can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing
our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated
events.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">These risk factors should be considered
in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue.
All written and oral forward-looking statements made in connection with this report that are attributable to our company or persons
acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution
investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts&rsquo;
expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances
after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Business Overview &amp; Recent Developments</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2014, we received a Good
Manufacturing Practices (&ldquo;GMP&rdquo;) certificate issued by the China Food and Drug Administration (&ldquo;CFDA&rdquo;)
for dried powder and liquid injectable product lines produced at our new manufacturing facility, and since then we have restarted
production of products with those formulations after a suspension of production from year end 2013 due to our inability to meet
a GMP upgrade deadline. GMP compliance timing issues also caused us to miss certain drug bids (generally with terms of around
two years) in several Chinese provinces prior to November 2014. These missed bids negatively impacted our previously-established
market share in those provinces, and reduced our overall sales in 2015 and 2016. Nevertheless, we continue to concentrate on enhancing
the fundamentals of our business. In January and December 2015, we completed upgrades to our manufacturing facilities and received
new GMP certificates for our tablet and capsule product lines and for the cephalosporin product lines at our old factories. The
upgrades referenced above were completed ahead of the deadline of the oral solution product lines under the new GMP requirement,
which have positioned us to better meet market demand.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to support our existing products
package we remain focused on pipeline development. We have experienced delays in obtaining approval for certain products in our
pipeline because of revisions of and enhancements to CFDA approval criteria and processes. These revisions have resulted in additional
supplemental materials and trials, higher costs, and longer approval times for certain applications.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 5, 2016, the Chinese State Council
issued &quot;<I>Opinions on Carrying out Consistency Evaluations of the Quality and Efficacy of Generic Drugs</I>&quot; (the &ldquo;Opinions&rdquo;).
The Opinions define the object of evaluations and establish deadlines, determine selection criteria for reference drugs, call
for a rational selection of evaluation methods, and identify pharmaceutical manufacturers as the principle in generic drug consistency
evaluations, and sets forth corresponding incentives. Subsequently, the CFDA issued &ldquo;<I>Comments from the General Office
of the State Council on the Consistency Evaluations of the Efficacy and Quality of Generic Drugs</I>&rdquo; in May 2016, in order
to further elaborate on assessment processes and related technical rules. Consistency evaluations apply to the majority of our
current existing marketed and pipeline products. Complying with consistency evaluations will become our core task in the near
future and will have a significant impact on our operations as well as our industrial structure.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 21pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result, the status of our pipeline
products as of March 31, 2017 remains the same as we reported in our Annual Report on Form 10-K for the year ended December 31,
2016.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Market Trends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Consumer demand for medicine is relatively
rigid and stable and is generally unaffected by seasonal business cycles. We have noticed that the growth rates of the pharmaceutical
manufacturing industry have been higher than GDP growth rates in China. According to the study <I>&ldquo;Deepening The Reform
of China's Medical and Healthcare System and Building A Value-Based Quality Service Delivery System</I>&quot; published by the
World Bank, if China maintains its existing healthcare system, total health expenditures will increase from 5.5% of GDP in 2014
to over 9% of GDP in 2035, with an average annual growth rate of 8.4%.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">The rapid development of the pharmaceutical
industry in China has been driven by the continuous growth of total healthcare costs, the establishment and improvement of the
universal Medicare system, increases in medical expenditures per capita, the aging population, and changes in the disease spectrum;
however, development has been negatively impacted by factors like Medicare cost controls and price pressure in drug tenders in
recent years.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">The PRC State Council issued &quot;<I>Guidance
on the Pilot Comprehensive Reform of Urban Public Hospitals</I>&quot; in 2015, which proposed that the pilot comprehensive reform
of urban public hospitals be fully implemented and that the personal spending component of total hygiene expenditures be reduced
to 30% or lower by 2017. In order to achieve this goal, the Chinese government's ongoing investment will be essential. The Central
Committee Political Bureau of the Communist Party of China approved the &quot;Healthy China 2030 Plan&quot; in August 2016, which
proposed to reduce personal hygiene spending to approximately 28% of total healthcare expenditures by 2020, and 25% of total healthcare
expenditures by 2030.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">In order to achieve the objectives of
the above-mentioned &quot;Healthy China 2030 Plan&quot; in the context of an aging population and an improving universal Medicare
system, we believe that the hygiene spending proportion of total fiscal expenditures will increase and that net annual Medicare
expenditures will increase as well. We anticipate that the use of generic drugs as a cost-effective medical solution will be further
promoted as a way to reduce the payment pressures of Medicare. As a generic drug company, we are presented with a huge domestic
market, and through further upgrades, especially in regards to compliance with consistency evaluations, we could meet European
and American production standards, enabling us to engage overseas markets through product exports.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2015, the State Council promulgated
&quot;<I>Opinions on and Examination of the Approval System for the Reform of Drugs and Medical Devices</I>&quot;, which gave
rise to the reform of the drug examination and approval system, the drug registration system, consistency evaluations of generic
drugs, and enhanced drug listing licensing systems, among other reforms. The CFDA has also subsequently introduced a number of
specific measures and technical details related to various areas of the above-mentioned reforms. These policies may change the
existing competitive landscape, development methods, and operating patterns and rules of the pharmaceutical industry and may have
a significant impact on the strategic choices and future development models of Chinese pharmaceutical companies.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, demand for pharmaceutical
products is still experiencing steady growth in China. We will continue to actively adapt to state policy guidance and further
evaluate market conditions for our current existing products, pipeline products, and competition in the market in order to optimizes
our development strategy.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Results of Operations for the Three
Months Ended March 31, 2017</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0 35.4pt; text-align: justify; text-indent: -30.85pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Revenue</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Revenue decreased by 9.8% to $3.3 million
for the three months ended March 31, 2017, as compared to $3.6 million for the three months ended March 31, 2016. This decrease
was primarily due to the impact from Chinese Spring Festival on purchase and logistic activities.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Set forth below are our revenues by product
category in millions (USD) for the three months ended March 31, 2017 and 2016:</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10.5pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: black 2.25pt double; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">Product
    Category</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">Three
    Months Ended March 31, </FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">Net
    Change</FONT></TD>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">%
    Change</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">2017</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">2016</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 36%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">CNS
    Cerebral &amp; Cardio Vascular</FONT></TD>
    <TD STYLE="width: 19%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">0.48
    </FONT></TD>
    <TD STYLE="width: 19%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">0.60
    </FONT></TD>
    <TD STYLE="width: 14%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">-0.12
    </FONT></TD>
    <TD STYLE="width: 12%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">-20%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">Anti-Viral/
    Infection &amp; Respiratory</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">2.17
    </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">2.53
    </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">-0.36
    </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">-14%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">Digestive
    Diseases</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">0.17
    </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">0.19
    </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">-0.02
    </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">-11%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">Other</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">0.45
    </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">0.31
    </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">0.14
    </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">46%</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">The most significant revenue decrease
in terms of dollar amount was in our &ldquo;Anti-Viral/Infection &amp; Respiratory&rdquo; product category, which generated $2.17
million in sales revenue in the three months ended March 31, 2017 compared to $2.53 million in the same period last year, a decrease
of $0.36 million. This decrease was mainly due to the sales decrease of our Cefaclor Dispersible Tablets in this category, which
was a result of CFDA rectification of market fluctuation.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Our &ldquo;Other&rdquo; product category
sales increased by $0.14 million to $0.45 million in the three months ended March 31, 2017 from $0.31 million in the same period
last year, mainly due to the increase in sales of Vitamin B6caused by market volatility.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales in the &ldquo;CNS Cerebral &amp;
Cardio Vascular&rdquo; category decreased by $0.12 million to $0.48 million in the three months ended March 31, 2017 compared
to $0.60 million in the same period last year, which decrease was mainly due to a drop in sales of Gastrodin, primarily the result
of volatility in market demand. Our &ldquo;Digestive Diseases&rdquo; category generated $0.17million and $0.19 million of sales
in the three months ended March 31, 2017 and 2016, respectively.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10.5pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD ROWSPAN="2" STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: black 2.25pt double; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">Product
    Category</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-top: Black 1pt solid; border-right: black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">Three
    Months Ended March 31, </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">2017</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">2016</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 48%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">CNS
    Cerebral &amp; Cardio Vascular</FONT></TD>
    <TD STYLE="width: 26%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">15%</FONT></TD>
    <TD STYLE="width: 26%; border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">17%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">Anti-Viral/
    Infection &amp; Respiratory</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">66%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">70%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">Digestive
    Diseases</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">5%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">5%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">Other</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">14%</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 107%"><FONT STYLE="font-size: 10pt">9%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31,
2017, revenue breakdown by product category remained close to that of the prior year. Sales of the &ldquo;Anti-Viral/Infection
&amp; Respiratory&rdquo; products category represented 66% and 70% of total sales in three months ended March 31, 2017 and 2016,
respectively. The &ldquo;CNS Cerebral &amp; Cardio Vascular&rdquo; category represented 15% of total revenue in the three months
ended March 31, 2017, compared to17% in the three months ended March 31, 2016. The &ldquo;Other&rdquo; category represented 14%
and 9% of revenues in the three months ended March 31, 2017 and 2016, respectively. The &ldquo;Digestive Diseases&rdquo; category
represented5% for both of the three months ended March 31, 2017 and 2016, respectively.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Cost of Revenue</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31,
2017, our cost of revenue was $2.6 million, or 78% of total revenue, which represented a decrease of $0.4 million from $3.0 million,
or 82% of total revenue, in the same period last year.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Gross Profit and Gross Margin</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Gross profit for the three months ended
March 31, 2017 was $0.7 million, compared to $0.6 million in the same period last year. Our gross profit margin in the three months
ended March 31, 2017 was 21.9% compared to 17.6% in the same period last year. This increase was primarily due to the increase
in gross profit margins of our major products in this period. However, new products could help support overall gross margin once
they are launched.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Selling Expenses</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Our selling expenses for the three months
ended March 31, 2017 were $0.7 million, a decrease of $0.3 million, compared to $1.0 million for the three months ended March
31, 2016.&nbsp;Selling expenses accounted for 21.8% of the total revenue in the three months ended March 31, 2017 compared to
26.6% in the same period last year.&nbsp; Because of adjustments in our sales practices resulting from health-care reform policies,
despite the overall decrease in sales, we may require additional personnel and expenses to support our sales and the collection
of accounts receivable.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Our general and administrative expenses
for the three months ended March 31, 2017 were $0.4 million, which represented an increase of $0.1 million compared to $0.3 million
in the same period last year. General and administrative expenses accounted for 12.7% and 8.7% of our total revenues in three
months ended March 31, 2017 and 2016, respectively. This increase was primarily due to several major payments for listing maintenance
happened in the three months ended March 31, 2017.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Our research and development expenses
for the three months ended March 31, 2017 were $0.03 million, compared to $0.09 million in the same period last year. The Consistency
Evaluations discussed under the &ldquo;Business Overview &amp; Recent Developments&rdquo; section hereof is expected to have a
significant impact on all generic products not only in our pipeline, but also throughout the existing Chinese market. Because
of the continuous introduction of detailed implementation rules under this policy, our pipeline did not have any further development
in the three months ended March 31, 2017.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Bad Debt Expenses</I></B></P>

<P STYLE="font: 12pt/107% SimSun; margin: 0; text-indent: 45.8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Our bad debt expenses for the three months
ended March 31, 2017 was $0.4 million, which represented a decrease of $0.2 million compared to $0.6 million in the same period
last year. The decline in our bad debt expenses was mainly the result of the decline in our revenues in recent years, which also
led to the corresponding decline in the net amount of accounts receivable aging over one year (according to our current accounting
policy, we are required to recognize a 70% bad debt allowance).</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">In general, our normal credit or
payment terms extended to customers are for 90 days. This has not changed in recent years. Due to the peculiarity of the
Chinese pharmaceutical market environment, deferred payments to pharmaceutical companies by state-owned hospitals and local
medicine distributors are a normal phenomenon. Our customers are primarily pharmaceutical distributors that sell our products
to mostly government-backed hospitals. Therefore, the aging of our receivables from our customers tends to be
longer-term.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">The amount of accounts receivable that
were past due (or the amount of accounts receivable that were more than 90 days old) was $3.5 million and $3.9 million as of March
31, 2017 and December 31, 2016, respectively.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table illustrates our accounts
receivable aging distribution in terms of percentage of total accounts receivable as of March 31, 2017 and December 31, 2016:</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10.5pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">March
    31, </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">December
    31, </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">2017</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">2016</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 31%; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%"><FONT STYLE="font-size: 10pt">1
    - 90 Days</FONT></TD>
    <TD STYLE="width: 19%; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 19%; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">4.4%</FONT></TD>
    <TD STYLE="width: 16%; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="width: 15%; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">8.8%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%"><FONT STYLE="font-size: 10pt">90
    - 180 Days</FONT></TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">6.8%</FONT></TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">2.6%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%"><FONT STYLE="font-size: 10pt">180
    - 360 Days</FONT></TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">6.3%</FONT></TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">6.7%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%"><FONT STYLE="font-size: 10pt">360
    - 720 Days</FONT></TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">9.8%</FONT></TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">13.4%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%"><FONT STYLE="font-size: 10pt">&gt;
    720 Days</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">72.7%</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">68.5%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">100.0%</FONT></TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: justify; line-height: 107%">&nbsp;</TD>
    <TD STYLE="padding-top: 0.75pt; padding-right: 0.75pt; padding-left: 0.75pt; text-align: right; line-height: 107%"><FONT STYLE="font-size: 10pt">100.0%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Our bad debt allowance estimate is currently
10% of accounts receivable that are less than 365 days old, 70% of accounts receivable that are between 365 days and 720 days
old, and 100% of accounts receivable that are greater than 720 days old.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize bad debt expenses per actual
write-offs as well as changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts
is higher than that of the previous period, we recognize a bad debt expense for the difference during the current period, and
when the current allowance is lower than that of the previous period, we recognize a bad debt benefit for the difference. The
allowance for doubtful accounts was $16.2 million and $15.7 million as of March 31, 2017 and December 31, 2016, respectively.
The changes in the allowances for doubtful accounts during the three months ended March 31, 2017 and 2016 were as follows:&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 11pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">For the Three Months Ended</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center"><FONT STYLE="font-size: 10pt">March 31,</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2017</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-top: black 1pt solid; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">2016</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; width: 52%"><FONT STYLE="font-size: 10pt">Balance, Beginning of Period</FONT></TD>
    <TD STYLE="text-align: right; width: 3%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; width: 16%"><FONT STYLE="font-size: 10pt">15,664,496</FONT></TD>
    <TD STYLE="text-align: justify; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; width: 19%"><FONT STYLE="font-size: 10pt">28,644,398</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Bad debt expense </FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">360,063</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">581,300</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Foreign currency translation adjustment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">136,693</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">373,005</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Balance, End of Period</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2pt double; text-align: justify"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2pt double; text-align: right"><FONT STYLE="font-size: 10pt">16,161,252</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2pt double; text-align: justify"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2pt double; text-align: right"><FONT STYLE="font-size: 10pt">29,598,703</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Loss from Operations</I></B></P>

<P STYLE="font: 12pt/107% SimSun; margin: 0; text-align: justify; text-indent: 45.8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operating loss for the three months
ended March 31, 2017 was $0.8 million, compared to an operating loss of $1.3 million in the same period last year.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Net Interest Expense</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Net interest expense for the three months
ended March 31, 2017 was $0.1 million, compared to $0.2 million in the same period last year. The decrease is primarily due to
overall decreased debt levels due to repayment of the line of credit in 2016 and the decrease in the interest incurred in conjunction
with the construction loan facility as discussed in Note 8 to the consolidated financial statements.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Income Tax Expense</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Our income tax rate was 25% for the
three months ended March 31, 2017, and 15% for the three months ended March 31, 2016.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Our income tax expense was $0.03 million
and $0.02 million for the three months ended March 31, 2017 and 2016, respectively. The expense arose as a result of certain deferred
tax liabilities recognized in prior years. We renewed our &quot;National High-Tech Enterprise&quot; status with the Chinese government
in the third quarter of 2013. With this designation, for the years ending December 31, 2015 and 2016, we enjoyed a preferential
tax rate of 15%, which is notably lower than the statutory income tax rate of 25%. However, our recent net loss results have put
the Company in an unfavorable position for the potential renewal of &quot;National High-Tech Enterprise&quot; status in 2017,
and after evaluating the feasibility of such a renewal, the Company has decided not to renew this status. As a result, our tax
rate for 2017 and the foreseeable future will be 25%.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Net Loss</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Net Loss for the three months ended
March 31, 2017 was $1.0 million, compared to a net loss of $1.6 million for the three months ended March 31, 2016. The
decrease in net loss was mainly a result of the decrease in bad debt expenses.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31,
2017, loss per basic and diluted common share was $(0.02), compared to loss per basic and diluted share of $(0.04) for the three
months ended March 31, 2016.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">The number of basic and diluted weighted-average
outstanding shares used to calculate loss per share was 43,579,557 for both the three months ended March 31, 2017 and 2016.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Our principal source of liquidity is
cash generated from operations.&nbsp;Our cash and cash equivalents were $2.5 million, representing 3.2% of our total
assets as of March 31, 2017 as compared to $2.7 million, representing 3.4% of our total assets as of December 31, 2016. All
of the $2.5 million of cash and cash equivalents as of March 31, 2017, is considered to be reinvested indefinitely in our
Chinese subsidiary, Helpson, and is not expected to be available for payment of dividends or for other payments to our parent
company or to its shareholders. We entered into an eight-year construction loan facility on September 21, 2013. The total
loan facility amount is RMB 80 million (approximately $13 million), which had been fully utilized through May 7, 2014.
We&rsquo;ve accumulatively repaid the principal of RMB 11 million (approximately $1.6 million) of the construction loans per
the payback schedule as of March 31, 2017. The current portion of the construction loan facility is $1.4 million as of March
31, 2017. The cash flow generated from operating activities was used to fund our daily operating expenses as well as
repayment of our loan facility.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on our current operating plan,
management believes that cash provided by operations will be sufficient to meet our working capital needs and our anticipated
capital expenditures, including expenditures for new formula acquisitions and the remaining new GMP upgrade related construction
and equipment in our existing facility for the next twelve months. However, if circumstances change and we do not follow our operating
plan as expected, we may be required to seek additional capital and/or to reduce certain discretionary spending, which could have
a material adverse effect on our ability to achieve our business objectives. Notwithstanding the foregoing, we may seek additional
financing as necessary for expansion purposes when we believe market conditions are most advantageous, which may include debt
and/or equity financing.&nbsp;&nbsp;There can be no assurance that any additional financing will be available on acceptable terms,
if at all.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Operating Activities</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by operating activities
was $10,000 in the three months ended March 31, 2017, compared to $1.3 million for the same period 2016.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2017, our accounts receivable
was $3.7 million, a decrease of $0.3 million from $4.0 million as of December 31, 2016.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2017, total inventory
was $7.0 million, a decrease of $0.3 million from $7.3 million as of December 31, 2016.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Investing Activities</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended March 31,
2017, net cash used in investing activities was ($0.03) million, compared to ($0.04) million for the three months ended March
31, 2016.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Financing Activities</I></B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash flow used in financing activities
was $0.1 million and $0.3 million in the three months ended March 31, 2017 and 2016, respectively. The financing activities
that occurred in the three months ended March 31, 2017 were primarily related to the scheduled payments of the construction loan
facility described in the first paragraph of this section entitled &ldquo;Liquidity and Capital Resources&rdquo; and as discussed
in Note 8 to the consolidated financial statements.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">According to relevant PRC laws, companies
registered in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax
net income, as determined under accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the
reserve account balances reach fifty percent (50%) of the companies&rsquo; registered capital prior to their remittance of funds
out of the PRC.&nbsp;&nbsp;Allocations to these reserves and funds can only be used for specific purposes and are not transferrable
to the parent company in the form of loans, advances or cash dividends.&nbsp;As of March 31, 2017 and December 31, 2016, the net
assets of Helpson were $54,726,000and $57,461,000, respectively. Due to the restriction on dividend distribution to overseas shareholders,
the amount of Helpson&rsquo;s net assets that were designated for general and statutory capital reserves, and thus could not be
transferred to our parent company as cash dividends, were $8,145,000 and $8,145,000 (50% of registered capital) for as of March
31, 2017 and December 31, 2016, respectively.&nbsp;Since the amount that Helpson must set aside for the statutory surplus fund
only accounts for 14.9% and 14.2%, respectively, of its total net assets, this reserve does not have a major impact on our liquidity.&nbsp;&nbsp;There
were no allocations to the statutory surplus reserve accounts during the three months ended March 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">The Chinese government also imposes controls
on the conversion of RMB into foreign currencies and the remittance of currencies out of China.&nbsp;&nbsp;Our businesses and
assets are primarily denominated in RMB.&nbsp;&nbsp;All foreign exchange transactions take place either through the People&rsquo;s
Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People&rsquo;s
Bank of China.&nbsp;Approval of foreign currency payments by the People&rsquo;s Bank of China or other regulatory institutions
requires the submission of a payment application form together with certain invoices and executed contracts.&nbsp;The currency
exchange control procedures imposed by the Chinese government authorities may restrict the ability of Helpson, our Chinese subsidiary,
to transfer its net assets to our parent company through loans, advances or cash dividends.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2017, we did not have
any off-balance sheet arrangements.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Commitments</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2017, we are obligated
to pay laboratories and other service providers approximately $4.4 million over approximately the next four years upon completion
of various phases of contracts required to obtain CFDA production approval of our medical formulas.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 45.8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">Management's discussion and analysis
of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared
in accordance with United States generally accepted accounting principles. Our financial statements reflect the selection and
application of accounting policies which require management to make significant estimates and judgments. The discussion of our
critical accounting policies contained in Note 1 to our consolidated financial statements, &ldquo;Organization and Significant
Accounting Policies&rdquo;, is incorporated herein by reference.&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>Item 3. Quantitative and Qualitative Disclosures about
Market Risk</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As a &quot;smaller reporting company&quot;
as defined by Item 10 of Regulation S-K, we are not required to provide information required by this item.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>Item 4. Controls and Procedures</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our Chief Executive
Officer and interim Chief Financial Officer, evaluated the effectiveness of our &quot;disclosure controls and procedures&quot;
(as defined in the Securities Exchange Act of 1934 (the &quot;Exchange Act&quot;) Rules 13a-15(e) or 15d-15(e)) as of the end
of the period covered by this quarterly report. Disclosure controls and procedures are controls and other procedures that are
designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act (a) is recorded,
processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms
and (b) is accumulated and communicated to management, including our Chief Executive Officer and interim Chief Financial Officer,
as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer
and interim Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of March 31, 2017,
due to ineffective internal controls over financial reporting that stemmed our lack of accounting financial reporting personnel
knowledgeable in US GAAP.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>Changes in Internal Controls over Financial Reporting</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">There were no changes
in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange
Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II OTHER INFORMATION&nbsp;</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><B>Item 6. Exhibits</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">The exhibits required by this item are set forth in the
Exhibit Index attached hereto.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 12pt Arial, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHINA PHARMA HOLDINGS, INC.</FONT></TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 11, 2017</FONT></TD>
    <TD><P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">By<FONT STYLE="background-color: #FEFEFE"><U>: /s/
        Zhilin Li_______________________</U></FONT></P>
        <P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Name: Zhilin Li</P>
        <P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Title: President and Chief Executive Officer</P>
        <P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">(principal executive officer)</P></TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: May 11, 2017</FONT></TD>
    <TD><P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">By: <FONT STYLE="background-color: #FEFEFE"><U>/s/
        Zhilin Li________________________</U></FONT></P>
        <P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Name: Zhilin Li</P>
        <P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Title: Interim Chief Financial Officer</P>
        <P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">(principal financial officer and principal</P>
        <P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">accounting officer)</P></TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: #FEFEFE">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><BR CLEAR="ALL">
<B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U>No. Description</U></B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">31.1 - Certification of Principal Executive
Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">31.2 - Certification of Principal Financial
Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">32.1 - Certification of Principal Executive
Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">101.INS - XBRL Instance Document</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">101.SCH - XBRL Taxonomy Extension Schema
Document</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">101.CAL - XBRL Taxonomy Extension Calculation
Linkbase Document</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">101.DEF - XBRL Taxonomy Extension Definition
Linkbase Document</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">101.LAB - XBRL Taxonomy Extension Label
Linkbase Document</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">101.PRE - XBRL Taxonomy Extension Presentation Linkbase
Document</P>



<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>2
<FILENAME>ex311.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 302</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">I, Zhilin Li, certify that:</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font: 12pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 98%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font: 12pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="width: 98%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font: 12pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="width: 98%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font: 12pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="width: 98%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">b) Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">c) Evaluated the effectiveness of the registrant's
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">d) Disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font: 12pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="width: 98%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">a) all significant deficiencies and material weaknesses
in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">b) any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant's internal control over financial reporting.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Date: May 11, 2017</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Zhilin Li</U></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Name: Zhilin Li</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Title: Chief Executive Officer</P>



<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>ex312.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font: 12pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 31.2</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 302</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">I, Zhilin Li, certify that:</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font: 12pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 98%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font: 12pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="width: 98%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font: 12pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="width: 98%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font: 12pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="width: 98%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">b) Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">c) Evaluated the effectiveness of the registrant's
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">d) Disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially
affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%; font: 12pt Arial, Helvetica, Sans-Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="width: 98%; font: 12pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">a) all significant deficiencies and material weaknesses
in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">b) any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant's internal control over financial reporting.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Date: May 11, 2017</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Zhilin Li</U></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Name: Zhilin Li</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Title: Interim Chief Financial Officer</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">(principal financial officer and principal accounting officer)</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>ex321.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;<B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>18 U.S.C. SECTION 1350,</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">The undersigned hereby certifies, in her capacity as Chief
Executive Officer and interim Chief Financial Officer of China Pharma Holdings, Inc. (the &quot;Company&quot;), for the purposes
of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">(1) The Company's Quarterly Report on Form 10-Q for the fiscal
quarter ended March 31, 2017 (the &quot;Report&quot;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934; and</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">(2) The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Dated: May 11, 2017</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Zhilin Li</U></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Name: Zhilin Li</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">President and Chief Executive Officer</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">(principal executive officer)</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0"><U>/s/ Zhilin Li</U></P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Name: Zhilin Li</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">Title: Interim Chief Financial Officer</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">(principal financial officer and principal</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">accounting officer)</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">This certification accompanies each Report pursuant to &sect;
906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed
filed by the Company for purposes of &sect;18 of the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/11.4pt Times New Roman, Times, Serif; margin: 0">A signed original of this written statement required by Section
906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission
or its staff upon request.</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>cphi-20170331.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Vistalytics - iFile Suite version 6.233 -->
<xbrl xmlns:nonnum='http://www.xbrl.org/dtr/type/non-numeric' xmlns='http://www.xbrl.org/2003/instance' xmlns:us-gaap='http://fasb.org/us-gaap/2016-01-31' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:dei='http://xbrl.sec.gov/dei/2014-01-31' xmlns:fil='http://www.chinapharmaholdings.com/20170331' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:num='http://www.xbrl.org/dtr/type/numeric' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns:xbrli='http://www.xbrl.org/2003/instance'>
	<link:schemaRef xlink:type='simple' xlink:href='cphi-20170331.xsd' />
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>16161252</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent decimals='INF' contextRef='E16' unitRef='USD'>15664496</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<fil:AllowanceForDoubtfulAccountsOnOtherReceivables decimals='INF' contextRef='E17Q1' unitRef='USD'>56157</fil:AllowanceForDoubtfulAccountsOnOtherReceivables>
	<fil:AllowanceForDoubtfulAccountsOnOtherReceivables decimals='INF' contextRef='E16' unitRef='USD'>71548</fil:AllowanceForDoubtfulAccountsOnOtherReceivables>
	<us-gaap:PreferredStockParOrStatedValuePerShare decimals='INF' contextRef='E17Q1' unitRef='UsdPerShare'>0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare decimals='INF' contextRef='E16' unitRef='UsdPerShare'>0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized decimals='INF' contextRef='E17Q1' unitRef='Shares'>5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized decimals='INF' contextRef='E16' unitRef='Shares'>5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued decimals='INF' contextRef='E17Q1' unitRef='Shares'>0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued decimals='INF' contextRef='E16' unitRef='Shares'>0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding decimals='INF' contextRef='E17Q1' unitRef='Shares'>0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding decimals='INF' contextRef='E16' unitRef='Shares'>0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:CommonStockParOrStatedValuePerShare decimals='INF' contextRef='E17Q1' unitRef='UsdPerShare'>0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare decimals='INF' contextRef='E16' unitRef='UsdPerShare'>0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized decimals='INF' contextRef='E17Q1' unitRef='Shares'>95000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized decimals='INF' contextRef='E16' unitRef='Shares'>95000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued decimals='INF' contextRef='E17Q1' unitRef='Shares'>43579557</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued decimals='INF' contextRef='E16' unitRef='Shares'>43579557</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding decimals='INF' contextRef='E17Q1' unitRef='Shares'>43579557</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding decimals='INF' contextRef='E16' unitRef='Shares'>43579557</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 1 &amp;#150; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Organization and Nature of Operations &amp;#150; &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People&apos;s Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot; style=&apos;background:white&apos;&gt;On December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&amp;nbsp;&amp;nbsp;The reincorporation merger was approved by stockholders holding the majority of the Company&amp;#146;s outstanding shares of common stock on December 21, 2012.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot; style=&apos;background:white&apos;&gt;The Foreign Investment Industrial Catalogue&lt;i&gt;&amp;nbsp;&lt;/i&gt;(the &amp;#147;Catalogue&amp;#148;) jointly issued by China&amp;#146;s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &amp;#147;FIE&amp;#148;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company&amp;#146;s business.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot; style=&apos;background:white&apos;&gt;Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&amp;#146;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson&amp;#146;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Consolidation and Basis of Presentation &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Helpson&amp;#146;s functional currency is the Chinese Renminbi. Helpson&amp;#146;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&amp;#146;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&amp;#146; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Accounting Estimates &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;- &lt;/font&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;The methodology used to prepare for the Company&amp;#146;s financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company (&amp;#147;Management&amp;#148;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Cash and Cash Equivalents &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&amp;#146;s acceptances purchased with maturities of three months or less.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Restricted Cash&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#150;&lt;b&gt;&amp;nbsp;&lt;/b&gt;Restricted cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker&apos;s acceptance notes issued by the Company as discussed in Note 7.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts &amp;#150; &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company&apos;s customer base. The Company reviews a customer&apos;s credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $360,063 and $581,300 for the three months ended March 31, 2017 and 2016, respectively.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectable trade accounts receivable balances in the amount of $0 against the allowance for both the three months ended March 31, 2017 and 2016, respectively. It is common practice in the pharmaceutical industry in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Advances to Suppliers and Advances from Customers&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; Common practice in the pharmaceutical industry in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier&apos;s credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected. The Company recognized no bad debt expense for the three months ended March 31, 2017 and 2016, respectively.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Inventories&amp;nbsp;&amp;#150;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or market. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated portion of the Company&amp;#146;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value. Market for raw materials is based on replacement cost. Provisions for inventory write-downs are included in cost of revenues in the consolidated statements of operations. Once written down, inventories are carried at this lower cost basis until sold or scrapped.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Valuation of Long-Lived Assets &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. There was no impairment adjustment required for the three months ended March 31, 2017 and 2016.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Property and Equipment&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Revenue Recognition&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved. Revenue is deferred when collectability is not considered to be reasonably assured.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Cost of Revenues&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery of products.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Research and Development&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; Research and development expenditures are recorded as expenses in the period in which they occur.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Basic and Diluted Loss per Common Share &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;- &lt;/font&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares. There were no potential dilutive common shares outstanding during the three months ended March 31, 2017 and 2016, respectively.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Credit Risk&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; The carrying amount of accounts receivable included in the balance sheet represents the Company&apos;s exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer&apos;s financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management&apos;s estimates.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&amp;#146; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&amp;nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&amp;#146;s deposits may be at a higher risk of loss.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Interest Rate Risk&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In May 2014, the FASB issued ASU 2014-09,&amp;nbsp;&lt;i&gt;&quot;Revenue from Contracts with Customers&quot;&lt;/i&gt;&amp;nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. &amp;nbsp;In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In February 2016, the FASB issued ASU No. 2016-02,&amp;nbsp;&lt;i&gt;Leases&lt;/i&gt;, a new standard on accounting for leases. The ASU introduces a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB&apos;s new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The pronouncement is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, using a modified retrospective approach. Early adoption is permitted. The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In June 2016, the FASB issued Accounting Standards Update 2016-13,&amp;nbsp;&lt;i&gt;Financial Instruments &amp;#150; Credit Losses (Topic 326)&lt;/i&gt;, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial assets with credit deterioration since their origination.&amp;nbsp;The pronouncement will be effective for Public business entities that are SEC filers in fiscal years beginning after&amp;nbsp;December 15, 2019, including interim periods within those fiscal years.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Early application of the guidance will be permitted for all entities for fiscal years beginning after&amp;nbsp;December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In August 2016, the FASB issued ASU No. 2016-15,&amp;nbsp;&lt;i&gt;Classification of Certain Cash Receipts and Cash Payments&lt;/i&gt;. The standard addresses the classification and presentation of eight specific cash flow issues that currently result in diverse practices. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The amendments in this ASU should be applied using a retrospective approach.&amp;nbsp; The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures, but does not expect the impact to be material.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In November 2016, the FASB issued ASU 2016-18,&amp;nbsp;&lt;i&gt;Statement of Cash Flows (Topic 230): Restricted Cash (&amp;#147;ASU 2016-18&amp;#148;)&lt;/i&gt;. The ASU requires an entity to explain the changes in the total of cash, cash equivalents, restricted cash, and restricted cash equivalents on the statement of cash flows and to provide a reconciliation of the totals in that statement to the related captions in the balance sheet when the cash, cash equivalents, restricted cash, and restricted cash equivalents are presented in more than one line item on the balance sheet. This ASU is effective for annual and interim periods beginning after December 15, 2017, and is required to be adopted using a retrospective approach, with early adoption permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-18 may have on its consolidated financial statements.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company&amp;#146;s financial position, result of operations or cash flows.&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 2 &amp;#150; INVENTORY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Inventory consisted of the following:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;March 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;December 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2017&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2016&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Raw materials&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;10,796,239&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;11,562,388&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Work in process&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;692,827&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;360,550&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Finished goods&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;1,397,514&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;1,530,641&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;12,886,580&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;13,453,579&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Obsolescence reserve&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;(5,900,615&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;(6,142,640&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:9pt;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Total Inventory&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;6,985,965&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;7,310,939&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 3 - PROPERTY AND EQUIPMENT&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Property and equipment consisted of the following:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;March 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;December 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2017&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2016&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Permit of land use&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;408,775&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;405,645&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Building&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;9,492,387&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;9,419,700&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Plant, machinery and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;26,379,439&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;26,151,029&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Motor vehicle&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;312,167&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;309,777&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Office equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;184,128&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;182,718&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:9pt;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;36,776,896&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;36,468,869&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;(12,354,523&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;(11,501,421&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Property and Equipment, net&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;24,422,373&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;24,967,448&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;71%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71%;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Asset&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;2%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:2%;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;27%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:27%;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;Life - years&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Permit of land use&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;40 - 70&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Building&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;20 - 49&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Plant, machinery and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;5 - 10&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Motor vehicle&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;5 - 10&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Office equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;3-5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the three months ended March 31, 2017 and 2016, depreciation expense was $764,614 and $790,254, respectively.&amp;nbsp;&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 4 - INTANGIBLE ASSETS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Intangible assets represent the cost of medical formulas approved for production by the China Food and Drug Administration (&amp;#147;CFDA&amp;#148;). The Company did not obtain CFDA production approval for any medical formula during the three months ended March 31, 2017 and 2016 and no costs were reclassified from advances to intangible assets during the three months ended March 31, 2017 and 2016, respectively.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.&amp;nbsp;&amp;nbsp;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $50,780 and $66,941 for the three months ended March 31, 2017 and 2016, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Company&amp;#146;s evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company&amp;#146;s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the three months ended March 31, 2017 and 2016.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Intangible assets consisted solely of CFDA approved medical formulas as follows:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;March 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;December 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2017&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2016&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Gross carrying amount&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;4,899,281&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;4,861,766&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Accumulated amortization&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;(4,411,237&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;(4,327,084&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Net carrying amount&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;488,044&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;534,682&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
	<fil:AdvancesForPurchasesOfIntangibleAssetsTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 5 &amp;#150; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In order to expand the number of medicines the Company manufactured and marketed, it has entered into contracts with independent laboratories and others for the purchase of medical formulas. Although CFDA approval had not been obtained for these medical formulas at the dates of the respective contracts, the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. The Company received the titles to two patents that relate to medical formulas currently in the CFDA approval process for the year end December 31, 2013. These patents have not expired.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Prior to entering into contracts with the Company, laboratories typically are required to complete all&amp;nbsp;research and development to determine the content of the medical formula and the method to produce the generic medicine. The application to the CFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the CFDA.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;A typical CFDA approval process for the production of a generic medical product involves a number of steps that generally require three to five years to complete. If the medical formula is purchased at the point when the generic medical product receives the CFDA&amp;#146;s approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to complete. After completing the clinical study, the results are submitted to the CFDA and a production approval application is filed with the CFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application and obtain CFDA approval. Upon approving the generic medical product, the CFDA issues a production certificate and the Company can commence the production and sales of the generic medical product. As a result of this process, CFDA approval is expected to be received in approximately two to five years from the date&amp;nbsp;the Company signs the medical formula contracts.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets. During the fiscal year of 2016, with CFDA&apos;s new regulations on scrutiny procedures in connection with its review of production applications and based on the Company&apos;s monitoring and assessment process, the Company determined five advanced payments to five independent laboratories were impaired. As a result, the Company recognized an impairment loss for the advances made to these laboratories in the amount of $3,962,141.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;As of March 31, 2017, the Company was obligated to pay laboratories and others approximately $4,400,000 upon the completion of various phases of contracts to obtain CFDA production approval of medical formulas.&lt;/font&gt;&lt;/p&gt;</fil:AdvancesForPurchasesOfIntangibleAssetsTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 6 &amp;#150; RELATED PARTY TRANSACTIONS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;A member of the Company&amp;#146;s board of directors (the &amp;#147;Board&amp;#148;) had previously advanced the Company an aggregate amount of $1,354,567 as of March 31, 2017 and December 31, 2016 which are recorded as Other payables &amp;#150; related parties on the accompanying consolidated balance sheets. The advances bear interest at a rate of 1.0% per year.&amp;nbsp;&amp;nbsp;Total interest expense of $3,386 was recognized for each of the three months ended March 31, 2017 and 2016.&lt;/font&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<fil:BankerSAcceptanceNotesPayableTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 7 &amp;#150; BANKER&apos;S ACCEPTANCE NOTES PAYABLE&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In April 2016, the Company entered into a Banker&apos;s Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company can issue banker&apos;s acceptance notes (the &quot;Banker&apos;s Notes&quot;) to any third party as payment of amounts owing to that third party. The Company is required to deposit with the bank an amount equal to the amounts represented by the Banker&apos;s Notes issued to the third parties. The amount of these deposited balances is shown as &quot;Restricted cash&quot; on the accompanying balance sheets as of March 31, 2017 and December 31, 2016. The maximum amount that the Company can issue under this agreement is limited to the lesser of RMB30,000,000 (approximately $4.5 million) or the amount of cash available to deposit against the Banker&apos;s Notes. In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank. At March 31, 2017 and December 31 2016, the Company had outstanding Banker&apos;s Acceptance Notes in the amount of $1,718,823 and $1,088,879, respectively.&lt;/font&gt;&lt;/p&gt;</fil:BankerSAcceptanceNotesPayableTextBlock>
	<us-gaap:LongTermDebtTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 8 &amp;#150; CONSTRUCTION LOAN FACILITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The Company obtained a construction loan facility in the amount of RMB 80,000,000 (approximately $13 million) from a construction loan facility dated June 21, 2013. The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date and is from the same bank that currently provides the line of credit as discussed in Note 7.&amp;nbsp;&amp;nbsp;The proceeds of the loan were used for and are collateralized by the construction of the Company&amp;#146;s new production facility and the included production line equipment and machinery. The loan currently bears weighted interest at 5.73%, based upon 110% of the PRC government&amp;#146;s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. On July 10, 2015 the interest rate was adjusted to 5.94% and on July 10, 2016 the rate was further adjusted to 5.39%. &amp;nbsp;The loan required interest only payments for the first two years. Beginning July 11, 2015, the balance of the principal is due in at least two (2) annual installments with the first annual payment being due within the six-month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2022 on the identical terms as described above for 2015. During the first quarter of 2017, the Company made a principal payment in the amount of approximately $145,000 (RMB1,000,000) with the remaining annual principal payment of approximately $1,306,000 (9,000,000 RMB) being due in July 2017. As of March 31, 2017, the Company had no additional amounts available to it under this facility.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Principal payments required for the next five years as of March 31, 2017 are as follows:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Year&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Amount&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;43%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:43%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2017&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;43%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:43%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;1,306,140&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2018&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2,176,901&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2,176,901&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2,176,901&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2,176,901&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$10,013,744&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Fair Value of Construction Loan Facility&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of the construction loan facility outstanding as of March 31, 2017 and December 31, 2016 approximated its fair value because the underlying instrument bears an interest rate that approximated current market rates.&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 9 - INCOME TAXES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in income in the period that includes the enactment date.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Undistributed earnings of Helpson, the Company&amp;#146;s foreign subsidiary, since its acquisition, amounted to approximately $30.5 million as of March 31, 2017. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Liabilities are established for uncertain tax positions expected to be taken in income tax return when such positions are judged to meet the &amp;#147;more-likely-than-not&amp;#148; threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through March 31, 2017, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2013 through December 31, 2016 and the Chinese income tax return for the year ended December 31, 2016 are open for possible examination.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;On March 16, 2007, the National People&amp;#146;s Congress of China passed the Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the Implementation Regulations for the EIT Law which took effect on January&amp;nbsp;1, 2008. The EIT Law and Implementation Regulations Rules impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify under certain limited exceptions.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The Company is located in a special region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax rate in the special region. The Company transitioned to the new 25% tax rate over a five year period which began on January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status in the PRC as a high technology enterprise. In 2013, the Company again applied for and received the same favorable tax rate for 2014 to 2016.&amp;nbsp;The recent&amp;nbsp;net losses put the Company in an unfavorable position for the potential renewal of&amp;nbsp;&quot;National High-Tech Enterprise&quot; status for 2017. After evaluating the feasibility of the renewal in 2016, the Company has decided not to renew this status.&amp;nbsp;&amp;nbsp;Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;39%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:39%;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10%;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; rowspan=&quot;2&quot; width=&quot;51%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:51%;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Enterprise Income&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Tax Rate&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Year&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;15%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2017&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;25%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;25%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The provision for income taxes consisted of the following:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;7&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Three Months Ended March 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2017&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2016&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Current&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Deferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;30,334&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;22,828&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Total income tax expense&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;30,334&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;22,828&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;As of March 31, 2017, the Company had net operating loss carryforwards for PRC tax purposes of approximately $52.2 million which are available to offset any future taxable income through 2022. These carryforwards begin to expire in 2018. The Company also has net operating losses for United States federal income tax purposes of approximately $4.6 million which are available to offset future taxable income, if any, through 2037.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&amp;nbsp;&amp;nbsp;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&amp;nbsp;&amp;nbsp;Management considers projected future taxable income and tax planning strategies in making this assessment.&amp;nbsp;&amp;nbsp;Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of March 31, 2017 and December 31, 2016.&amp;nbsp;&amp;nbsp;Therefore, the Company provided for a valuation allowance against its deferred tax assets of $21,963,335 and $21,452,802 as of March 31, 2017 and December 31, 2016, respectively.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.&lt;b&gt;&amp;nbsp;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 11 - STOCKHOLDERS&apos; EQUITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The Company is authorized to issue 95,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company&amp;#146;s Board.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;u&gt;&lt;font lang=&quot;EN-US&quot;&gt;Employee Stock Options&lt;/font&gt;&lt;/u&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;2010 Incentive Plan&lt;/font&gt;&lt;/i&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;On November 12, 2010, the Company&amp;#146;s Board adopted the Company&amp;#146;s 2010 Incentive Plan (the &amp;#147;Plan&amp;#148;), which was then approved by stockholders on December 22, 2010. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through March 31, 2017, there were 175,000 shares of restricted stock granted and outstanding under the Plan.&amp;nbsp; No options were outstanding as of March 31, 2017 under the Plan.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;There were no securities issued from the Plan during each of the three months ended March 31, 2017 and 2016.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The Company recognized no compensation expense related to the awards of common shares and the grants and modifications of stock options during each of the three months ended March 31, 2017 and 2016.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model. Expected volatility is based on the historical volatility of the Company&amp;#146;s common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;As of March 31, 2017, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.&lt;/font&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 12 &amp;#150; COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Economic environment &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;- &lt;/font&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Substantially all of the Company&apos;s operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company&apos;s results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company&amp;#146;s operations.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In addition, all of the Company&apos;s revenue is denominated in the PRC&apos;s currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 13 &amp;#150; CONCENTRATIONS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;For the three months ended March 31, 2017, no customer accounted for more than 10% of sales and two customers accounted for 46.2% and 15% of accounts receivable.&amp;nbsp;Four suppliers accounted for 23.7%, 17.3%, 13.6% and 12.7% of raw material purchases.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;For the three months ended March 31, 2016, no customer accounted for more than 10% of sales and&amp;nbsp;three customers accounted for 28.5%, 11.4% and 11.0%&amp;nbsp;of accounts receivable, respectively.&amp;nbsp;No supplier accounted for greater than 10% of raw material purchases.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
	<us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;background:white;margin:0cm 0cm 0pt;line-height:10.25pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;NOTE 10 &amp;#150; FAIR VALUE MEASUREMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;background:white;margin:0cm 0cm 0pt;line-height:10.25pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;background:white;text-align:justify;margin:0cm 0cm 0pt;line-height:10.25pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &amp;#150; Quoted prices in active markets for identical assets or liabilities. Level 2 &amp;#150; Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 &amp;#150; Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The Company uses fair value to measure the derivative warrant liability on a recurring basis because fair value is the primary measure for accounting. The Company also uses fair value to measure the value of the banker&apos;s acceptance notes it holds.&amp;nbsp;&amp;nbsp;The Company values its derivative warrants using a valuation method explained above.&amp;nbsp;&amp;nbsp;The banker&apos;s acceptance notes are recorded at cost which approximates fair value.&amp;nbsp;&amp;nbsp;As of December 31, 2016, the Company had no banker&apos;s acceptance notes to be recorded at fair value.&amp;nbsp; The Company held the following assets and liabilities recorded at fair value as of March 31, 2017:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;11&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Fair Value Measurements at&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;10&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Reporting Date Using&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Description&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;March 31, 2017&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Level 1&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Level 2&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Level 3&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;40%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:40%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Banker&apos;s acceptance notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;3%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;14,513&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;3%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;3%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;14,513&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;3%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;14,513&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;14,513&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
	<us-gaap:NatureOfOperations contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Organization and Nature of Operations &amp;#150; &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp;amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People&apos;s Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot; style=&apos;background:white&apos;&gt;On December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&amp;nbsp;&amp;nbsp;The reincorporation merger was approved by stockholders holding the majority of the Company&amp;#146;s outstanding shares of common stock on December 21, 2012.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot; style=&apos;background:white&apos;&gt;The Foreign Investment Industrial Catalogue&lt;i&gt;&amp;nbsp;&lt;/i&gt;(the &amp;#147;Catalogue&amp;#148;) jointly issued by China&amp;#146;s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &amp;#147;FIE&amp;#148;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company&amp;#146;s business.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot; style=&apos;background:white&apos;&gt;Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&amp;#146;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson&amp;#146;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.&lt;/font&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
	<us-gaap:ConsolidationPolicyTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Consolidation and Basis of Presentation &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Helpson&amp;#146;s functional currency is the Chinese Renminbi. Helpson&amp;#146;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&amp;#146;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&amp;#146; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:UseOfEstimates contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Accounting Estimates &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;- &lt;/font&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;The methodology used to prepare for the Company&amp;#146;s financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company (&amp;#147;Management&amp;#148;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Cash and Cash Equivalents &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&amp;#146;s acceptances purchased with maturities of three months or less.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:ReceivablesPolicyTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts &amp;#150; &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company&apos;s customer base. The Company reviews a customer&apos;s credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $360,063 and $581,300 for the three months ended March 31, 2017 and 2016, respectively.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectable trade accounts receivable balances in the amount of $0 against the allowance for both the three months ended March 31, 2017 and 2016, respectively. It is common practice in the pharmaceutical industry in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts.&lt;/font&gt;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
	<fil:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Advances to Suppliers and Advances from Customers&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; Common practice in the pharmaceutical industry in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier&apos;s credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected. The Company recognized no bad debt expense for the three months ended March 31, 2017 and 2016, respectively.&lt;/font&gt;&lt;/p&gt;</fil:AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Inventories&amp;nbsp;&amp;#150;&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or market. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated portion of the Company&amp;#146;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value. Market for raw materials is based on replacement cost. Provisions for inventory write-downs are included in cost of revenues in the consolidated statements of operations. Once written down, inventories are carried at this lower cost basis until sold or scrapped.&lt;/font&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Valuation of Long-Lived Assets &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. There was no impairment adjustment required for the three months ended March 31, 2017 and 2016.&lt;/font&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Property and Equipment&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Revenue Recognition&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved. Revenue is deferred when collectability is not considered to be reasonably assured.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Cost of Revenues&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery of products.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Research and Development&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; Research and development expenditures are recorded as expenses in the period in which they occur.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Basic and Diluted Loss per Common Share &lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;- &lt;/font&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares. There were no potential dilutive common shares outstanding during the three months ended March 31, 2017 and 2016, respectively.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Credit Risk&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; The carrying amount of accounts receivable included in the balance sheet represents the Company&apos;s exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer&apos;s financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management&apos;s estimates.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&amp;#146; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&amp;nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&amp;#146;s deposits may be at a higher risk of loss.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<fil:InterestRateRiskPolicyTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Interest Rate Risk&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt; &amp;#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.&lt;/font&gt;&lt;/p&gt;</fil:InterestRateRiskPolicyTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In May 2014, the FASB issued ASU 2014-09,&amp;nbsp;&lt;i&gt;&quot;Revenue from Contracts with Customers&quot;&lt;/i&gt;&amp;nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. &amp;nbsp;In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In February 2016, the FASB issued ASU No. 2016-02,&amp;nbsp;&lt;i&gt;Leases&lt;/i&gt;, a new standard on accounting for leases. The ASU introduces a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB&apos;s new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The pronouncement is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, using a modified retrospective approach. Early adoption is permitted. The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In June 2016, the FASB issued Accounting Standards Update 2016-13,&amp;nbsp;&lt;i&gt;Financial Instruments &amp;#150; Credit Losses (Topic 326)&lt;/i&gt;, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial assets with credit deterioration since their origination.&amp;nbsp;The pronouncement will be effective for Public business entities that are SEC filers in fiscal years beginning after&amp;nbsp;December 15, 2019, including interim periods within those fiscal years.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Early application of the guidance will be permitted for all entities for fiscal years beginning after&amp;nbsp;December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In August 2016, the FASB issued ASU No. 2016-15,&amp;nbsp;&lt;i&gt;Classification of Certain Cash Receipts and Cash Payments&lt;/i&gt;. The standard addresses the classification and presentation of eight specific cash flow issues that currently result in diverse practices. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The amendments in this ASU should be applied using a retrospective approach.&amp;nbsp; The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures, but does not expect the impact to be material.&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;In November 2016, the FASB issued ASU 2016-18,&amp;nbsp;&lt;i&gt;Statement of Cash Flows (Topic 230): Restricted Cash (&amp;#147;ASU 2016-18&amp;#148;)&lt;/i&gt;. The ASU requires an entity to explain the changes in the total of cash, cash equivalents, restricted cash, and restricted cash equivalents on the statement of cash flows and to provide a reconciliation of the totals in that statement to the related captions in the balance sheet when the cash, cash equivalents, restricted cash, and restricted cash equivalents are presented in more than one line item on the balance sheet. This ASU is effective for annual and interim periods beginning after December 15, 2017, and is required to be adopted using a retrospective approach, with early adoption permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-18 may have on its consolidated financial statements.&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company&amp;#146;s financial position, result of operations or cash flows.&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<fil:RestrictedCashTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;i&gt;&lt;font lang=&quot;EN-US&quot;&gt;Restricted Cash&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#150;&lt;b&gt;&amp;nbsp;&lt;/b&gt;Restricted cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker&apos;s acceptance notes issued by the Company as discussed in Note 7.&lt;/font&gt;&lt;/p&gt;</fil:RestrictedCashTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Inventory consisted of the following:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;March 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;December 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2017&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2016&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Raw materials&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;10,796,239&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;11,562,388&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Work in process&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;692,827&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;360,550&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Finished goods&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;1,397,514&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;1,530,641&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;12,886,580&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;13,453,579&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Obsolescence reserve&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;(5,900,615&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;(6,142,640&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:9pt;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Total Inventory&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;6,985,965&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;7,310,939&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Property and equipment consisted of the following:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;March 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;December 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2017&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2016&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Permit of land use&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;408,775&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;405,645&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Building&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;9,492,387&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;9,419,700&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Plant, machinery and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;26,379,439&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;26,151,029&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Motor vehicle&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;312,167&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;309,777&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Office equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;184,128&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;182,718&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:9pt;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Total&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;36,776,896&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;36,468,869&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;(12,354,523&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;(11,501,421&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Property and Equipment, net&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;24,422,373&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;24,967,448&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<fil:UsefulLivesOfTheAssetsTableTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;71%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:71%;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Asset&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;2%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:2%;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;27%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:27%;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;Life - years&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Permit of land use&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;40 - 70&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Building&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;20 - 49&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Plant, machinery and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;5 - 10&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Motor vehicle&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;5 - 10&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Office equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;3-5&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fil:UsefulLivesOfTheAssetsTableTextBlock>
	<fil:IntangibleAssetsMedicalFormulasTablesTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Intangible assets consisted solely of CFDA approved medical formulas as follows:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;March 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;December 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2017&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2016&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Gross carrying amount&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;4,899,281&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;4,861,766&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Accumulated amortization&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;(4,411,237&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;(4,327,084&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Net carrying amount&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;488,044&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;534,682&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fil:IntangibleAssetsMedicalFormulasTablesTextBlock>
	<us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Principal payments required for the next five years as of March 31, 2017 are as follows:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Year&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Amount&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;43%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:43%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2017&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;43%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:43%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;1,306,140&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2018&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2,176,901&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2019&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2,176,901&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2020&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2,176,901&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2021&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2,176,901&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$10,013,744&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
	<fil:ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The Company has decided not to renew this status.&amp;nbsp;&amp;nbsp;Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;39%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:39%;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10%;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; rowspan=&quot;2&quot; width=&quot;51%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:51%;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Enterprise Income&lt;/font&gt;&lt;/b&gt;&lt;/p&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Tax Rate&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Year&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2016&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;15%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;2017&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;25%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Thereafter&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;25%&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</fil:ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The provision for income taxes consisted of the following:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;7&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Three Months Ended March 31,&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2017&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;2016&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Current&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;56%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Deferred&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;30,334&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;8%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;12%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;22,828&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Total income tax expense&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;30,334&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;22,828&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef='Y17Q1'>&lt;!--egx--&gt;&lt;p style=&apos;text-align:justify;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;The banker&apos;s acceptance notes to be recorded at fair value.&amp;nbsp; The Company held the following assets and liabilities recorded at fair value as of March 31, 2017:&lt;/font&gt;&lt;/p&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt; &lt;table cellspacing=&quot;0&quot; cellpadding=&quot;0&quot; width=&quot;100%&quot; border=&quot;0&quot; style=&apos;width:100%;border-collapse:collapse&apos;&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;3&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;11&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Fair Value Measurements at&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; colspan=&quot;10&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Reporting Date Using&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Description&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;center&quot; style=&apos;text-align:center;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;March 31, 2017&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Level 1&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Level 2&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;Level 3&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; width=&quot;40%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:40%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Banker&apos;s acceptance notes&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;3%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;14,513&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;3%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;3%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;14,513&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;3%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;10%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; width=&quot;1%&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;Total&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;14,513&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;14,513&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;$&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p align=&quot;right&quot; style=&apos;text-align:right;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;#151;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt; &lt;td valign=&quot;bottom&quot; style=&apos;border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm&apos;&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;p style=&apos;margin:0cm 0cm 0pt&apos;&gt;&lt;b&gt;&lt;font lang=&quot;EN-US&quot;&gt;&amp;nbsp;&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
	<us-gaap:Cash decimals='INF' contextRef='E17Q1' unitRef='USD'>2523541</us-gaap:Cash>
	<us-gaap:Cash decimals='INF' contextRef='E16' unitRef='USD'>2665802</us-gaap:Cash>
	<us-gaap:RestrictedCashAndCashEquivalents decimals='INF' contextRef='E17Q1' unitRef='USD'>1718823</us-gaap:RestrictedCashAndCashEquivalents>
	<us-gaap:RestrictedCashAndCashEquivalents decimals='INF' contextRef='E16' unitRef='USD'>1088879</us-gaap:RestrictedCashAndCashEquivalents>
	<us-gaap:OtherRestrictedAssetsCurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>14513</us-gaap:OtherRestrictedAssetsCurrent>
	<us-gaap:OtherRestrictedAssetsCurrent decimals='INF' contextRef='E16' unitRef='USD'>0</us-gaap:OtherRestrictedAssetsCurrent>
	<fil:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1 decimals='INF' contextRef='E17Q1' unitRef='USD'>3703593</fil:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1>
	<fil:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1 decimals='INF' contextRef='E16' unitRef='USD'>3999809</fil:TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1>
	<us-gaap:AccountsAndOtherReceivablesNetCurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>272097</us-gaap:AccountsAndOtherReceivablesNetCurrent>
	<us-gaap:AccountsAndOtherReceivablesNetCurrent decimals='INF' contextRef='E16' unitRef='USD'>224373</us-gaap:AccountsAndOtherReceivablesNetCurrent>
	<fil:AdvancesToSuppliers decimals='INF' contextRef='E17Q1' unitRef='USD'>2036758</fil:AdvancesToSuppliers>
	<fil:AdvancesToSuppliers decimals='INF' contextRef='E16' unitRef='USD'>2003792</fil:AdvancesToSuppliers>
	<us-gaap:InventoryNet decimals='INF' contextRef='E17Q1' unitRef='USD'>6985965</us-gaap:InventoryNet>
	<us-gaap:InventoryNet decimals='INF' contextRef='E16' unitRef='USD'>7310939</us-gaap:InventoryNet>
	<us-gaap:PrepaidExpenseCurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>205293</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:PrepaidExpenseCurrent decimals='INF' contextRef='E16' unitRef='USD'>226357</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:AssetsCurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>17460583</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent decimals='INF' contextRef='E16' unitRef='USD'>17519951</us-gaap:AssetsCurrent>
	<fil:AdvancesForPurchasesOfIntangibleAssets decimals='INF' contextRef='E17Q1' unitRef='USD'>35771976</fil:AdvancesForPurchasesOfIntangibleAssets>
	<fil:AdvancesForPurchasesOfIntangibleAssets decimals='INF' contextRef='E16' unitRef='USD'>35498059</fil:AdvancesForPurchasesOfIntangibleAssets>
	<us-gaap:PropertyPlantAndEquipmentNet decimals='INF' contextRef='E17Q1' unitRef='USD'>24422373</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet decimals='INF' contextRef='E16' unitRef='USD'>24967448</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill decimals='INF' contextRef='E17Q1' unitRef='USD'>488044</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill decimals='INF' contextRef='E16' unitRef='USD'>534682</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:Assets decimals='INF' contextRef='E17Q1' unitRef='USD'>78142976</us-gaap:Assets>
	<us-gaap:Assets decimals='INF' contextRef='E16' unitRef='USD'>78520140</us-gaap:Assets>
	<us-gaap:AccountsPayableTradeCurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>2877412</us-gaap:AccountsPayableTradeCurrent>
	<us-gaap:AccountsPayableTradeCurrent decimals='INF' contextRef='E16' unitRef='USD'>3060374</us-gaap:AccountsPayableTradeCurrent>
	<us-gaap:AccruedLiabilitiesCurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>90232</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent decimals='INF' contextRef='E16' unitRef='USD'>139830</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableOtherCurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>2355365</us-gaap:AccountsPayableOtherCurrent>
	<us-gaap:AccountsPayableOtherCurrent decimals='INF' contextRef='E16' unitRef='USD'>2502694</us-gaap:AccountsPayableOtherCurrent>
	<us-gaap:CustomerAdvancesCurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>703915</us-gaap:CustomerAdvancesCurrent>
	<us-gaap:CustomerAdvancesCurrent decimals='INF' contextRef='E16' unitRef='USD'>811232</us-gaap:CustomerAdvancesCurrent>
	<us-gaap:DueToRelatedPartiesCurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>1354567</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:DueToRelatedPartiesCurrent decimals='INF' contextRef='E16' unitRef='USD'>1354567</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:LongTermConstructionLoanCurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>1440154</us-gaap:LongTermConstructionLoanCurrent>
	<us-gaap:LongTermConstructionLoanCurrent decimals='INF' contextRef='E16' unitRef='USD'>1440154</us-gaap:LongTermConstructionLoanCurrent>
	<fil:BankersAcceptanceNotesPayable decimals='INF' contextRef='E17Q1' unitRef='USD'>1718823</fil:BankersAcceptanceNotesPayable>
	<fil:BankersAcceptanceNotesPayable decimals='INF' contextRef='E16' unitRef='USD'>1088879</fil:BankersAcceptanceNotesPayable>
	<us-gaap:LiabilitiesCurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>10540468</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent decimals='INF' contextRef='E16' unitRef='USD'>10397730</us-gaap:LiabilitiesCurrent>
	<us-gaap:LongtermConstructionLoanCurrentAndNoncurrent decimals='INF' contextRef='E17Q1' unitRef='USD'>8573590</us-gaap:LongtermConstructionLoanCurrentAndNoncurrent>
	<us-gaap:LongtermConstructionLoanCurrentAndNoncurrent decimals='INF' contextRef='E16' unitRef='USD'>8640927</us-gaap:LongtermConstructionLoanCurrentAndNoncurrent>
	<us-gaap:DeferredTaxLiabilities decimals='INF' contextRef='E17Q1' unitRef='USD'>607090</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities decimals='INF' contextRef='E16' unitRef='USD'>572349</us-gaap:DeferredTaxLiabilities>
	<us-gaap:Liabilities decimals='INF' contextRef='E17Q1' unitRef='USD'>19721148</us-gaap:Liabilities>
	<us-gaap:Liabilities decimals='INF' contextRef='E16' unitRef='USD'>19611006</us-gaap:Liabilities>
	<us-gaap:PreferredStockValue decimals='INF' contextRef='E17Q1' unitRef='USD'>0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue decimals='INF' contextRef='E16' unitRef='USD'>0</us-gaap:PreferredStockValue>
	<us-gaap:CommonStockValue decimals='INF' contextRef='E17Q1' unitRef='USD'>43580</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue decimals='INF' contextRef='E16' unitRef='USD'>43580</us-gaap:CommonStockValue>
	<us-gaap:AdditionalPaidInCapital decimals='INF' contextRef='E17Q1' unitRef='USD'>23590204</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital decimals='INF' contextRef='E16' unitRef='USD'>23590204</us-gaap:AdditionalPaidInCapital>
	<us-gaap:RetainedEarningsAccumulatedDeficit decimals='INF' contextRef='E17Q1' unitRef='USD'>23790476</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit decimals='INF' contextRef='E16' unitRef='USD'>24757374</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:PreconfirmationAccumulatedOtherComprehensiveIncomeLoss decimals='INF' contextRef='E17Q1' unitRef='USD'>10997568</us-gaap:PreconfirmationAccumulatedOtherComprehensiveIncomeLoss>
	<us-gaap:PreconfirmationAccumulatedOtherComprehensiveIncomeLoss decimals='INF' contextRef='E16' unitRef='USD'>10517976</us-gaap:PreconfirmationAccumulatedOtherComprehensiveIncomeLoss>
	<us-gaap:StockholdersEquity decimals='INF' contextRef='E17Q1' unitRef='USD'>58421828</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity decimals='INF' contextRef='E16' unitRef='USD'>58909134</us-gaap:StockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity decimals='INF' contextRef='E17Q1' unitRef='USD'>78142976</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity decimals='INF' contextRef='E16' unitRef='USD'>78520140</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:Revenues decimals='INF' contextRef='Y17Q1' unitRef='USD'>3285203</us-gaap:Revenues>
	<us-gaap:Revenues decimals='INF' contextRef='Y16Q1' unitRef='USD'>3640494</us-gaap:Revenues>
	<us-gaap:CostOfRevenue decimals='INF' contextRef='Y17Q1' unitRef='USD'>2567350</us-gaap:CostOfRevenue>
	<us-gaap:CostOfRevenue decimals='INF' contextRef='Y16Q1' unitRef='USD'>2999675</us-gaap:CostOfRevenue>
	<us-gaap:GrossProfit decimals='INF' contextRef='Y17Q1' unitRef='USD'>717853</us-gaap:GrossProfit>
	<us-gaap:GrossProfit decimals='INF' contextRef='Y16Q1' unitRef='USD'>640819</us-gaap:GrossProfit>
	<us-gaap:SellingExpense decimals='INF' contextRef='Y17Q1' unitRef='USD'>717637</us-gaap:SellingExpense>
	<us-gaap:SellingExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>968507</us-gaap:SellingExpense>
	<us-gaap:GeneralAndAdministrativeExpense decimals='INF' contextRef='Y17Q1' unitRef='USD'>416726</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>318930</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:ResearchAndDevelopmentExpense decimals='INF' contextRef='Y17Q1' unitRef='USD'>26060</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>93433</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ProvisionForDoubtfulAccounts decimals='INF' contextRef='Y17Q1' unitRef='USD'>360063</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts decimals='INF' contextRef='Y16Q1' unitRef='USD'>581300</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:OperatingExpenses decimals='INF' contextRef='Y17Q1' unitRef='USD'>1520486</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses decimals='INF' contextRef='Y16Q1' unitRef='USD'>1962170</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss decimals='INF' contextRef='Y17Q1' unitRef='USD'>-802633</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss decimals='INF' contextRef='Y16Q1' unitRef='USD'>-1321351</us-gaap:OperatingIncomeLoss>
	<us-gaap:InvestmentIncomeInterest decimals='INF' contextRef='Y17Q1' unitRef='USD'>5033</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest decimals='INF' contextRef='Y16Q1' unitRef='USD'>33592</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InterestExpense decimals='INF' contextRef='Y17Q1' unitRef='USD'>-138964</us-gaap:InterestExpense>
	<us-gaap:InterestExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>-242309</us-gaap:InterestExpense>
	<us-gaap:OtherExpenses decimals='INF' contextRef='Y17Q1' unitRef='USD'>-133931</us-gaap:OtherExpenses>
	<us-gaap:OtherExpenses decimals='INF' contextRef='Y16Q1' unitRef='USD'>-208717</us-gaap:OtherExpenses>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals='INF' contextRef='Y17Q1' unitRef='USD'>-936564</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest decimals='INF' contextRef='Y16Q1' unitRef='USD'>-1530068</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<fil:IncomeTaxExpense1 decimals='INF' contextRef='Y17Q1' unitRef='USD'>-30334</fil:IncomeTaxExpense1>
	<fil:IncomeTaxExpense1 decimals='INF' contextRef='Y16Q1' unitRef='USD'>-22828</fil:IncomeTaxExpense1>
	<us-gaap:NetIncomeLoss decimals='INF' contextRef='Y17Q1' unitRef='USD'>-966898</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss decimals='INF' contextRef='Y16Q1' unitRef='USD'>-1552896</us-gaap:NetIncomeLoss>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax decimals='INF' contextRef='Y17Q1' unitRef='USD'>0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax decimals='INF' contextRef='Y16Q1' unitRef='USD'>480430</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax decimals='INF' contextRef='Y17Q1' unitRef='USD'>-966898</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax decimals='INF' contextRef='Y16Q1' unitRef='USD'>-1072466</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:EarningsPerShareBasicAndDiluted decimals='INF' contextRef='Y17Q1' unitRef='UsdPerShare'>-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted decimals='INF' contextRef='Y16Q1' unitRef='UsdPerShare'>-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted decimals='INF' contextRef='Y17Q1' unitRef='Shares'>43579557</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted decimals='INF' contextRef='Y16Q1' unitRef='Shares'>43579557</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:ProfitLoss decimals='INF' contextRef='Y17Q1' unitRef='USD'>-966898</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss decimals='INF' contextRef='Y16Q1' unitRef='USD'>-1552896</us-gaap:ProfitLoss>
	<us-gaap:DepreciationDepletionAndAmortization decimals='INF' contextRef='Y17Q1' unitRef='USD'>815394</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization decimals='INF' contextRef='Y16Q1' unitRef='USD'>857195</us-gaap:DepreciationDepletionAndAmortization>
	<fil:BadDebtExpense decimals='INF' contextRef='Y17Q1' unitRef='USD'>360063</fil:BadDebtExpense>
	<fil:BadDebtExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>581300</fil:BadDebtExpense>
	<us-gaap:IncreaseDecreaseInIncomeTaxes decimals='INF' contextRef='Y17Q1' unitRef='USD'>30334</us-gaap:IncreaseDecreaseInIncomeTaxes>
	<us-gaap:IncreaseDecreaseInIncomeTaxes decimals='INF' contextRef='Y16Q1' unitRef='USD'>22828</us-gaap:IncreaseDecreaseInIncomeTaxes>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables decimals='INF' contextRef='Y17Q1' unitRef='USD'>-261377</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables decimals='INF' contextRef='Y16Q1' unitRef='USD'>-61069</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
	<us-gaap:IncreaseDecreaseInDepositOtherAssets decimals='INF' contextRef='Y17Q1' unitRef='USD'>-17509</us-gaap:IncreaseDecreaseInDepositOtherAssets>
	<us-gaap:IncreaseDecreaseInDepositOtherAssets decimals='INF' contextRef='Y16Q1' unitRef='USD'>-92039</us-gaap:IncreaseDecreaseInDepositOtherAssets>
	<us-gaap:IncreaseDecreaseInInventories decimals='INF' contextRef='Y17Q1' unitRef='USD'>549500</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories decimals='INF' contextRef='Y16Q1' unitRef='USD'>215496</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInAccountsPayableTrade decimals='INF' contextRef='Y17Q1' unitRef='USD'>-206599</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
	<us-gaap:IncreaseDecreaseInAccountsPayableTrade decimals='INF' contextRef='Y16Q1' unitRef='USD'>888212</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
	<us-gaap:IncreaseDecreaseInAccruedTaxesPayable decimals='INF' contextRef='Y17Q1' unitRef='USD'>-71575</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedTaxesPayable decimals='INF' contextRef='Y16Q1' unitRef='USD'>-53955</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities decimals='INF' contextRef='Y17Q1' unitRef='USD'>-130772</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities decimals='INF' contextRef='Y16Q1' unitRef='USD'>25514</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInCustomerAdvances decimals='INF' contextRef='Y17Q1' unitRef='USD'>-113615</us-gaap:IncreaseDecreaseInCustomerAdvances>
	<us-gaap:IncreaseDecreaseInCustomerAdvances decimals='INF' contextRef='Y16Q1' unitRef='USD'>328354</us-gaap:IncreaseDecreaseInCustomerAdvances>
	<us-gaap:IncreaseDecreaseInPrepaidExpense decimals='INF' contextRef='Y17Q1' unitRef='USD'>22818</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInPrepaidExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>144262</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities decimals='INF' contextRef='Y17Q1' unitRef='USD'>9764</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities decimals='INF' contextRef='Y16Q1' unitRef='USD'>1303202</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment decimals='INF' contextRef='Y17Q1' unitRef='USD'>-26628</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment decimals='INF' contextRef='Y16Q1' unitRef='USD'>-39248</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities decimals='INF' contextRef='Y17Q1' unitRef='USD'>-26628</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities decimals='INF' contextRef='Y16Q1' unitRef='USD'>-39248</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:ProceedsFromConstructionLoansPayable decimals='INF' contextRef='Y17Q1' unitRef='USD'>-145176</us-gaap:ProceedsFromConstructionLoansPayable>
	<us-gaap:ProceedsFromConstructionLoansPayable decimals='INF' contextRef='Y16Q1' unitRef='USD'>-305835</us-gaap:ProceedsFromConstructionLoansPayable>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities decimals='INF' contextRef='Y17Q1' unitRef='USD'>-145176</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities decimals='INF' contextRef='Y16Q1' unitRef='USD'>-305835</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents decimals='INF' contextRef='Y17Q1' unitRef='USD'>19779</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents decimals='INF' contextRef='Y16Q1' unitRef='USD'>54898</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease decimals='INF' contextRef='Y17Q1' unitRef='USD'>-142261</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease decimals='INF' contextRef='Y16Q1' unitRef='USD'>1013017</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<fil:CashAndCashEquivalentsAtBeginningOfPeriod decimals='INF' contextRef='Y17Q1' unitRef='USD'>2665802</fil:CashAndCashEquivalentsAtBeginningOfPeriod>
	<fil:CashAndCashEquivalentsAtBeginningOfPeriod decimals='INF' contextRef='Y16Q1' unitRef='USD'>6248760</fil:CashAndCashEquivalentsAtBeginningOfPeriod>
	<fil:CashAndCashEquivalentsAtEndOfPeriod decimals='INF' contextRef='Y17Q1' unitRef='USD'>2523541</fil:CashAndCashEquivalentsAtEndOfPeriod>
	<fil:CashAndCashEquivalentsAtEndOfPeriod decimals='INF' contextRef='Y16Q1' unitRef='USD'>7261777</fil:CashAndCashEquivalentsAtEndOfPeriod>
	<us-gaap:InterestPaid decimals='INF' contextRef='Y17Q1' unitRef='USD'>138964</us-gaap:InterestPaid>
	<us-gaap:InterestPaid decimals='INF' contextRef='Y16Q1' unitRef='USD'>242309</us-gaap:InterestPaid>
	<fil:IssuanceOfBankerSAcceptances decimals='INF' contextRef='Y17Q1' unitRef='USD'>621753</fil:IssuanceOfBankerSAcceptances>
	<fil:IssuanceOfBankerSAcceptances decimals='INF' contextRef='Y16Q1' unitRef='USD'>0</fil:IssuanceOfBankerSAcceptances>
	<fil:AccountsReceivableCollectedWithBankerSAcceptances decimals='INF' contextRef='Y17Q1' unitRef='USD'>182499</fil:AccountsReceivableCollectedWithBankerSAcceptances>
	<fil:AccountsReceivableCollectedWithBankerSAcceptances decimals='INF' contextRef='Y16Q1' unitRef='USD'>517770</fil:AccountsReceivableCollectedWithBankerSAcceptances>
	<fil:InventoryPurchasedWithBankerSAcceptances decimals='INF' contextRef='Y17Q1' unitRef='USD'>167981</fil:InventoryPurchasedWithBankerSAcceptances>
	<fil:InventoryPurchasedWithBankerSAcceptances decimals='INF' contextRef='Y16Q1' unitRef='USD'>403081</fil:InventoryPurchasedWithBankerSAcceptances>
	<fil:PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited decimals='INF' contextRef='E17Q1' unitRef='Pure'>1.0000</fil:PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited>
	<fil:PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1 decimals='INF' contextRef='E17Q1' unitRef='Pure'>1.0000</fil:PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1>
	<fil:PercetageOfAcquiredByOnnyInHelpson decimals='INF' contextRef='E17Q1' unitRef='Pure'>1.0000</fil:PercetageOfAcquiredByOnnyInHelpson>
	<fil:BadDebtExpenseTotaled decimals='INF' contextRef='Y17Q1' unitRef='USD'>360063</fil:BadDebtExpenseTotaled>
	<fil:BadDebtExpenseTotaled decimals='INF' contextRef='Y16Q1' unitRef='USD'>581300</fil:BadDebtExpenseTotaled>
	<fil:TradeAccountsReceivableBalances decimals='INF' contextRef='Y17Q1' unitRef='USD'>0</fil:TradeAccountsReceivableBalances>
	<fil:TradeAccountsReceivableBalances decimals='INF' contextRef='Y16Q1' unitRef='USD'>0</fil:TradeAccountsReceivableBalances>
	<fil:RawMaterials decimals='INF' contextRef='E17Q1' unitRef='USD'>10796239</fil:RawMaterials>
	<fil:RawMaterials decimals='INF' contextRef='E16' unitRef='USD'>11562388</fil:RawMaterials>
	<fil:WorkInProcess decimals='INF' contextRef='E17Q1' unitRef='USD'>692827</fil:WorkInProcess>
	<fil:WorkInProcess decimals='INF' contextRef='E16' unitRef='USD'>360550</fil:WorkInProcess>
	<fil:FinishedGoods decimals='INF' contextRef='E17Q1' unitRef='USD'>1397514</fil:FinishedGoods>
	<fil:FinishedGoods decimals='INF' contextRef='E16' unitRef='USD'>1530641</fil:FinishedGoods>
	<fil:InventoryGross1 decimals='INF' contextRef='E17Q1' unitRef='USD'>12886580</fil:InventoryGross1>
	<fil:InventoryGross1 decimals='INF' contextRef='E16' unitRef='USD'>13453579</fil:InventoryGross1>
	<us-gaap:InventoryValuationReserves decimals='INF' contextRef='E17Q1' unitRef='USD'>-5900615</us-gaap:InventoryValuationReserves>
	<us-gaap:InventoryValuationReserves decimals='INF' contextRef='E16' unitRef='USD'>-6142640</us-gaap:InventoryValuationReserves>
	<fil:TotalInventory decimals='INF' contextRef='E17Q1' unitRef='USD'>6985965</fil:TotalInventory>
	<fil:TotalInventory decimals='INF' contextRef='E16' unitRef='USD'>7310939</fil:TotalInventory>
	<us-gaap:LandAndLandImprovements decimals='INF' contextRef='E17Q1' unitRef='USD'>408775</us-gaap:LandAndLandImprovements>
	<us-gaap:LandAndLandImprovements decimals='INF' contextRef='E16' unitRef='USD'>405645</us-gaap:LandAndLandImprovements>
	<us-gaap:BuildingsAndImprovementsGross decimals='INF' contextRef='E17Q1' unitRef='USD'>9492387</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:BuildingsAndImprovementsGross decimals='INF' contextRef='E16' unitRef='USD'>9419700</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:MachineryAndEquipmentGross decimals='INF' contextRef='E17Q1' unitRef='USD'>26379439</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:MachineryAndEquipmentGross decimals='INF' contextRef='E16' unitRef='USD'>26151029</us-gaap:MachineryAndEquipmentGross>
	<fil:MotorVehicle decimals='INF' contextRef='E17Q1' unitRef='USD'>312167</fil:MotorVehicle>
	<fil:MotorVehicle decimals='INF' contextRef='E16' unitRef='USD'>309777</fil:MotorVehicle>
	<fil:OfficeEquipment decimals='INF' contextRef='E17Q1' unitRef='USD'>184128</fil:OfficeEquipment>
	<fil:OfficeEquipment decimals='INF' contextRef='E16' unitRef='USD'>182718</fil:OfficeEquipment>
	<fil:Total decimals='INF' contextRef='E17Q1' unitRef='USD'>36776896</fil:Total>
	<fil:Total decimals='INF' contextRef='E16' unitRef='USD'>36468869</fil:Total>
	<fil:LessAccumulatedDepreciation decimals='INF' contextRef='E17Q1' unitRef='USD'>-12354523</fil:LessAccumulatedDepreciation>
	<fil:LessAccumulatedDepreciation decimals='INF' contextRef='E16' unitRef='USD'>-11501421</fil:LessAccumulatedDepreciation>
	<fil:PropertyAndEquipmentNet decimals='INF' contextRef='E17Q1' unitRef='USD'>24422373</fil:PropertyAndEquipmentNet>
	<fil:PropertyAndEquipmentNet decimals='INF' contextRef='E16' unitRef='USD'>24967448</fil:PropertyAndEquipmentNet>
	<fil:PermitOfLandUseMinimumLife decimals='INF' contextRef='E17Q1' unitRef='Pure'>40</fil:PermitOfLandUseMinimumLife>
	<fil:PermitOfLandUseMaximumLife decimals='INF' contextRef='E17Q1' unitRef='Pure'>70</fil:PermitOfLandUseMaximumLife>
	<fil:BuildingMinimumLife decimals='INF' contextRef='E17Q1' unitRef='Pure'>20</fil:BuildingMinimumLife>
	<fil:BuildingMaximumLife decimals='INF' contextRef='E17Q1' unitRef='Pure'>49</fil:BuildingMaximumLife>
	<fil:PlantMachineryAndEquipmentMinimumLife decimals='INF' contextRef='E17Q1' unitRef='Pure'>5</fil:PlantMachineryAndEquipmentMinimumLife>
	<fil:PlantMachineryAndEquipmentMaximumLife decimals='INF' contextRef='E17Q1' unitRef='Pure'>10</fil:PlantMachineryAndEquipmentMaximumLife>
	<fil:MotorVehicleMinimumLife decimals='INF' contextRef='E17Q1' unitRef='Pure'>5</fil:MotorVehicleMinimumLife>
	<fil:MotorVehicleMaximumLife decimals='INF' contextRef='E17Q1' unitRef='Pure'>10</fil:MotorVehicleMaximumLife>
	<fil:OfficeEquipmentMinimumLife decimals='INF' contextRef='E17Q1' unitRef='Pure'>3</fil:OfficeEquipmentMinimumLife>
	<fil:OfficeEquipmentMaximumLife decimals='INF' contextRef='E17Q1' unitRef='Pure'>5</fil:OfficeEquipmentMaximumLife>
	<fil:DepreciationExpensePropertyAndEquipment decimals='INF' contextRef='Y17Q1' unitRef='USD'>764614</fil:DepreciationExpensePropertyAndEquipment>
	<fil:DepreciationExpensePropertyAndEquipment decimals='INF' contextRef='Y16Q1' unitRef='USD'>790254</fil:DepreciationExpensePropertyAndEquipment>
	<fil:GrossCarryingAmount decimals='INF' contextRef='E17Q1' unitRef='USD'>4899281</fil:GrossCarryingAmount>
	<fil:GrossCarryingAmount decimals='INF' contextRef='E16' unitRef='USD'>4861766</fil:GrossCarryingAmount>
	<fil:AccumulatedAmortization decimals='INF' contextRef='E17Q1' unitRef='USD'>-4411237</fil:AccumulatedAmortization>
	<fil:AccumulatedAmortization decimals='INF' contextRef='E16' unitRef='USD'>-4327084</fil:AccumulatedAmortization>
	<fil:NetCarryingAmount decimals='INF' contextRef='E17Q1' unitRef='USD'>488044</fil:NetCarryingAmount>
	<fil:NetCarryingAmount decimals='INF' contextRef='E16' unitRef='USD'>534682</fil:NetCarryingAmount>
	<fil:AmortizationExpensesRelatingToIntangibleAssets decimals='INF' contextRef='Y17Q1' unitRef='USD'>50780</fil:AmortizationExpensesRelatingToIntangibleAssets>
	<fil:AmortizationExpensesRelatingToIntangibleAssets decimals='INF' contextRef='Y16Q1' unitRef='USD'>66941</fil:AmortizationExpensesRelatingToIntangibleAssets>
	<fil:CompanyWasObligatedToPayLaboratories decimals='INF' contextRef='E17Q1' unitRef='USD'>4400000</fil:CompanyWasObligatedToPayLaboratories>
	<fil:CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories decimals='INF' contextRef='E17Q1' unitRef='USD'>3962141</fil:CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories>
	<fil:AdavancesOwingToBoard decimals='INF' contextRef='E17Q1' unitRef='USD'>1354567</fil:AdavancesOwingToBoard>
	<fil:AdavancesOwingToBoard decimals='INF' contextRef='E16' unitRef='USD'>1354567</fil:AdavancesOwingToBoard>
	<fil:InterestRateOnAdvancesFromMemberOfBOD decimals='INF' contextRef='E17Q1' unitRef='Pure'>0.0100</fil:InterestRateOnAdvancesFromMemberOfBOD>
	<fil:InterestRateOnAdvancesFromMemberOfBOD decimals='INF' contextRef='E16' unitRef='Pure'>0.0100</fil:InterestRateOnAdvancesFromMemberOfBOD>
	<fil:TotalInterestExpenseRecognizedForThePeriod decimals='INF' contextRef='Y17Q1' unitRef='USD'>3386</fil:TotalInterestExpenseRecognizedForThePeriod>
	<fil:TotalInterestExpenseRecognizedForThePeriod decimals='INF' contextRef='Y16Q1' unitRef='USD'>3386</fil:TotalInterestExpenseRecognizedForThePeriod>
	<fil:MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes decimals='INF' contextRef='E17Q1' unitRef='USD'>4500000</fil:MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes>
	<fil:MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes decimals='INF' contextRef='E16' unitRef='USD'>4500000</fil:MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes>
	<fil:AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank decimals='INF' contextRef='E17Q1' unitRef='Pure'>0.0005</fil:AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank>
	<fil:AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank decimals='INF' contextRef='E16' unitRef='Pure'>0.0005</fil:AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank>
	<fil:CompanyHadOutstandingBankerSAcceptanceNotes decimals='INF' contextRef='E17Q1' unitRef='USD'>1718823</fil:CompanyHadOutstandingBankerSAcceptanceNotes>
	<fil:CompanyHadOutstandingBankerSAcceptanceNotes decimals='INF' contextRef='E16' unitRef='USD'>1088879</fil:CompanyHadOutstandingBankerSAcceptanceNotes>
	<fil:TotalLoanFacilityAmountRmb80000000 decimals='INF' contextRef='E17Q1' unitRef='USD'>13000000</fil:TotalLoanFacilityAmountRmb80000000>
	<fil:CompanyMadeAPrincipalPayment decimals='INF' contextRef='E17Q1' unitRef='USD'>145000</fil:CompanyMadeAPrincipalPayment>
	<fil:RemainingAnnualPrincipalPayment decimals='INF' contextRef='E17Q1' unitRef='USD'>1306000</fil:RemainingAnnualPrincipalPayment>
	<fil:PrincipalPayments2017 decimals='INF' contextRef='E17Q1' unitRef='USD'>1306140</fil:PrincipalPayments2017>
	<fil:PrincipalPayments2018 decimals='INF' contextRef='E17Q1' unitRef='USD'>2176901</fil:PrincipalPayments2018>
	<fil:PrincipalPayments2019 decimals='INF' contextRef='E17Q1' unitRef='USD'>2176901</fil:PrincipalPayments2019>
	<fil:PrincipalPayments2020 decimals='INF' contextRef='E17Q1' unitRef='USD'>2176901</fil:PrincipalPayments2020>
	<fil:PrincipalPayments2021 decimals='INF' contextRef='E17Q1' unitRef='USD'>2176901</fil:PrincipalPayments2021>
	<fil:TotalPrincipalPaymentsDue decimals='INF' contextRef='E17Q1' unitRef='USD'>10013744</fil:TotalPrincipalPaymentsDue>
	<fil:UndistributedEarningsOfHelpson decimals='INF' contextRef='E17Q1' unitRef='USD'>30500000</fil:UndistributedEarningsOfHelpson>
	<fil:InvestmentInHelpsonAForeignSubsidiaryForTheCompany decimals='INF' contextRef='E17Q1' unitRef='USD'>23300000</fil:InvestmentInHelpsonAForeignSubsidiaryForTheCompany>
	<fil:EnterpriseIncomeTaxRatesForTheYear2016 decimals='INF' contextRef='E17Q1' unitRef='Pure'>0.1500</fil:EnterpriseIncomeTaxRatesForTheYear2016>
	<fil:EnterpriseIncomeTaxRatesForTheYear2017 decimals='INF' contextRef='E17Q1' unitRef='Pure'>0.2500</fil:EnterpriseIncomeTaxRatesForTheYear2017>
	<fil:EnterpriseIncomeTaxRateThereafter decimals='INF' contextRef='E17Q1' unitRef='Pure'>0.2500</fil:EnterpriseIncomeTaxRateThereafter>
	<fil:NetOperatingLossCarryforwardsForPrcTaxPurposes1 decimals='INF' contextRef='E17Q1' unitRef='USD'>52200000</fil:NetOperatingLossCarryforwardsForPrcTaxPurposes1>
	<fil:NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1 decimals='INF' contextRef='E17Q1' unitRef='USD'>4600000</fil:NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1>
	<us-gaap:CurrentFederalTaxExpenseBenefit decimals='INF' contextRef='Y17Q1' unitRef='USD'>0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit decimals='INF' contextRef='Y17Q1' unitRef='USD'>30334</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit decimals='INF' contextRef='Y16Q1' unitRef='USD'>22828</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<fil:TotalIncomeTaxBenefitExpense decimals='INF' contextRef='Y17Q1' unitRef='USD'>30334</fil:TotalIncomeTaxBenefitExpense>
	<fil:TotalIncomeTaxBenefitExpense decimals='INF' contextRef='Y16Q1' unitRef='USD'>22828</fil:TotalIncomeTaxBenefitExpense>
	<fil:ValuationAllowanceAgainstDeferredTaxAssets decimals='INF' contextRef='E17Q1' unitRef='USD'>21963335</fil:ValuationAllowanceAgainstDeferredTaxAssets>
	<fil:ValuationAllowanceAgainstDeferredTaxAssets decimals='INF' contextRef='E16' unitRef='USD'>21452802</fil:ValuationAllowanceAgainstDeferredTaxAssets>
	<fil:BankersAcceptanceNotes decimals='INF' contextRef='E17Q1' unitRef='USD'>14513</fil:BankersAcceptanceNotes>
	<fil:Total1 decimals='INF' contextRef='E17Q1' unitRef='USD'>14513</fil:Total1>
	<fil:BankersAcceptanceNotesLevel1 decimals='INF' contextRef='E17Q1' unitRef='USD'>0</fil:BankersAcceptanceNotesLevel1>
	<fil:TotalLevel1 decimals='INF' contextRef='E17Q1' unitRef='USD'>0</fil:TotalLevel1>
	<fil:BankersAcceptanceNotesLevel2 decimals='INF' contextRef='E17Q1' unitRef='USD'>14513</fil:BankersAcceptanceNotesLevel2>
	<fil:TotalLevel2 decimals='INF' contextRef='E17Q1' unitRef='USD'>14513</fil:TotalLevel2>
	<fil:BankersAcceptanceNotesLevel3 decimals='INF' contextRef='E17Q1' unitRef='USD'>0</fil:BankersAcceptanceNotesLevel3>
	<fil:TotalLevel3 decimals='INF' contextRef='E17Q1' unitRef='USD'>0</fil:TotalLevel3>
	<fil:CommonSharesAuthorized decimals='INF' contextRef='E17Q1' unitRef='Shares'>95000000</fil:CommonSharesAuthorized>
	<fil:PreferredSharesAuthorized decimals='INF' contextRef='E17Q1' unitRef='Shares'>5000000</fil:PreferredSharesAuthorized>
	<fil:PreferredSharesParValue decimals='INF' contextRef='E17Q1' unitRef='UsdPerShare'>0.001</fil:PreferredSharesParValue>
	<fil:NumberOfCommonShares decimals='INF' contextRef='I101112' unitRef='Shares'>4000000</fil:NumberOfCommonShares>
	<fil:SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan decimals='INF' contextRef='E17Q1' unitRef='Shares'>175000</fil:SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan>
	<fil:FirstCustomerAccountedAccountsReceivable decimals='INF' contextRef='Y17Q1' unitRef='Pure'>0.4620</fil:FirstCustomerAccountedAccountsReceivable>
	<fil:FirstCustomerAccountedAccountsReceivable decimals='INF' contextRef='Y16Q1' unitRef='Pure'>0.2850</fil:FirstCustomerAccountedAccountsReceivable>
	<fil:SecondCustomerAccountedAccountsReceivable decimals='INF' contextRef='Y17Q1' unitRef='Pure'>0.1500</fil:SecondCustomerAccountedAccountsReceivable>
	<fil:SecondCustomerAccountedAccountsReceivable decimals='INF' contextRef='Y16Q1' unitRef='Pure'>0.1140</fil:SecondCustomerAccountedAccountsReceivable>
	<fil:ThirdCustomerAccountedAccountsReceivable decimals='INF' contextRef='Y16Q1' unitRef='Pure'>0.1100</fil:ThirdCustomerAccountedAccountsReceivable>
	<fil:FirstSupplierAccountedForRawMaterialPurchases decimals='INF' contextRef='Y17Q1' unitRef='Pure'>0.2370</fil:FirstSupplierAccountedForRawMaterialPurchases>
	<fil:SecondSupplierAccountedForRawMaterialPurchases decimals='INF' contextRef='Y17Q1' unitRef='Pure'>0.1730</fil:SecondSupplierAccountedForRawMaterialPurchases>
	<fil:ThirdSupplierAccountedForRawMaterialPurchases decimals='INF' contextRef='Y17Q1' unitRef='Pure'>0.1360</fil:ThirdSupplierAccountedForRawMaterialPurchases>
	<fil:FourthSupplierAccountedForRawMaterialPurchases decimals='INF' contextRef='Y17Q1' unitRef='Pure'>0.1270</fil:FourthSupplierAccountedForRawMaterialPurchases>
	<dei:DocumentType contextRef='Y17Q1'>10-Q</dei:DocumentType>
	<dei:DocumentPeriodEndDate contextRef='Y17Q1'>2017-03-31</dei:DocumentPeriodEndDate>
	<dei:AmendmentFlag contextRef='Y17Q1'>false</dei:AmendmentFlag>
	<dei:EntityRegistrantName contextRef='Y17Q1'>CHINA PHARMA HOLDINGS, INC.</dei:EntityRegistrantName>
	<dei:EntityCentralIndexKey contextRef='Y17Q1'>0001106644</dei:EntityCentralIndexKey>
	<dei:TradingSymbol contextRef='Y17Q1'>cphi</dei:TradingSymbol>
	<dei:CurrentFiscalYearEndDate contextRef='Y17Q1'>--12-31</dei:CurrentFiscalYearEndDate>
	<dei:EntityCommonStockSharesOutstanding decimals='INF' contextRef='I170510' unitRef='Shares'>43579557</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef='Y17Q1'>Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityCurrentReportingStatus contextRef='Y17Q1'>Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityVoluntaryFilers contextRef='Y17Q1'>No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef='Y17Q1'>No</dei:EntityWellKnownSeasonedIssuer>
	<dei:DocumentFiscalYearFocus contextRef='Y17Q1'>2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentFiscalPeriodFocus contextRef='Y17Q1'>Q1</dei:DocumentFiscalPeriodFocus>
	<context id='Y17Q1'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<startDate>2017-01-01</startDate>
			<endDate>2017-03-31</endDate>
		</period>
	</context>
	<context id='I170510'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2017-05-10</instant>
		</period>
	</context>
	<context id='E17Q1'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2017-03-31</instant>
		</period>
	</context>
	<context id='E16'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2016-12-31</instant>
		</period>
	</context>
	<context id='Y16Q1'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<startDate>2016-01-01</startDate>
			<endDate>2016-03-31</endDate>
		</period>
	</context>
	<context id='I101112'>
		<entity>
			<identifier scheme='http://www.sec.gov/CIK'>0001106644</identifier>
		</entity>
		<period>
			<instant>2010-11-12</instant>
		</period>
	</context>
	<unit id='Shares'>
		<measure>shares</measure>
	</unit>
	<unit id='USD'>
		<measure>iso4217:USD</measure>
	</unit>
	<unit id='UsdPerShare'>
		<divide>
			<unitNumerator>
				<measure>iso4217:USD</measure>
			</unitNumerator>
			<unitDenominator>
				<measure>shares</measure>
			</unitDenominator>
		</divide>
	</unit>
	<unit id='Pure'>
		<measure>pure</measure>
	</unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cphi-20170331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Vistalytics - iFile Suite version 6.233 -->
<schema xmlns:nonnum='http://www.xbrl.org/dtr/type/non-numeric' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:us-gaap='http://fasb.org/us-gaap/2016-01-31' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:dei='http://xbrl.sec.gov/dei/2014-01-31' xmlns:fil='http://www.chinapharmaholdings.com/20170331' targetNamespace='http://www.chinapharmaholdings.com/20170331' xmlns:num='http://www.xbrl.org/dtr/type/numeric' xmlns:link='http://www.xbrl.org/2003/linkbase' attributeFormDefault='unqualified' xmlns:xbrli='http://www.xbrl.org/2003/instance' elementFormDefault='qualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20170331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20170331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20170331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20170331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_BANKERSACCEPTANCENOTESPAYABLEDetails" id="idr_BANKERSACCEPTANCENOTESPAYABLEDetails">
				<link:definition>000370 - Statement - BANKER&apos;S ACCEPTANCE NOTES PAYABLE (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES" id="idr_DisclosureACCOUNTINGPOLICIESPOLICIES">
				<link:definition>000190 - Disclosure - ACCOUNTING POLICIES (POLICIES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINTANGIBLEASSETS" id="idr_DisclosureINTANGIBLEASSETS">
				<link:definition>000090 - Disclosure - INTANGIBLE ASSETS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICALS" id="idr_CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICALS">
				<link:definition>000030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS PARENTHETICALS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_TRADEACCOUNTSRECEIVABLEANDALLOWANCEFORDOUBTFULACCOUNTSDETAILS" id="idr_TRADEACCOUNTSRECEIVABLEANDALLOWANCEFORDOUBTFULACCOUNTSDETAILS">
				<link:definition>000270 - Statement - TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETS" id="idr_CONDENSEDCONSOLIDATEDBALANCESHEETS">
				<link:definition>000020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINTANGIBLEASSETSTABLES" id="idr_DisclosureINTANGIBLEASSETSTABLES">
				<link:definition>000220 - Disclosure - INTANGIBLE ASSETS (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINCOMETAXES" id="idr_DisclosureINCOMETAXES">
				<link:definition>000140 - Disclosure - INCOME TAXES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS" id="idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS">
				<link:definition>000100 - Disclosure - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" id="idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
				<link:definition>000050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS" id="idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS">
				<link:definition>000420 - Statement - DEFERRED INCOME TAX ASSETS AND LIABILITY (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS" id="idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS">
				<link:definition>000290 - Statement - PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES" id="idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES">
				<link:definition>000230 - Disclosure - SCHEDULE OF CONSTRUCTION LOAN FACILITY (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCONCENTRATIONS" id="idr_DisclosureCONCENTRATIONS">
				<link:definition>000180 - Disclosure - CONCENTRATIONS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES" id="idr_DisclosurePROPERTYANDEQUIPMENTTABLES">
				<link:definition>000210 - Disclosure - PROPERTY AND EQUIPMENT (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_STOCKOPTIONPLANDETAILS" id="idr_STOCKOPTIONPLANDETAILS">
				<link:definition>000450 - Statement - 2010 STOCK OPTION PLAN (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_INCOMETAXESUNDISTRIBUTEDEARNINGSANDINCOMRTAXRATESDETAILS" id="idr_INCOMETAXESUNDISTRIBUTEDEARNINGSANDINCOMRTAXRATESDETAILS">
				<link:definition>000400 - Statement - INCOME TAXES UNDISTRIBUTED EARNINGS AND INCOMR TAX RATES (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_RELATEDPARTYTRANSACTIONSOWINGSDETAILS" id="idr_RELATEDPARTYTRANSACTIONSOWINGSDETAILS">
				<link:definition>000350 - Statement - RELATED PARTY TRANSACTIONS OWINGS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINVENTORY" id="idr_DisclosureINVENTORY">
				<link:definition>000070 - Disclosure - INVENTORY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES" id="idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES">
				<link:definition>000250 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENTS (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureFAIRVALUEMEASUREMENTS" id="idr_DisclosureFAIRVALUEMEASUREMENTS">
				<link:definition>000150 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_AMORTIZATIONEXPENSEDETAILS" id="idr_AMORTIZATIONEXPENSEDETAILS">
				<link:definition>000330 - Statement - AMORTIZATION EXPENSE (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINVENTORYTABLES" id="idr_DisclosureINVENTORYTABLES">
				<link:definition>000200 - Disclosure - INVENTORY (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCONSTRUCTIONLOANFACILITY" id="idr_DisclosureCONSTRUCTIONLOANFACILITY">
				<link:definition>000130 - Disclosure - CONSTRUCTION LOAN FACILITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_INVENTORYCONSISTEDOFTHEFOLLOWINGDETAILS" id="idr_INVENTORYCONSISTEDOFTHEFOLLOWINGDETAILS">
				<link:definition>000280 - Statement - INVENTORY CONSISTED OF THE FOLLOWING (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" id="idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails">
				<link:definition>000260 - Statement - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosurePROPERTYANDEQUIPMENT" id="idr_DisclosurePROPERTYANDEQUIPMENT">
				<link:definition>000080 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_ASSETSDEPRECIATIONDETAILS" id="idr_ASSETSDEPRECIATIONDETAILS">
				<link:definition>000310 - Statement - ASSETS DEPRECIATION (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSTOCKHOLDERSEQUITY" id="idr_DisclosureSTOCKHOLDERSEQUITY">
				<link:definition>000160 - Disclosure - STOCKHOLDERS&apos; EQUITY</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS" id="idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS">
				<link:definition>000340 - Statement - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE" id="idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE">
				<link:definition>000120 - Disclosure - BANKER&apos;S ACCEPTANCE NOTES PAYABLE</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINCOMETAXESTABLES" id="idr_DisclosureINCOMETAXESTABLES">
				<link:definition>000240 - Disclosure - INCOME TAXES (TABLES)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_RELATEDPARTYTRANSACTIONSMEMBEROFBODDETAILS" id="idr_RELATEDPARTYTRANSACTIONSMEMBEROFBODDETAILS">
				<link:definition>000360 - Statement - RELATED PARTY TRANSACTIONS MEMBER OF BOD (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS" id="idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS">
				<link:definition>000320 - Statement - INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS" id="idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS">
				<link:definition>000430 - Statement - FAIR VALUE MEASUREMENTS AT REPORTING DATE USING (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES" id="idr_DisclosureCOMMITMENTSANDCONTINGENCIES">
				<link:definition>000170 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureRELATEDPARTYTRANSACTIONS" id="idr_DisclosureRELATEDPARTYTRANSACTIONS">
				<link:definition>000110 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS" id="idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS">
				<link:definition>000390 - Statement - PRINCIPAL PAYMENTS REQUIRED FOR THE NEXT FIVE YEARS ARE AS FOLLOWS: (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" id="idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
				<link:definition>000060 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONSTRUCTIONLOANFACILITYDETAILS" id="idr_CONSTRUCTIONLOANFACILITYDETAILS">
				<link:definition>000380 - Statement - CONSTRUCTION LOAN FACILITY (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" id="idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited">
				<link:definition>000040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_INCOMETAXESPROVISIONDETAILS" id="idr_INCOMETAXESPROVISIONDETAILS">
				<link:definition>000410 - Statement - INCOME TAXES PROVISION (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONCENTRATIONSDETAILS" id="idr_CONCENTRATIONSDETAILS">
				<link:definition>000450 - Statement - CONCENTRATIONS (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_PROPERTYANDEQUIPMENTASSETSLIFEDETAILS" id="idr_PROPERTYANDEQUIPMENTASSETSLIFEDETAILS">
				<link:definition>000300 - Statement - PROPERTY AND EQUIPMENT ASSETS LIFE (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_PREFERREDCOMMONSTOCKDETAILS" id="idr_PREFERREDCOMMONSTOCKDETAILS">
				<link:definition>000440 - Statement - PREFERRED COMMON STOCK (DETAILS)</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/numeric'/>
	<import schemaLocation='http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd' namespace='http://www.xbrl.org/dtr/type/non-numeric'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import namespace='http://fasb.org/us-gaap/2016-01-31' schemaLocation='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd' />
	<import namespace='http://xbrl.sec.gov/dei/2014-01-31' schemaLocation='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DocumentAndEntityInformationAbstract' name='DocumentAndEntityInformationAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AdvancesToSuppliers' name='AdvancesToSuppliers' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' name='AllowanceForDoubtfulAccountsOnOtherReceivables' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_InventoryPurchasedWithBankerSAcceptances' name='InventoryPurchasedWithBankerSAcceptances' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_AccountsReceivableCollectedWithBankerSAcceptances' name='AccountsReceivableCollectedWithBankerSAcceptances' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' name='AdvancesForPurchasesOfIntangibleAssetsAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' name='AdvancesForPurchasesOfIntangibleAssetsTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_InventoryTablesAbstract' name='InventoryTablesAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PropertyAndEquipmentTablesAbstract' name='PropertyAndEquipmentTablesAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_UsefulLivesOfTheAssetsTableTextBlock' name='UsefulLivesOfTheAssetsTableTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IntangibleAssetsTablesAbstract' name='IntangibleAssetsTablesAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IntangibleAssetsMedicalFormulasTablesTextBlock' name='IntangibleAssetsMedicalFormulasTablesTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IncomeTaxesTablesAbstract' name='IncomeTaxesTablesAbstract' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PercetageOfAcquiredByOnnyInHelpson' name='PercetageOfAcquiredByOnnyInHelpson' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_OfficeEquipmentMaximumLife' name='OfficeEquipmentMaximumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_MotorVehicleMaximumLife' name='MotorVehicleMaximumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_BuildingMaximumLife' name='BuildingMaximumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PermitOfLandUseMaximumLife' name='PermitOfLandUseMaximumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_OfficeEquipmentMinimumLife' name='OfficeEquipmentMinimumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_MotorVehicleMinimumLife' name='MotorVehicleMinimumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_BuildingMinimumLife' name='BuildingMinimumLife' />
	<element nillable='true' type='xbrli:pureItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PermitOfLandUseMinimumLife' name='PermitOfLandUseMinimumLife' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_GrossCarryingAmount' name='GrossCarryingAmount' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_NetCarryingAmount' name='NetCarryingAmount' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_CommonSharesAuthorized' name='CommonSharesAuthorized' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PreferredSharesAuthorized' name='PreferredSharesAuthorized' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_NumberOfCommonShares' name='NumberOfCommonShares' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_InterestRateOnAdvancesFromMemberOfBOD' name='InterestRateOnAdvancesFromMemberOfBOD' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' name='PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CashAndCashEquivalentsAtBeginningOfPeriod' name='CashAndCashEquivalentsAtBeginningOfPeriod' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_CashAndCashEquivalentsAtEndOfPeriod' name='CashAndCashEquivalentsAtEndOfPeriod' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DebtAbstract' name='DebtAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AdvancesForPurchasesOfIntangibleAssets' name='AdvancesForPurchasesOfIntangibleAssets' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' name='PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' name='AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ConstructionLoanFacilityDetailsAbstract' name='ConstructionLoanFacilityDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_CommitmentAndContingenciesAbstract' name='CommitmentAndContingenciesAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleOfLongTermDebtInstrumentsAbstract' name='ScheduleOfLongTermDebtInstrumentsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2017' name='PrincipalPayments2017' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2018' name='PrincipalPayments2018' />
	<element nillable='true' type='xbrli:sharesItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' name='SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PlantMachineryAndEquipmentMaximumLife' name='PlantMachineryAndEquipmentMaximumLife' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_PrincipalPayments2019' name='PrincipalPayments2019' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='credit' id='fil_TotalPrincipalPaymentsDue' name='TotalPrincipalPaymentsDue' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ConcentrationsDetailsAbstract' name='ConcentrationsDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AccumulatedAmortization' name='AccumulatedAmortization' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TotalLoanFacilityAmountRmb80000000' name='TotalLoanFacilityAmountRmb80000000' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' name='PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' />
	<element nillable='true' type='xbrli:decimalItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PlantMachineryAndEquipmentMinimumLife' name='PlantMachineryAndEquipmentMinimumLife' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' name='OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AccountingPoliciesAbstract1' name='AccountingPoliciesAbstract1' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' name='AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_BadDebtExpense' name='BadDebtExpense' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_AmortizationExpensesRelatingToIntangibleAssets' name='AmortizationExpensesRelatingToIntangibleAssets' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2020' name='PrincipalPayments2020' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PrincipalPayments2021' name='PrincipalPayments2021' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EnterpriseIncomeTaxRateThereafter' name='EnterpriseIncomeTaxRateThereafter' />
	<element nillable='true' type='num:perShareItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_PreferredSharesParValue' name='PreferredSharesParValue' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_InterestRateRiskPolicyTextBlock' name='InterestRateRiskPolicyTextBlock' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' name='ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_BankersAcceptanceNotesPayable' name='BankersAcceptanceNotesPayable' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_IssuanceOfBankerSAcceptances' name='IssuanceOfBankerSAcceptances' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BankerSAcceptanceNotesPayableAbstract' name='BankerSAcceptanceNotesPayableAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BankerSAcceptanceNotesPayableTextBlock' name='BankerSAcceptanceNotesPayableTextBlock' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' name='OrganizationAndSignificantAccountingPoliciesDetailsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_BankerSAcceptanceNotesPayableDetailsAbstract' name='BankerSAcceptanceNotesPayableDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1' name='TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_FairValueMeasuresAndDisclosuresAbstract' name='FairValueMeasuresAndDisclosuresAbstract' />
	<element nillable='true' type='nonnum:textBlockItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_RestrictedCashTextBlock' name='RestrictedCashTextBlock' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_IncomeTaxExpense1' name='IncomeTaxExpense1' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_FairValueMeasurementsAbstract' name='FairValueMeasurementsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' name='TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_BadDebtExpenseTotaled' name='BadDebtExpenseTotaled' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_TradeAccountsReceivableBalances' name='TradeAccountsReceivableBalances' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_InventoryConsistedOfTheFollowingDetailsAbstract' name='InventoryConsistedOfTheFollowingDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TotalInventory' name='TotalInventory' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_WorkInProcess' name='WorkInProcess' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_FinishedGoods' name='FinishedGoods' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_InventoryGross1' name='InventoryGross1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_RawMaterials' name='RawMaterials' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' name='PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_MotorVehicle' name='MotorVehicle' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_OfficeEquipment' name='OfficeEquipment' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_Total' name='Total' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_LessAccumulatedDepreciation' name='LessAccumulatedDepreciation' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_PropertyAndEquipmentNet' name='PropertyAndEquipmentNet' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PropertyAndEquipmentAssetsLifeAbstract' name='PropertyAndEquipmentAssetsLifeAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AssetsDepreciationDetailsAbstract' name='AssetsDepreciationDetailsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_DepreciationExpensePropertyAndEquipment' name='DepreciationExpensePropertyAndEquipment' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract' name='IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_AmortizationExpenseAbstract' name='AmortizationExpenseAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_CompanyWasObligatedToPayLaboratories' name='CompanyWasObligatedToPayLaboratories' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories' name='CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_RelatedPartyTransactionsOwingsAbstract' name='RelatedPartyTransactionsOwingsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_AdavancesOwingToBoard' name='AdavancesOwingToBoard' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_RelatedPartyTransactionsMemberOfBod1Abstract' name='RelatedPartyTransactionsMemberOfBod1Abstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_TotalInterestExpenseRecognizedForThePeriod' name='TotalInterestExpenseRecognizedForThePeriod' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes' name='MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank' name='AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_CompanyHadOutstandingBankerSAcceptanceNotes' name='CompanyHadOutstandingBankerSAcceptanceNotes' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_CompanyMadeAPrincipalPayment' name='CompanyMadeAPrincipalPayment' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_RemainingAnnualPrincipalPayment' name='RemainingAnnualPrincipalPayment' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IncomeTaxesUndistributedEarningsAbstract' name='IncomeTaxesUndistributedEarningsAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_UndistributedEarningsOfHelpson' name='UndistributedEarningsOfHelpson' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' name='InvestmentInHelpsonAForeignSubsidiaryForTheCompany' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EnterpriseIncomeTaxRatesForTheYear2016' name='EnterpriseIncomeTaxRatesForTheYear2016' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' id='fil_EnterpriseIncomeTaxRatesForTheYear2017' name='EnterpriseIncomeTaxRatesForTheYear2017' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1' name='NetOperatingLossCarryforwardsForPrcTaxPurposes1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1' name='NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_IncomeTaxesProvisionAbstract' name='IncomeTaxesProvisionAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' xbrli:balance='debit' id='fil_TotalIncomeTaxBenefitExpense' name='TotalIncomeTaxBenefitExpense' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_DeferredIncomeTaxAssetsAndLiabilityAbstract' name='DeferredIncomeTaxAssetsAndLiabilityAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_ValuationAllowanceAgainstDeferredTaxAssets' name='ValuationAllowanceAgainstDeferredTaxAssets' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_FairValueMeasurementsAtReportingDateUsingAbstract' name='FairValueMeasurementsAtReportingDateUsingAbstract' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_BankersAcceptanceNotes' name='BankersAcceptanceNotes' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_Total1' name='Total1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_BankersAcceptanceNotesLevel1' name='BankersAcceptanceNotesLevel1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TotalLevel1' name='TotalLevel1' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_BankersAcceptanceNotesLevel2' name='BankersAcceptanceNotesLevel2' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TotalLevel2' name='TotalLevel2' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_BankersAcceptanceNotesLevel3' name='BankersAcceptanceNotesLevel3' />
	<element nillable='true' type='xbrli:monetaryItemType' substitutionGroup='xbrli:item' xbrli:periodType='instant' xbrli:balance='debit' id='fil_TotalLevel3' name='TotalLevel3' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_PreferredCommonStockAndWarrantsAbstract' name='PreferredCommonStockAndWarrantsAbstract' />
	<element abstract='true' nillable='true' type='xbrli:stringItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_StockholdersEquity2010StockOptionPlanAbstract' name='StockholdersEquity2010StockOptionPlanAbstract' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_FirstCustomerAccountedAccountsReceivable' name='FirstCustomerAccountedAccountsReceivable' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_SecondCustomerAccountedAccountsReceivable' name='SecondCustomerAccountedAccountsReceivable' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ThirdCustomerAccountedAccountsReceivable' name='ThirdCustomerAccountedAccountsReceivable' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_FirstSupplierAccountedForRawMaterialPurchases' name='FirstSupplierAccountedForRawMaterialPurchases' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_SecondSupplierAccountedForRawMaterialPurchases' name='SecondSupplierAccountedForRawMaterialPurchases' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_ThirdSupplierAccountedForRawMaterialPurchases' name='ThirdSupplierAccountedForRawMaterialPurchases' />
	<element nillable='true' type='num:percentItemType' substitutionGroup='xbrli:item' xbrli:periodType='duration' id='fil_FourthSupplierAccountedForRawMaterialPurchases' name='FourthSupplierAccountedForRawMaterialPurchases' />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cphi-20170331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Vistalytics - iFile Suite version 6.233 -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20170331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssets' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='2.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='3.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_Assets' xlink:to='us-gaap_AssetsCurrent' use='optional' order='4.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_Liabilities' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='us-gaap_StockholdersEquity' use='optional' order='2.0' weight='1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_Revenues' use='optional' order='1.0' weight='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue' xlink:label='us-gaap_CostOfRevenue'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_GrossProfit' xlink:to='us-gaap_CostOfRevenue' use='optional' order='2.0' weight='-1.0'/>
	</link:calculationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
	<link:calculationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConstructionLoansPayable' xlink:label='us-gaap_ProceedsFromConstructionLoansPayable'/>
		<link:calculationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/summation-item' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='us-gaap_ProceedsFromConstructionLoansPayable' use='optional' order='1.0' weight='1.0'/>
	</link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cphi-20170331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Vistalytics - iFile Suite version 6.233 -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20170331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DocumentDocumentAndEntityInformation"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICALS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICALS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICALS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINVENTORY" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureINVENTORY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINVENTORY"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosurePROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosurePROPERTYANDEQUIPMENT"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosurePROPERTYANDEQUIPMENT"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureINTANGIBLEASSETS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINTANGIBLEASSETS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureRELATEDPARTYTRANSACTIONS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureRELATEDPARTYTRANSACTIONS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCONSTRUCTIONLOANFACILITY" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureCONSTRUCTIONLOANFACILITY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCONSTRUCTIONLOANFACILITY"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINCOMETAXES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureINCOMETAXES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINCOMETAXES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureFAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureFAIRVALUEMEASUREMENTS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureFAIRVALUEMEASUREMENTS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureSTOCKHOLDERSEQUITY"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSTOCKHOLDERSEQUITY"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureCOMMITMENTSANDCONTINGENCIES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCONCENTRATIONS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureCONCENTRATIONS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCONCENTRATIONS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureACCOUNTINGPOLICIESPOLICIES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINVENTORYTABLES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureINVENTORYTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINVENTORYTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosurePROPERTYANDEQUIPMENTTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINTANGIBLEASSETSTABLES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureINTANGIBLEASSETSTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINTANGIBLEASSETSTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINCOMETAXESTABLES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureINCOMETAXESTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINCOMETAXESTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_TRADEACCOUNTSRECEIVABLEANDALLOWANCEFORDOUBTFULACCOUNTSDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_TRADEACCOUNTSRECEIVABLEANDALLOWANCEFORDOUBTFULACCOUNTSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_TRADEACCOUNTSRECEIVABLEANDALLOWANCEFORDOUBTFULACCOUNTSDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_INVENTORYCONSISTEDOFTHEFOLLOWINGDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_INVENTORYCONSISTEDOFTHEFOLLOWINGDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_INVENTORYCONSISTEDOFTHEFOLLOWINGDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_PROPERTYANDEQUIPMENTASSETSLIFEDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_PROPERTYANDEQUIPMENTASSETSLIFEDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_PROPERTYANDEQUIPMENTASSETSLIFEDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_ASSETSDEPRECIATIONDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_ASSETSDEPRECIATIONDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_ASSETSDEPRECIATIONDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_AMORTIZATIONEXPENSEDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_AMORTIZATIONEXPENSEDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_AMORTIZATIONEXPENSEDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_RELATEDPARTYTRANSACTIONSOWINGSDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_RELATEDPARTYTRANSACTIONSOWINGSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_RELATEDPARTYTRANSACTIONSOWINGSDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_RELATEDPARTYTRANSACTIONSMEMBEROFBODDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_RELATEDPARTYTRANSACTIONSMEMBEROFBODDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_RELATEDPARTYTRANSACTIONSMEMBEROFBODDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_BANKERSACCEPTANCENOTESPAYABLEDetails" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_BANKERSACCEPTANCENOTESPAYABLEDetails"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_BANKERSACCEPTANCENOTESPAYABLEDetails"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONSTRUCTIONLOANFACILITYDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONSTRUCTIONLOANFACILITYDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONSTRUCTIONLOANFACILITYDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_INCOMETAXESUNDISTRIBUTEDEARNINGSANDINCOMRTAXRATESDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_INCOMETAXESUNDISTRIBUTEDEARNINGSANDINCOMRTAXRATESDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_INCOMETAXESUNDISTRIBUTEDEARNINGSANDINCOMRTAXRATESDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_INCOMETAXESPROVISIONDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_INCOMETAXESPROVISIONDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_INCOMETAXESPROVISIONDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_PREFERREDCOMMONSTOCKDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_PREFERREDCOMMONSTOCKDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_PREFERREDCOMMONSTOCKDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_STOCKOPTIONPLANDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_STOCKOPTIONPLANDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_STOCKOPTIONPLANDETAILS"/>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONCENTRATIONSDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONCENTRATIONSDETAILS"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONCENTRATIONSDETAILS"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cphi-20170331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Vistalytics - iFile Suite version 6.233 -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20170331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FourthSupplierAccountedForRawMaterialPurchases' xlink:label='fil_FourthSupplierAccountedForRawMaterialPurchases'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FourthSupplierAccountedForRawMaterialPurchases' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fourth Supplier accounted for raw material purchases</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_FourthSupplierAccountedForRawMaterialPurchases' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Fourth Supplier accounted for raw material purchases</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FourthSupplierAccountedForRawMaterialPurchases' xlink:to='lab_fil_FourthSupplierAccountedForRawMaterialPurchases'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalLevel3' xlink:label='fil_TotalLevel3'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel3' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Level 3</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel3' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total Level 3</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalLevel3' xlink:to='lab_fil_TotalLevel3'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PrincipalPayments2017' xlink:label='fil_PrincipalPayments2017'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2017' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2017</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2017' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the total principal payments made during the annual reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2017' xlink:to='lab_fil_PrincipalPayments2017'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_GrossCarryingAmount' xlink:label='fil_GrossCarryingAmount'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross carrying amount</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_GrossCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Gross carrying amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_GrossCarryingAmount' xlink:to='lab_fil_GrossCarryingAmount'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' xlink:label='fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' xlink:to='lab_fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryValuationReserves' xlink:label='us-gaap_InventoryValuationReserves'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryValuationReserves' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Obsolescence reserve</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryValuationReserves' xlink:to='lab_us-gaap_InventoryValuationReserves'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InventoryTablesAbstract' xlink:label='fil_InventoryTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY (TABLES)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryTablesAbstract' xlink:to='lab_fil_InventoryTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Purchases of property and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:to='lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:label='us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued taxes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders&apos; Equity:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='lab_us-gaap_StockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Current Liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrent' xlink:to='lab_us-gaap_LiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ThirdCustomerAccountedAccountsReceivable' xlink:label='fil_ThirdCustomerAccountedAccountsReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ThirdCustomerAccountedAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Third Customer accounted accounts receivable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ThirdCustomerAccountedAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Third Customer accounted accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ThirdCustomerAccountedAccountsReceivable' xlink:to='lab_fil_ThirdCustomerAccountedAccountsReceivable'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IncomeTaxesUndistributedEarningsAbstract' xlink:label='fil_IncomeTaxesUndistributedEarningsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxesUndistributedEarningsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income Taxes Undistributed Earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncomeTaxesUndistributedEarningsAbstract' xlink:to='lab_fil_IncomeTaxesUndistributedEarningsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AccumulatedAmortization' xlink:label='fil_AccumulatedAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated amortization</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccumulatedAmortization' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Accumulated amortization on long-term land leases capitalized as part of real property.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccumulatedAmortization' xlink:to='lab_fil_AccumulatedAmortization'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AssetsDepreciationDetailsAbstract' xlink:label='fil_AssetsDepreciationDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AssetsDepreciationDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Assets Depreciation Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AssetsDepreciationDetailsAbstract' xlink:to='lab_fil_AssetsDepreciationDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BadDebtExpenseTotaled' xlink:label='fil_BadDebtExpenseTotaled'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpenseTotaled' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bad debt expense totaled</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpenseTotaled' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bad debt expense totaled</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BadDebtExpenseTotaled' xlink:to='lab_fil_BadDebtExpenseTotaled'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IncomeTaxesTablesAbstract' xlink:label='fil_IncomeTaxesTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxesTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='lab_fil_IncomeTaxesTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock' xlink:label='us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerSharePolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic and Diluted (Loss) Earnings per Common Share</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerSharePolicyTextBlock' xlink:to='lab_us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract' xlink:label='us-gaap_EquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EquityAbstract' xlink:to='lab_us-gaap_EquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:label='fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounts receivable collected with banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Accounts receivable collected with banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:to='lab_fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:label='fil_CashAndCashEquivalentsAtBeginningOfPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and Cash Equivalents at Beginning of Period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:to='lab_fil_CashAndCashEquivalentsAtBeginningOfPeriod'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProvisionForDoubtfulAccounts' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bad debt expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProvisionForDoubtfulAccounts' xlink:to='lab_us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Fiscal Year End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ThirdSupplierAccountedForRawMaterialPurchases' xlink:label='fil_ThirdSupplierAccountedForRawMaterialPurchases'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ThirdSupplierAccountedForRawMaterialPurchases' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Third Supplier accounted for raw material purchases</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ThirdSupplierAccountedForRawMaterialPurchases' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Third Supplier accounted for raw material purchases</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ThirdSupplierAccountedForRawMaterialPurchases' xlink:to='lab_fil_ThirdSupplierAccountedForRawMaterialPurchases'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankersAcceptanceNotesLevel2' xlink:label='fil_BankersAcceptanceNotesLevel2'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel2' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptance notes Level 2</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel2' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 2</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotesLevel2' xlink:to='lab_fil_BankersAcceptanceNotesLevel2'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2017' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2017'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesForTheYear2017' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rates for the year 2017</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesForTheYear2017' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rates for the year 2017</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRatesForTheYear2017' xlink:to='lab_fil_EnterpriseIncomeTaxRatesForTheYear2017'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ConstructionLoanFacilityDetailsAbstract' xlink:label='fil_ConstructionLoanFacilityDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConstructionLoanFacilityDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Construction loan facility details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConstructionLoanFacilityDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>ConstructionLoanFacilityDetailsAbstract [Abstract]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='lab_fil_ConstructionLoanFacilityDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdavancesOwingToBoard' xlink:label='fil_AdavancesOwingToBoard'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdavancesOwingToBoard' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Adavances owing to board</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdavancesOwingToBoard' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Adavances owing to board</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdavancesOwingToBoard' xlink:to='lab_fil_AdavancesOwingToBoard'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_MotorVehicleMinimumLife' xlink:label='fil_MotorVehicleMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Motor vehicle minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MotorVehicleMinimumLife' xlink:to='lab_fil_MotorVehicleMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FinishedGoods' xlink:label='fil_FinishedGoods'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FinishedGoods' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Finished goods</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_FinishedGoods' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FinishedGoods' xlink:to='lab_fil_FinishedGoods'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:label='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='lab_fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory consists</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations' xlink:label='us-gaap_NatureOfOperations'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NatureOfOperations' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Organization and Nature of Operations</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NatureOfOperations' xlink:to='lab_us-gaap_NatureOfOperations'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The entire disclosure of advances for purchases of intangible assets.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:to='lab_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>PROPERTY AND EQUIPMENT</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:label='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Supplemental Noncash Investing and Financing Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BadDebtExpense' xlink:label='fil_BadDebtExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bad debt expense {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Bad debt expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BadDebtExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BadDebtExpense' xlink:to='lab_fil_BadDebtExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Comprehensive loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total operating expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpenses' xlink:to='lab_us-gaap_OperatingExpenses'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' xlink:label='us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accumulated other comprehensive income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' xlink:to='lab_us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital' xlink:label='us-gaap_AdditionalPaidInCapital'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AdditionalPaidInCapital' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Additional paid-in capital</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AdditionalPaidInCapital' xlink:to='lab_us-gaap_AdditionalPaidInCapital'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' xlink:label='us-gaap_LongtermConstructionLoanCurrentAndNoncurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Construction loan facility</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' xlink:to='lab_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccruedLiabilitiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccruedLiabilitiesCurrent' xlink:to='lab_us-gaap_AccruedLiabilitiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>TOTAL ASSETS</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Assets' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>TOTAL ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Assets' xlink:to='lab_us-gaap_Assets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Current Reporting Status</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_NumberOfCommonShares' xlink:label='fil_NumberOfCommonShares'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonShares' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common shares</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NumberOfCommonShares' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum number of common shares permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NumberOfCommonShares' xlink:to='lab_fil_NumberOfCommonShares'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PreferredSharesParValue' xlink:label='fil_PreferredSharesParValue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesParValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred shares par value</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesParValue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PreferredSharesParValue' xlink:to='lab_fil_PreferredSharesParValue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_DeferredIncomeTaxAssetsAndLiabilityAbstract' xlink:label='fil_DeferredIncomeTaxAssetsAndLiabilityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DeferredIncomeTaxAssetsAndLiabilityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred Income Tax Assets And Liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DeferredIncomeTaxAssetsAndLiabilityAbstract' xlink:to='lab_fil_DeferredIncomeTaxAssetsAndLiabilityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PrincipalPayments2019' xlink:label='fil_PrincipalPayments2019'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2019' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2019</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2019' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Principal amount paid by the company in 2019</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2019' xlink:to='lab_fil_PrincipalPayments2019'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CompanyHadOutstandingBankerSAcceptanceNotes' xlink:label='fil_CompanyHadOutstandingBankerSAcceptanceNotes'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyHadOutstandingBankerSAcceptanceNotes' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company had outstanding Banker&apos;s Acceptance Notes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyHadOutstandingBankerSAcceptanceNotes' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company had outstanding Banker&apos;s Acceptance Notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyHadOutstandingBankerSAcceptanceNotes' xlink:to='lab_fil_CompanyHadOutstandingBankerSAcceptanceNotes'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_LessAccumulatedDepreciation' xlink:label='fil_LessAccumulatedDepreciation'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_LessAccumulatedDepreciation' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Less: accumulated depreciation</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_LessAccumulatedDepreciation' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Less: accumulated depreciation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_LessAccumulatedDepreciation' xlink:to='lab_fil_LessAccumulatedDepreciation'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock' xlink:label='us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company held the following assets and liabilities recorded at fair value as of December 31, 2016</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock' xlink:to='lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:label='fil_IntangibleAssetsMedicalFormulasTablesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible Assets Medical Formulas</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabluar disclosure of Intangible Assets Medical Formulas</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:to='lab_fil_IntangibleAssetsMedicalFormulasTablesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:label='us-gaap_ResearchAndDevelopmentExpensePolicy'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research and Development</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpensePolicy'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:label='us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>STOCKHOLDERS&apos; EQUITY {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:to='lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:label='us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>RELATED PARTY TRANSACTIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:to='lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryGross' xlink:label='us-gaap_InventoryGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory Gross</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryGross' xlink:to='lab_us-gaap_InventoryGross'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryRawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Raw materials</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryRawMaterials' xlink:to='lab_us-gaap_InventoryRawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SupplementalCashFlowInformationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Supplemental Cash Flow Information:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='lab_us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts payable {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Trade accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInDepositOtherAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances to suppliers {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Advances to suppliers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:to='lab_us-gaap_IncreaseDecreaseInDepositOtherAssets'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract' xlink:label='us-gaap_EarningsPerShareAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Loss per share:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='lab_us-gaap_EarningsPerShareAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other comprehensive income - foreign currency translation adjustment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:to='lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IncomeTaxExpense1' xlink:label='fil_IncomeTaxExpense1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxExpense1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income tax expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxExpense1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited) For the Three Months ended March 31, 2017 For the Three Months ended March 31, 2016 Revenues Revenue 32,85,203 36,40,494 Cost of revenue 25,67,350 29,99,675 Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncomeTaxExpense1' xlink:to='lab_fil_IncomeTaxExpense1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GeneralAndAdministrativeExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>General and administrative expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GeneralAndAdministrativeExpense' xlink:to='lab_us-gaap_GeneralAndAdministrativeExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding' xlink:label='us-gaap_PreferredStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesOutstanding' xlink:to='lab_us-gaap_PreferredStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_SecondSupplierAccountedForRawMaterialPurchases' xlink:label='fil_SecondSupplierAccountedForRawMaterialPurchases'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SecondSupplierAccountedForRawMaterialPurchases' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Second Supplier accounted for raw material purchases</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SecondSupplierAccountedForRawMaterialPurchases' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Second Supplier accounted for raw material purchases</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SecondSupplierAccountedForRawMaterialPurchases' xlink:to='lab_fil_SecondSupplierAccountedForRawMaterialPurchases'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_Total1' xlink:label='fil_Total1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Total1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Total1' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Total</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Total1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Total1' xlink:to='lab_fil_Total1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CompanyWasObligatedToPayLaboratories' xlink:label='fil_CompanyWasObligatedToPayLaboratories'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyWasObligatedToPayLaboratories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company was obligated to pay laboratories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyWasObligatedToPayLaboratories' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company was obligated to pay laboratories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyWasObligatedToPayLaboratories' xlink:to='lab_fil_CompanyWasObligatedToPayLaboratories'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BuildingMaximumLife' xlink:label='fil_BuildingMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Building maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BuildingMaximumLife' xlink:to='lab_fil_BuildingMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:label='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Helpson Medical &amp; Biotechnology Co., Ltd.</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:to='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock' xlink:label='us-gaap_ScheduleOfDebtInstrumentsTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Principal payments required for the next five years as of December 31, 2015</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfDebtInstrumentsTextBlock' xlink:to='lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment consists</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Recent Accounting Pronouncements</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:to='lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates' xlink:label='us-gaap_UseOfEstimates'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_UseOfEstimates' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounting Estimates</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_UseOfEstimates' xlink:to='lab_us-gaap_UseOfEstimates'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:to='lab_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:label='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:to='lab_fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IssuanceOfBankerSAcceptances' xlink:label='fil_IssuanceOfBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IssuanceOfBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Issuance of banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_IssuanceOfBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Issuance of banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IssuanceOfBankerSAcceptances' xlink:to='lab_fil_IssuanceOfBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PreferredCommonStockAndWarrantsAbstract' xlink:label='fil_PreferredCommonStockAndWarrantsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredCommonStockAndWarrantsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred Common Stock And Warrants</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PreferredCommonStockAndWarrantsAbstract' xlink:to='lab_fil_PreferredCommonStockAndWarrantsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredForeignIncomeTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax provision</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredForeignIncomeTaxExpenseBenefit' xlink:to='lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1' xlink:label='fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net operating losses for United States federal income tax purposes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Net operating losses for United States federal income tax purposes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1' xlink:to='lab_fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PrincipalPayments2020' xlink:label='fil_PrincipalPayments2020'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2020' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2020</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2020' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the total principal payments made during the annual reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2020' xlink:to='lab_fil_PrincipalPayments2020'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PrincipalPayments2018' xlink:label='fil_PrincipalPayments2018'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2018' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2018</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2018' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the total principal payments made during the annual reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2018' xlink:to='lab_fil_PrincipalPayments2018'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalInterestExpenseRecognizedForThePeriod' xlink:label='fil_TotalInterestExpenseRecognizedForThePeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInterestExpenseRecognizedForThePeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total interest expense recognized for the period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInterestExpenseRecognizedForThePeriod' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total interest expense recognized for the period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalInterestExpenseRecognizedForThePeriod' xlink:to='lab_fil_TotalInterestExpenseRecognizedForThePeriod'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_NetCarryingAmount' xlink:label='fil_NetCarryingAmount'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net carrying amount</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetCarryingAmount' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Net carrying amount</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetCarryingAmount' xlink:to='lab_fil_NetCarryingAmount'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_MotorVehicle' xlink:label='fil_MotorVehicle'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicle' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Motor vehicle</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicle' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Motor vehicle</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MotorVehicle' xlink:to='lab_fil_MotorVehicle'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PropertyAndEquipmentTablesAbstract' xlink:label='fil_PropertyAndEquipmentTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='lab_fil_PropertyAndEquipmentTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:label='us-gaap_FairValueMeasurementInputsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>FAIR VALUE MEASUREMENTS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:to='lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConstructionLoansPayable' xlink:label='us-gaap_ProceedsFromConstructionLoansPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProceedsFromConstructionLoansPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Payments of construction term loan</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProceedsFromConstructionLoansPayable' xlink:to='lab_us-gaap_ProceedsFromConstructionLoansPayable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:label='us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances from customers {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Advances from customers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:to='lab_us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:label='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts and other receivables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:to='lab_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue' xlink:label='us-gaap_CostOfRevenue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CostOfRevenue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of revenue</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CostOfRevenue' xlink:to='lab_us-gaap_CostOfRevenue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, shares issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesIssued' xlink:to='lab_us-gaap_CommonStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:label='us-gaap_StockTransactionsParentheticalDisclosuresAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Parentheticals</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='lab_us-gaap_StockTransactionsParentheticalDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockValue' xlink:to='lab_us-gaap_CommonStockValue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1' xlink:label='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts receivable, less allowance for doubtful accounts of $16,161,252 and $15,664,496, respectively</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Trade accounts receivable, less allowance for doubtful accounts</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1' xlink:to='lab_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Central Index Key</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Period End Date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Type</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_DocumentAndEntityInformationAbstract' xlink:label='fil_DocumentAndEntityInformationAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DocumentAndEntityInformationAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document and Entity Information</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='lab_fil_DocumentAndEntityInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FirstSupplierAccountedForRawMaterialPurchases' xlink:label='fil_FirstSupplierAccountedForRawMaterialPurchases'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FirstSupplierAccountedForRawMaterialPurchases' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>First Supplier accounted for raw material purchases</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_FirstSupplierAccountedForRawMaterialPurchases' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>First Supplier accounted for raw material purchases</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FirstSupplierAccountedForRawMaterialPurchases' xlink:to='lab_fil_FirstSupplierAccountedForRawMaterialPurchases'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_UndistributedEarningsOfHelpson' xlink:label='fil_UndistributedEarningsOfHelpson'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_UndistributedEarningsOfHelpson' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Undistributed earnings of Helpson</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_UndistributedEarningsOfHelpson' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Undistributed earnings of Helpson</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_UndistributedEarningsOfHelpson' xlink:to='lab_fil_UndistributedEarningsOfHelpson'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalLoanFacilityAmountRmb80000000' xlink:label='fil_TotalLoanFacilityAmountRmb80000000'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLoanFacilityAmountRmb80000000' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Loan facility amount (RMB 80,000,000)</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLoanFacilityAmountRmb80000000' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total loan facility amount (RMB 80,000,000)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalLoanFacilityAmountRmb80000000' xlink:to='lab_fil_TotalLoanFacilityAmountRmb80000000'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_DepreciationExpensePropertyAndEquipment' xlink:label='fil_DepreciationExpensePropertyAndEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DepreciationExpensePropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation Expense property and equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_DepreciationExpensePropertyAndEquipment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets&apos; useful lives. Includes production and non-production related depreciation.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DepreciationExpensePropertyAndEquipment' xlink:to='lab_fil_DepreciationExpensePropertyAndEquipment'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TradeAccountsReceivableBalances' xlink:label='fil_TradeAccountsReceivableBalances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TradeAccountsReceivableBalances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts receivable balances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TradeAccountsReceivableBalances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Trade accounts receivable balances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TradeAccountsReceivableBalances' xlink:to='lab_fil_TradeAccountsReceivableBalances'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PercetageOfAcquiredByOnnyInHelpson' xlink:label='fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercetageOfAcquiredByOnnyInHelpson' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percetage of acquired by Onny in Helpson</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercetageOfAcquiredByOnnyInHelpson' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percetage of acquired by Onny in Helpson</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercetageOfAcquiredByOnnyInHelpson' xlink:to='lab_fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and Equipment, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtTextBlock' xlink:label='us-gaap_LongTermDebtTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongTermDebtTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONSTRUCTION LOAN FACILITY {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongTermDebtTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>CONSTRUCTION LOAN FACILITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LongTermDebtTextBlock' xlink:to='lab_us-gaap_LongTermDebtTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:label='fil_CashAndCashEquivalentsAtEndOfPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and Cash Equivalents at End of Period</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:to='lab_fil_CashAndCashEquivalentsAtEndOfPeriod'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInInventories' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Inventory</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInInventories' xlink:to='lab_us-gaap_IncreaseDecreaseInInventories'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Loss before income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:to='lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Revenues' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Revenues' xlink:to='lab_us-gaap_Revenues'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>TOTAL LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>TOTAL LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquity' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_StockholdersEquity' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Stockholders&apos; Equity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_StockholdersEquity' xlink:to='lab_us-gaap_StockholdersEquity'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RetainedEarningsAccumulatedDeficit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Retained earnings</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RetainedEarningsAccumulatedDeficit' xlink:to='lab_us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash' xlink:label='us-gaap_Cash'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Cash' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and cash equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Cash' xlink:to='lab_us-gaap_Cash'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsAbstract' xlink:to='lab_us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalLevel2' xlink:label='fil_TotalLevel2'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel2' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Level 2</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel2' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total Level 2</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalLevel2' xlink:to='lab_fil_TotalLevel2'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1' xlink:label='fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net operating loss carryforwards for PRC tax purposes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Net operating loss carryforwards for PRC tax purposes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1' xlink:to='lab_fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankerSAcceptanceNotesPayableDetailsAbstract' xlink:label='fil_BankerSAcceptanceNotesPayableDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankerSAcceptanceNotesPayableDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>BANKER&apos;S ACCEPTANCE NOTES PAYABLE Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankerSAcceptanceNotesPayableDetailsAbstract' xlink:to='lab_fil_BankerSAcceptanceNotesPayableDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_RelatedPartyTransactionsMemberOfBod1Abstract' xlink:label='fil_RelatedPartyTransactionsMemberOfBod1Abstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RelatedPartyTransactionsMemberOfBod1Abstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS Member Of BOD</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RelatedPartyTransactionsMemberOfBod1Abstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Adavances owing to board</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RelatedPartyTransactionsMemberOfBod1Abstract' xlink:to='lab_fil_RelatedPartyTransactionsMemberOfBod1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:label='fil_AmortizationExpensesRelatingToIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amortization expenses relating to intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:to='lab_fil_AmortizationExpensesRelatingToIntangibleAssets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BuildingMinimumLife' xlink:label='fil_BuildingMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Building minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BuildingMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BuildingMinimumLife' xlink:to='lab_fil_BuildingMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InventoryGross1' xlink:label='fil_InventoryGross1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryGross1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory Gross {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryGross1' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Inventory Gross</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryGross1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryGross1' xlink:to='lab_fil_InventoryGross1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenue Recognition</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CommitmentAndContingenciesAbstract' xlink:label='fil_CommitmentAndContingenciesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommitmentAndContingenciesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>COMMITMENTS AND CONTINGENCIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommitmentAndContingenciesAbstract' xlink:to='lab_fil_CommitmentAndContingenciesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization' xlink:label='us-gaap_DepreciationDepletionAndAmortization'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DepreciationDepletionAndAmortization' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Depreciation and amortization</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DepreciationDepletionAndAmortization' xlink:to='lab_us-gaap_DepreciationDepletionAndAmortization'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetIncomeLoss' xlink:to='lab_us-gaap_NetIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherExpenses' xlink:label='us-gaap_OtherExpenses'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherExpenses' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net other expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherExpenses' xlink:to='lab_us-gaap_OtherExpenses'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ResearchAndDevelopmentExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Research and development expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ResearchAndDevelopmentExpense' xlink:to='lab_us-gaap_ResearchAndDevelopmentExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, shares authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesAuthorized' xlink:to='lab_us-gaap_CommonStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Current Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrent' xlink:to='lab_us-gaap_AssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent' xlink:label='us-gaap_AccountsAndOtherReceivablesNetCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsAndOtherReceivablesNetCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other receivables, less allowance for doubtful accounts of $56,157 and $71,548, respectively</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsAndOtherReceivablesNetCurrent' xlink:to='lab_us-gaap_AccountsAndOtherReceivablesNetCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FirstCustomerAccountedAccountsReceivable' xlink:label='fil_FirstCustomerAccountedAccountsReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FirstCustomerAccountedAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>First Customer accounted accounts receivable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_FirstCustomerAccountedAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>First Customer accounted accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FirstCustomerAccountedAccountsReceivable' xlink:to='lab_fil_FirstCustomerAccountedAccountsReceivable'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ValuationAllowanceAgainstDeferredTaxAssets' xlink:label='fil_ValuationAllowanceAgainstDeferredTaxAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ValuationAllowanceAgainstDeferredTaxAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Valuation allowance against deferred tax assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ValuationAllowanceAgainstDeferredTaxAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Valuation allowance against deferred tax assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ValuationAllowanceAgainstDeferredTaxAssets' xlink:to='lab_fil_ValuationAllowanceAgainstDeferredTaxAssets'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalPrincipalPaymentsDue' xlink:label='fil_TotalPrincipalPaymentsDue'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalPrincipalPaymentsDue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total principal payments due</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalPrincipalPaymentsDue' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total Principal amount due by the company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalPrincipalPaymentsDue' xlink:to='lab_fil_TotalPrincipalPaymentsDue'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CompanyMadeAPrincipalPayment' xlink:label='fil_CompanyMadeAPrincipalPayment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyMadeAPrincipalPayment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company made a principal payment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyMadeAPrincipalPayment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company made a principal payment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyMadeAPrincipalPayment' xlink:to='lab_fil_CompanyMadeAPrincipalPayment'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:label='fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest rate on advances from Member of BOD</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Interest rate on advances from Member of BOD</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:to='lab_fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PropertyAndEquipmentNet' xlink:label='fil_PropertyAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and Equipment, net</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PropertyAndEquipmentNet' xlink:to='lab_fil_PropertyAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InterestRateRiskPolicyTextBlock' xlink:label='fil_InterestRateRiskPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateRiskPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest Rate Risk</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InterestRateRiskPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Disclosure for accounting policy on interest rate risk</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InterestRateRiskPolicyTextBlock' xlink:to='lab_fil_InterestRateRiskPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock' xlink:label='us-gaap_InventoryPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryPolicyTextBlock' xlink:to='lab_us-gaap_InventoryPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock' xlink:label='us-gaap_ConsolidationPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConsolidationPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Consolidation and Basis of Presentation</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ConsolidationPolicyTextBlock' xlink:to='lab_us-gaap_ConsolidationPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FairValueMeasurementsAbstract' xlink:label='fil_FairValueMeasurementsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FairValueMeasurementsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>FAIR VALUE MEASUREMENTS:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FairValueMeasurementsAbstract' xlink:to='lab_fil_FairValueMeasurementsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract' xlink:label='us-gaap_InventoryDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureAbstract' xlink:to='lab_us-gaap_InventoryDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestPaid' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash paid for interest</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestPaid' xlink:to='lab_us-gaap_InterestPaid'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Cash Used in Financing Activity</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash Flows from Financing Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash Flows from Investing Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Cash Provided by Operating Activities</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Net Cash Provided by Operating Activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other payables and accrued expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:to='lab_us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Changes in assets and liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, par value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockValue' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockValue' xlink:to='lab_us-gaap_PreferredStockValue'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AssetsCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Assets:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='lab_us-gaap_AssetsCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalYearFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Year Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalYearFocus' xlink:to='lab_dei_DocumentFiscalYearFocus'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Common Stock, Shares Outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankersAcceptanceNotesLevel1' xlink:label='fil_BankersAcceptanceNotesLevel1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptance notes Level 1</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotesLevel1' xlink:to='lab_fil_BankersAcceptanceNotesLevel1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories' xlink:label='fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Company recognized an impairment loss for the advances made to these laboratories</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company recognized an impairment loss for the advances made to these laboratories</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories' xlink:to='lab_fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:label='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for purchase of intangible assets details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract [Abstract]</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:to='lab_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PermitOfLandUseMaximumLife' xlink:label='fil_PermitOfLandUseMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Permit of land use maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PermitOfLandUseMaximumLife' xlink:to='lab_fil_PermitOfLandUseMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalInventory' xlink:label='fil_TotalInventory'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInventory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Inventory</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalInventory' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalInventory' xlink:to='lab_fil_TotalInventory'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AccountingPoliciesAbstract1' xlink:label='fil_AccountingPoliciesAbstract1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AccountingPoliciesAbstract1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Accounting Policies:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='lab_fil_AccountingPoliciesAbstract1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankerSAcceptanceNotesPayableAbstract' xlink:label='fil_BankerSAcceptanceNotesPayableAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankerSAcceptanceNotesPayableAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>BANKER&apos;S ACCEPTANCE NOTES PAYABLE</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankerSAcceptanceNotesPayableAbstract' xlink:to='lab_fil_BankerSAcceptanceNotesPayableAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INTANGIBLE ASSETS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>INTANGIBLE ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:to='lab_us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest' xlink:label='us-gaap_InvestmentIncomeInterest'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InvestmentIncomeInterest' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest income</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InvestmentIncomeInterest' xlink:to='lab_us-gaap_InvestmentIncomeInterest'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized' xlink:label='us-gaap_PreferredStockSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, shares authorized</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesAuthorized' xlink:to='lab_us-gaap_PreferredStockSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities' xlink:label='us-gaap_DeferredTaxLiabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DeferredTaxLiabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred tax liability</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DeferredTaxLiabilities' xlink:to='lab_us-gaap_DeferredTaxLiabilities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent' xlink:label='us-gaap_PrepaidExpenseCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PrepaidExpenseCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PrepaidExpenseCurrent' xlink:to='lab_us-gaap_PrepaidExpenseCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:label='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shares of restricted stock granted and outstanding under the 2010 Incentive Plan</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>shares of restricted stock granted and outstanding under the 2010 Incentive Plan</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:to='lab_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_StockholdersEquity2010StockOptionPlanAbstract' xlink:label='fil_StockholdersEquity2010StockOptionPlanAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_StockholdersEquity2010StockOptionPlanAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Stockholders Equity 2010 Stock Option Plan</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_StockholdersEquity2010StockOptionPlanAbstract' xlink:to='lab_fil_StockholdersEquity2010StockOptionPlanAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CommonSharesAuthorized' xlink:label='fil_CommonSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common shares authorized</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_CommonSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum number of common shares permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_CommonSharesAuthorized' xlink:to='lab_fil_CommonSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IncomeTaxesProvisionAbstract' xlink:label='fil_IncomeTaxesProvisionAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IncomeTaxesProvisionAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Income Taxes Provision</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IncomeTaxesProvisionAbstract' xlink:to='lab_fil_IncomeTaxesProvisionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PrincipalPayments2021' xlink:label='fil_PrincipalPayments2021'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2021' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal Payments 2021</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPayments2021' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of the total principal payments made during the annual reporting period.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPayments2021' xlink:to='lab_fil_PrincipalPayments2021'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes' xlink:label='fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Maximum amount that the Company can issue under this agreement against the Banker&apos;s Notes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Maximum amount that the Company can issue under this agreement against the Banker&apos;s Notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes' xlink:to='lab_fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_OfficeEquipment' xlink:label='fil_OfficeEquipment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Office equipment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Office equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OfficeEquipment' xlink:to='lab_fil_OfficeEquipment'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FairValueMeasuresAndDisclosuresAbstract' xlink:label='fil_FairValueMeasuresAndDisclosuresAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FairValueMeasuresAndDisclosuresAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SCHEDULE OF FAIR VALUE MEASUREMENTS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FairValueMeasuresAndDisclosuresAbstract' xlink:to='lab_fil_FairValueMeasuresAndDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:label='fil_UsefulLivesOfTheAssetsTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Useful lives of the assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabular disclosure of useful lives of the assets.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:to='lab_fil_UsefulLivesOfTheAssetsTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:label='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Valuation of Long-Lived Assets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:to='lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract' xlink:label='us-gaap_IncomeTaxDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxDisclosureAbstract' xlink:to='lab_us-gaap_IncomeTaxDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:label='us-gaap_IncreaseDecreaseInPrepaidExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Prepaid expenses {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Prepaid expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:to='lab_us-gaap_IncreaseDecreaseInPrepaidExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash Flows from Operating Activities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesCurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current Liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesCurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Property and equipment, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentNet' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryNet' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryNet' xlink:to='lab_us-gaap_InventoryNet'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesToSuppliers' xlink:label='fil_AdvancesToSuppliers'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances to suppliers</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliers' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Carrying amount as of the balance sheet date of advances to suppliers.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesToSuppliers' xlink:to='lab_fil_AdvancesToSuppliers'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents' xlink:label='us-gaap_RestrictedCashAndCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RestrictedCashAndCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Restricted cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RestrictedCashAndCashEquivalents' xlink:to='lab_us-gaap_RestrictedCashAndCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' xlink:label='fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Investment in Helpson, a foreign subsidiary for the company</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Investment in Helpson, a foreign subsidiary for the company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' xlink:to='lab_fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:label='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Principal payments required for the next five years are as follows:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='lab_fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract' xlink:label='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract' xlink:to='lab_fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_OfficeEquipmentMaximumLife' xlink:label='fil_OfficeEquipmentMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Office equipment maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OfficeEquipmentMaximumLife' xlink:to='lab_fil_OfficeEquipmentMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InventoryConsistedOfTheFollowingDetailsAbstract' xlink:label='fil_InventoryConsistedOfTheFollowingDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryConsistedOfTheFollowingDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY CONSISTED OF THE FOLLOWING (DETAILS)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryConsistedOfTheFollowingDetailsAbstract' xlink:to='lab_fil_InventoryConsistedOfTheFollowingDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy' xlink:label='us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Restricted Cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy' xlink:to='lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract' xlink:label='us-gaap_RisksAndUncertaintiesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RisksAndUncertaintiesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONCENTRATIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RisksAndUncertaintiesAbstract' xlink:to='lab_us-gaap_RisksAndUncertaintiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:label='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>COMMITMENTS AND CONTINGENCIES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>COMMITMENTS AND CONTINGENCIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:to='lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_DebtAbstract' xlink:label='fil_DebtAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_DebtAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONSTRUCTION LOAN FACILITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_DebtAbstract' xlink:to='lab_fil_DebtAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract' xlink:label='us-gaap_RelatedPartyTransactionsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RelatedPartyTransactionsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RelatedPartyTransactionsAbstract' xlink:to='lab_us-gaap_RelatedPartyTransactionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:label='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INTANGIBLE ASSETS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:to='lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract' xlink:label='us-gaap_PropertyPlantAndEquipmentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PropertyPlantAndEquipmentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PropertyPlantAndEquipmentAbstract' xlink:to='lab_us-gaap_PropertyPlantAndEquipmentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:to='lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:label='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net (Decrease) Increase in Cash and Cash Equivalents</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:to='lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Effect of Exchange Rate Changes on Cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:to='lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract' xlink:label='us-gaap_OtherIncomeAndExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherIncomeAndExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other income (expense):</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='lab_us-gaap_OtherIncomeAndExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerAdvancesCurrent' xlink:label='us-gaap_CustomerAdvancesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CustomerAdvancesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances from customers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CustomerAdvancesCurrent' xlink:to='lab_us-gaap_CustomerAdvancesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankersAcceptanceNotesLevel3' xlink:label='fil_BankersAcceptanceNotesLevel3'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel3' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptance notes Level 3</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesLevel3' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes Level 3</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotesLevel3' xlink:to='lab_fil_BankersAcceptanceNotesLevel3'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit' xlink:label='us-gaap_CurrentFederalTaxExpenseBenefit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CurrentFederalTaxExpenseBenefit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current tax provision</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CurrentFederalTaxExpenseBenefit' xlink:to='lab_us-gaap_CurrentFederalTaxExpenseBenefit'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PermitOfLandUseMinimumLife' xlink:label='fil_PermitOfLandUseMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Permit of land use minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PermitOfLandUseMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PermitOfLandUseMinimumLife' xlink:to='lab_fil_PermitOfLandUseMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentGross' xlink:label='us-gaap_MachineryAndEquipmentGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_MachineryAndEquipmentGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Plant, machinery and equipment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_MachineryAndEquipmentGross' xlink:to='lab_us-gaap_MachineryAndEquipmentGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_RawMaterials' xlink:label='fil_RawMaterials'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RawMaterials' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Raw materials {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RawMaterials' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Raw materials</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RawMaterials' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RawMaterials' xlink:to='lab_fil_RawMaterials'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:label='fil_ScheduleOfLongTermDebtInstrumentsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Construction Loan Facility:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:to='lab_fil_ScheduleOfLongTermDebtInstrumentsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk' xlink:label='us-gaap_ConcentrationRiskCreditRisk'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConcentrationRiskCreditRisk' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Credit Risk</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ConcentrationRiskCreditRisk' xlink:to='lab_us-gaap_ConcentrationRiskCreditRisk'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INVENTORY {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InventoryDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>INVENTORY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InventoryDisclosureTextBlock' xlink:to='lab_us-gaap_InventoryDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:label='us-gaap_IncreaseDecreaseInIncomeTaxes'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Deferred income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:to='lab_us-gaap_IncreaseDecreaseInIncomeTaxes'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingExpensesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Operating expenses:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='lab_us-gaap_OperatingExpensesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract' xlink:label='us-gaap_LiabilitiesNoncurrentAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesNoncurrentAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Non-current Liabilities:</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='lab_us-gaap_LiabilitiesNoncurrentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_SecondCustomerAccountedAccountsReceivable' xlink:label='fil_SecondCustomerAccountedAccountsReceivable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_SecondCustomerAccountedAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Second Customer accounted accounts receivable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_SecondCustomerAccountedAccountsReceivable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Second Customer accounted accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_SecondCustomerAccountedAccountsReceivable' xlink:to='lab_fil_SecondCustomerAccountedAccountsReceivable'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ConcentrationsDetailsAbstract' xlink:label='fil_ConcentrationsDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConcentrationsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Concentrations Details</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ConcentrationsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Company made payments as per Construction agreement</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='lab_fil_ConcentrationsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FairValueMeasurementsAtReportingDateUsingAbstract' xlink:label='fil_FairValueMeasurementsAtReportingDateUsingAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_FairValueMeasurementsAtReportingDateUsingAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>FAIR VALUE MEASUREMENTS AT REPORTING DATE USING</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_FairValueMeasurementsAtReportingDateUsingAbstract' xlink:to='lab_fil_FairValueMeasurementsAtReportingDateUsingAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_RemainingAnnualPrincipalPayment' xlink:label='fil_RemainingAnnualPrincipalPayment'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingAnnualPrincipalPayment' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Remaining annual principal payment</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RemainingAnnualPrincipalPayment' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Remaining annual principal payment</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RemainingAnnualPrincipalPayment' xlink:to='lab_fil_RemainingAnnualPrincipalPayment'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:label='fil_PropertyAndEquipmentAssetsLifeAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>PROPERTY AND EQUIPMENT Assets Life</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:to='lab_fil_PropertyAndEquipmentAssetsLifeAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:label='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:to='lab_fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:label='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:to='lab_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:label='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Enterprise Income Tax Rates</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tabular disclosure is about the Enterprise Income Tax Rates under the current tax law in the PRC, the Company is and will be subject to.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:to='lab_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock' xlink:label='us-gaap_ReceivablesPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ReceivablesPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade Accounts Receivable and Allowance for Doubtful Accounts, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ReceivablesPolicyTextBlock' xlink:to='lab_us-gaap_ReceivablesPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:label='us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cash and Cash Equivalents, Policy</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:to='lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:label='us-gaap_ConcentrationRiskDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>CONCENTRATIONS {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>CONCENTRATIONS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:to='lab_us-gaap_ConcentrationRiskDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock' xlink:label='us-gaap_IncomeTaxDisclosureTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>INCOME TAXES {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IncomeTaxDisclosureTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>INCOME TAXES</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IncomeTaxDisclosureTextBlock' xlink:to='lab_us-gaap_IncomeTaxDisclosureTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InventoryPurchasedWithBankerSAcceptances' xlink:label='fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryPurchasedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Inventory purchased with banker&apos;s acceptances</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_InventoryPurchasedWithBankerSAcceptances' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Inventory purchased with banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_InventoryPurchasedWithBankerSAcceptances' xlink:to='lab_fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net Cash Used in Investing Activities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:to='lab_us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Net loss {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ProfitLoss' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Net loss</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ProfitLoss' xlink:to='lab_us-gaap_ProfitLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued' xlink:label='us-gaap_PreferredStockSharesIssued'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockSharesIssued' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, shares issued</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockSharesIssued' xlink:to='lab_us-gaap_PreferredStockSharesIssued'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentFiscalPeriodFocus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Document Fiscal Period Focus</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentFiscalPeriodFocus' xlink:to='lab_dei_DocumentFiscalPeriodFocus'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalLevel1' xlink:label='fil_TotalLevel1'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Level 1</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalLevel1' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total Level 1</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalLevel1' xlink:to='lab_fil_TotalLevel1'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2016' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2016'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesForTheYear2016' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rates for the year 2016</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRatesForTheYear2016' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rates for the year 2016</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRatesForTheYear2016' xlink:to='lab_fil_EnterpriseIncomeTaxRatesForTheYear2016'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_RelatedPartyTransactionsOwingsAbstract' xlink:label='fil_RelatedPartyTransactionsOwingsAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RelatedPartyTransactionsOwingsAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>RELATED PARTY TRANSACTIONS OWINGS</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RelatedPartyTransactionsOwingsAbstract' xlink:to='lab_fil_RelatedPartyTransactionsOwingsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_OfficeEquipmentMinimumLife' xlink:label='fil_OfficeEquipmentMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Office equipment minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_OfficeEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_OfficeEquipmentMinimumLife' xlink:to='lab_fil_OfficeEquipmentMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandAndLandImprovements' xlink:label='us-gaap_LandAndLandImprovements'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LandAndLandImprovements' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Permit of land use</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LandAndLandImprovements' xlink:to='lab_us-gaap_LandAndLandImprovements'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_WorkInProcess' xlink:label='fil_WorkInProcess'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_WorkInProcess' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Work in process</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_WorkInProcess' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_WorkInProcess' xlink:to='lab_fil_WorkInProcess'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:label='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances to Suppliers and Advances from Customers</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Disclosure for accounting policy of advances to Suppliers and Advances from Customers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:to='lab_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankerSAcceptanceNotesPayableTextBlock' xlink:label='fil_BankerSAcceptanceNotesPayableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankerSAcceptanceNotesPayableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>BANKER&apos;S ACCEPTANCE NOTES PAYABLE {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankerSAcceptanceNotesPayableTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>BANKER&apos;S ACCEPTANCE NOTES PAYABLE</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankerSAcceptanceNotesPayableTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The entire disclosure is about the bankers&apos; acceptance notes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankerSAcceptanceNotesPayableTextBlock' xlink:to='lab_fil_BankerSAcceptanceNotesPayableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted' xlink:label='us-gaap_EarningsPerShareBasicAndDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_EarningsPerShareBasicAndDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Basic and diluted</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_EarningsPerShareBasicAndDiluted' xlink:to='lab_us-gaap_EarningsPerShareBasicAndDiluted'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent' xlink:label='us-gaap_DueToRelatedPartiesCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_DueToRelatedPartiesCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other payables - related parties</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_DueToRelatedPartiesCurrent' xlink:to='lab_us-gaap_DueToRelatedPartiesCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableOtherCurrent' xlink:label='us-gaap_AccountsPayableOtherCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableOtherCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Other payables</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableOtherCurrent' xlink:to='lab_us-gaap_AccountsPayableOtherCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>LIABILITIES AND STOCKHOLDERS&apos; EQUITY</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherRestrictedAssetsCurrent' xlink:label='us-gaap_OtherRestrictedAssetsCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OtherRestrictedAssetsCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Banker&apos;s acceptances</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OtherRestrictedAssetsCurrent' xlink:to='lab_us-gaap_OtherRestrictedAssetsCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Voluntary Filers</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PreferredSharesAuthorized' xlink:label='fil_PreferredSharesAuthorized'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred shares authorized</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PreferredSharesAuthorized' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity&apos;s charter and bylaws.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PreferredSharesAuthorized' xlink:to='lab_fil_PreferredSharesAuthorized'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalIncomeTaxBenefitExpense' xlink:label='fil_TotalIncomeTaxBenefitExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalIncomeTaxBenefitExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total income tax (benefit) expense</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_TotalIncomeTaxBenefitExpense' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_TotalIncomeTaxBenefitExpense' xlink:to='lab_fil_TotalIncomeTaxBenefitExpense'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_EnterpriseIncomeTaxRateThereafter' xlink:label='fil_EnterpriseIncomeTaxRateThereafter'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRateThereafter' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Enterprise Income Tax Rates There after</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_EnterpriseIncomeTaxRateThereafter' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Enterprise Income Tax Rate Thereafter</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_EnterpriseIncomeTaxRateThereafter' xlink:to='lab_fil_EnterpriseIncomeTaxRateThereafter'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank' xlink:label='fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Agreement calls for the payment of fees equal to the note amount to the bank</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Agreement calls for the payment of fees equal to the note amount to the bank</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank' xlink:to='lab_fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PlantMachineryAndEquipmentMaximumLife' xlink:label='fil_PlantMachineryAndEquipmentMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Plant, machinery and equipment maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PlantMachineryAndEquipmentMaximumLife' xlink:to='lab_fil_PlantMachineryAndEquipmentMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_Total' xlink:label='fil_Total'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_Total' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_Total' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Total</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_Total' xlink:to='lab_fil_Total'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingsAndImprovementsGross' xlink:label='us-gaap_BuildingsAndImprovementsGross'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_BuildingsAndImprovementsGross' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Building</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_BuildingsAndImprovementsGross' xlink:to='lab_us-gaap_BuildingsAndImprovementsGross'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IntangibleAssetsTablesAbstract' xlink:label='fil_IntangibleAssetsTablesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_IntangibleAssetsTablesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible Assets (Tables)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_IntangibleAssetsTablesAbstract' xlink:to='lab_fil_IntangibleAssetsTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Cost of Revenues</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' xlink:to='lab_us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_RestrictedCashTextBlock' xlink:label='fil_RestrictedCashTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_RestrictedCashTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Restricted Cash {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RestrictedCashTextBlock' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Restricted Cash</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_RestrictedCashTextBlock' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Restricted Cash</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_RestrictedCashTextBlock' xlink:to='lab_fil_RestrictedCashTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense' xlink:label='us-gaap_InterestExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_InterestExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interest expense</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_InterestExpense' xlink:to='lab_us-gaap_InterestExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingExpense' xlink:label='us-gaap_SellingExpense'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_SellingExpense' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Selling expenses</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_SellingExpense' xlink:to='lab_us-gaap_SellingExpense'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare' xlink:label='us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_PreferredStockParOrStatedValuePerShare' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Preferred stock, par value</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_PreferredStockParOrStatedValuePerShare' xlink:to='lab_us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:label='fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for doubtful accounts on other receivables</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>A valuation allowance for other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:to='lab_fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermConstructionLoanCurrent' xlink:label='us-gaap_LongTermConstructionLoanCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_LongTermConstructionLoanCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current portion of construction loan facility</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_LongTermConstructionLoanCurrent' xlink:to='lab_us-gaap_LongTermConstructionLoanCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableTradeCurrent' xlink:label='us-gaap_AccountsPayableTradeCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AccountsPayableTradeCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trade accounts payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AccountsPayableTradeCurrent' xlink:to='lab_us-gaap_AccountsPayableTradeCurrent'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankersAcceptanceNotes' xlink:label='fil_BankersAcceptanceNotes'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotes' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers acceptance notes</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotes' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers acceptance notes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotes' xlink:to='lab_fil_BankersAcceptanceNotes'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AmortizationExpenseAbstract' xlink:label='fil_AmortizationExpenseAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AmortizationExpenseAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>AMORTIZATION EXPENSE</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AmortizationExpenseAbstract' xlink:to='lab_fil_AmortizationExpenseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_MotorVehicleMaximumLife' xlink:label='fil_MotorVehicleMaximumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMaximumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Motor vehicle maximum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_MotorVehicleMaximumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_MotorVehicleMaximumLife' xlink:to='lab_fil_MotorVehicleMaximumLife'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PlantMachineryAndEquipmentMinimumLife' xlink:label='fil_PlantMachineryAndEquipmentMinimumLife'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Plant, machinery and equipment minimum life</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_PlantMachineryAndEquipmentMinimumLife' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Plant, machinery and equipment minimum life</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_PlantMachineryAndEquipmentMinimumLife' xlink:to='lab_fil_PlantMachineryAndEquipmentMinimumLife'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' xlink:label='us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Schedule of Provision for income taxes</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' xlink:to='lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' xlink:label='us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Weighted average shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' xlink:to='lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_OperatingIncomeLoss' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Loss from operations</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_OperatingIncomeLoss' xlink:to='lab_us-gaap_OperatingIncomeLoss'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Gross profit</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_GrossProfit' xlink:role='http://www.xbrl.org/2003/role/totalLabel' xml:lang='en-US'>Gross profit</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_GrossProfit' xlink:to='lab_us-gaap_GrossProfit'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract' xlink:label='us-gaap_RevenuesAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenuesAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Revenues {1}</link:label>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_RevenuesAbstract' xlink:role='http://www.xbrl.org/2003/role/terseLabel' xml:lang='en-US'>Revenues</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_RevenuesAbstract' xlink:to='lab_us-gaap_RevenuesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_CommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Common stock, shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_CommonStockSharesOutstanding' xlink:to='lab_us-gaap_CommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:label='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Allowance for doubtful accounts on trade accounts receivable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:to='lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_Liabilities' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Total Liabilities</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_Liabilities' xlink:to='lab_us-gaap_Liabilities'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankersAcceptanceNotesPayable' xlink:label='fil_BankersAcceptanceNotesPayable'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesPayable' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Bankers&apos; acceptance notes payable</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_BankersAcceptanceNotesPayable' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>Bankers&apos; acceptance notes payable</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_BankersAcceptanceNotesPayable' xlink:to='lab_fil_BankersAcceptanceNotesPayable'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Intangible assets, net</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:to='lab_us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Advances for purchases of intangible assets</link:label>
		<link:label xlink:type='resource' xlink:label='lab_fil_AdvancesForPurchasesOfIntangibleAssets' xlink:role='http://www.xbrl.org/2003/role/documentation' xml:lang='en-US'>AdvancesForPurchasesOfIntangibleAssets</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssets' xlink:to='lab_fil_AdvancesForPurchasesOfIntangibleAssets'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cphi-20170331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Vistalytics - iFile Suite version 6.233 -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://www.chinapharmaholdings.com/20170331"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_DocumentAndEntityInformationAbstract' xlink:label='fil_DocumentAndEntityInformationAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_TradingSymbol' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentType' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus' xlink:label='dei_DocumentFiscalYearFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentFiscalYearFocus' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus' xlink:label='dei_DocumentFiscalPeriodFocus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_DocumentFiscalPeriodFocus' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DocumentAndEntityInformationAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='16.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract' xlink:label='us-gaap_AssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract' xlink:label='us-gaap_AssetsCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_AssetsCurrentAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Cash' xlink:label='us-gaap_Cash'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_Cash' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents' xlink:label='us-gaap_RestrictedCashAndCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_RestrictedCashAndCashEquivalents' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherRestrictedAssetsCurrent' xlink:label='us-gaap_OtherRestrictedAssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_OtherRestrictedAssetsCurrent' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1' xlink:label='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent' xlink:label='us-gaap_AccountsAndOtherReceivablesNetCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AccountsAndOtherReceivablesNetCurrent' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesToSuppliers' xlink:label='fil_AdvancesToSuppliers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='fil_AdvancesToSuppliers' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet' xlink:label='us-gaap_InventoryNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_InventoryNet' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseCurrent' xlink:label='us-gaap_PrepaidExpenseCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_PrepaidExpenseCurrent' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent' xlink:label='us-gaap_AssetsCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_AssetsCurrent' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesForPurchasesOfIntangibleAssets' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssets' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet' xlink:label='us-gaap_PropertyPlantAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentNet' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill' xlink:label='us-gaap_IntangibleAssetsNetExcludingGoodwill'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_IntangibleAssetsNetExcludingGoodwill' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets' xlink:label='us-gaap_Assets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsCurrentAbstract' xlink:to='us-gaap_Assets' use='optional' order='13.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:label='us-gaap_LiabilitiesAndStockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_AssetsAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquityAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract' xlink:label='us-gaap_LiabilitiesCurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesCurrentAbstract' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableTradeCurrent' xlink:label='us-gaap_AccountsPayableTradeCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccountsPayableTradeCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent' xlink:label='us-gaap_AccruedLiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccruedLiabilitiesCurrent' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableOtherCurrent' xlink:label='us-gaap_AccountsPayableOtherCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_AccountsPayableOtherCurrent' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CustomerAdvancesCurrent' xlink:label='us-gaap_CustomerAdvancesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_CustomerAdvancesCurrent' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent' xlink:label='us-gaap_DueToRelatedPartiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_DueToRelatedPartiesCurrent' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermConstructionLoanCurrent' xlink:label='us-gaap_LongTermConstructionLoanCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_LongTermConstructionLoanCurrent' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankersAcceptanceNotesPayable' xlink:label='fil_BankersAcceptanceNotesPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='fil_BankersAcceptanceNotesPayable' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent' xlink:label='us-gaap_LiabilitiesCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesCurrentAbstract' xlink:to='us-gaap_LiabilitiesCurrent' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract' xlink:label='us-gaap_LiabilitiesNoncurrentAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesNoncurrentAbstract' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' xlink:label='us-gaap_LongtermConstructionLoanCurrentAndNoncurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='us-gaap_LongtermConstructionLoanCurrentAndNoncurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilities' xlink:label='us-gaap_DeferredTaxLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='us-gaap_DeferredTaxLiabilities' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities' xlink:label='us-gaap_Liabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesNoncurrentAbstract' xlink:to='us-gaap_Liabilities' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract' xlink:label='us-gaap_StockholdersEquityAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_StockholdersEquityAbstract' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue' xlink:label='us-gaap_PreferredStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_PreferredStockValue' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue' xlink:label='us-gaap_CommonStockValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_CommonStockValue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital' xlink:label='us-gaap_AdditionalPaidInCapital'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_AdditionalPaidInCapital' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit' xlink:label='us-gaap_RetainedEarningsAccumulatedDeficit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_RetainedEarningsAccumulatedDeficit' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' xlink:label='us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity' xlink:label='us-gaap_StockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockholdersEquityAbstract' xlink:to='us-gaap_StockholdersEquity' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity' xlink:label='us-gaap_LiabilitiesAndStockholdersEquity'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_LiabilitiesAndStockholdersEquityAbstract' xlink:to='us-gaap_LiabilitiesAndStockholdersEquity' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICALS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICALS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICALS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:label='us-gaap_StockTransactionsParentheticalDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' xlink:label='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AllowanceForDoubtfulAccountsOnOtherReceivables' xlink:label='fil_AllowanceForDoubtfulAccountsOnOtherReceivables'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='fil_AllowanceForDoubtfulAccountsOnOtherReceivables' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare' xlink:label='us-gaap_PreferredStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_PreferredStockParOrStatedValuePerShare' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized' xlink:label='us-gaap_PreferredStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_PreferredStockSharesAuthorized' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued' xlink:label='us-gaap_PreferredStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_PreferredStockSharesIssued' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding' xlink:label='us-gaap_PreferredStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_PreferredStockSharesOutstanding' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare' xlink:label='us-gaap_CommonStockParOrStatedValuePerShare'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_CommonStockParOrStatedValuePerShare' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized' xlink:label='us-gaap_CommonStockSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_CommonStockSharesAuthorized' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued' xlink:label='us-gaap_CommonStockSharesIssued'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_CommonStockSharesIssued' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding' xlink:label='us-gaap_CommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_StockTransactionsParentheticalDisclosuresAbstract' xlink:to='us-gaap_CommonStockSharesOutstanding' use='optional' order='10.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenuesAbstract' xlink:label='us-gaap_RevenuesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues' xlink:label='us-gaap_Revenues'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_Revenues' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue' xlink:label='us-gaap_CostOfRevenue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_CostOfRevenue' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit' xlink:label='us-gaap_GrossProfit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_GrossProfit' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract' xlink:label='us-gaap_OperatingExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_OperatingExpensesAbstract' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingExpense' xlink:label='us-gaap_SellingExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_SellingExpense' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense' xlink:label='us-gaap_GeneralAndAdministrativeExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_GeneralAndAdministrativeExpense' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense' xlink:label='us-gaap_ResearchAndDevelopmentExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_ResearchAndDevelopmentExpense' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts' xlink:label='us-gaap_ProvisionForDoubtfulAccounts'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_ProvisionForDoubtfulAccounts' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses' xlink:label='us-gaap_OperatingExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_OperatingExpenses' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss' xlink:label='us-gaap_OperatingIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OperatingExpensesAbstract' xlink:to='us-gaap_OperatingIncomeLoss' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract' xlink:label='us-gaap_OtherIncomeAndExpensesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_OtherIncomeAndExpensesAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentIncomeInterest' xlink:label='us-gaap_InvestmentIncomeInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_InvestmentIncomeInterest' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense' xlink:label='us-gaap_InterestExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_InterestExpense' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherExpenses' xlink:label='us-gaap_OtherExpenses'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_OtherExpenses' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' xlink:label='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IncomeTaxExpense1' xlink:label='fil_IncomeTaxExpense1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='fil_IncomeTaxExpense1' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss' xlink:label='us-gaap_NetIncomeLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_NetIncomeLoss' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax' xlink:label='us-gaap_OtherComprehensiveIncomeLossNetOfTax'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_OtherIncomeAndExpensesAbstract' xlink:to='us-gaap_OtherComprehensiveIncomeLossNetOfTax' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract' xlink:label='us-gaap_EarningsPerShareAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RevenuesAbstract' xlink:to='us-gaap_EarningsPerShareAbstract' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted' xlink:label='us-gaap_EarningsPerShareBasicAndDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='us-gaap_EarningsPerShareBasicAndDiluted' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' xlink:label='us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_EarningsPerShareAbstract' xlink:to='us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss' xlink:label='us-gaap_ProfitLoss'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_ProfitLoss' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization' xlink:label='us-gaap_DepreciationDepletionAndAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_DepreciationDepletionAndAmortization' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BadDebtExpense' xlink:label='fil_BadDebtExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='fil_BadDebtExpense' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes' xlink:label='us-gaap_IncreaseDecreaseInIncomeTaxes'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_IncreaseDecreaseInIncomeTaxes' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:label='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' xlink:label='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets' xlink:label='us-gaap_IncreaseDecreaseInDepositOtherAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInDepositOtherAssets' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories' xlink:label='us-gaap_IncreaseDecreaseInInventories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInInventories' use='optional' order='3.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade' xlink:label='us-gaap_IncreaseDecreaseInAccountsPayableTrade'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccountsPayableTrade' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable' xlink:label='us-gaap_IncreaseDecreaseInAccruedTaxesPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedTaxesPayable' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities' xlink:label='us-gaap_IncreaseDecreaseInAccruedLiabilities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInAccruedLiabilities' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvances' xlink:label='us-gaap_IncreaseDecreaseInCustomerAdvances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInCustomerAdvances' use='optional' order='7.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense' xlink:label='us-gaap_IncreaseDecreaseInPrepaidExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_IncreaseDecreaseInPrepaidExpense' use='optional' order='8.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInOperatingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncreaseDecreaseInOperatingCapitalAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInOperatingActivities' use='optional' order='9.0' preferredLabel='http://www.xbrl.org/2003/role/totalLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' xlink:label='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_PaymentsToAcquirePropertyPlantAndEquipment' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInInvestingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInInvestingActivities' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConstructionLoansPayable' xlink:label='us-gaap_ProceedsFromConstructionLoansPayable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_ProceedsFromConstructionLoansPayable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities' xlink:label='us-gaap_NetCashProvidedByUsedInFinancingActivities'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract' xlink:to='us-gaap_NetCashProvidedByUsedInFinancingActivities' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' xlink:label='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' xlink:label='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CashAndCashEquivalentsAtBeginningOfPeriod' xlink:label='fil_CashAndCashEquivalentsAtBeginningOfPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='fil_CashAndCashEquivalentsAtBeginningOfPeriod' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CashAndCashEquivalentsAtEndOfPeriod' xlink:label='fil_CashAndCashEquivalentsAtEndOfPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='fil_CashAndCashEquivalentsAtEndOfPeriod' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract' xlink:label='us-gaap_SupplementalCashFlowInformationAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_SupplementalCashFlowInformationAbstract' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid' xlink:label='us-gaap_InterestPaid'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_SupplementalCashFlowInformationAbstract' xlink:to='us-gaap_InterestPaid' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:label='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract' xlink:to='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IssuanceOfBankerSAcceptances' xlink:label='fil_IssuanceOfBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_IssuanceOfBankerSAcceptances' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AccountsReceivableCollectedWithBankerSAcceptances' xlink:label='fil_AccountsReceivableCollectedWithBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_AccountsReceivableCollectedWithBankerSAcceptances' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InventoryPurchasedWithBankerSAcceptances' xlink:label='fil_InventoryPurchasedWithBankerSAcceptances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract' xlink:to='fil_InventoryPurchasedWithBankerSAcceptances' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:label='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' xlink:label='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1' xlink:to='us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINVENTORY" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureINVENTORY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINVENTORY">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureAbstract' xlink:label='us-gaap_InventoryDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryDisclosureTextBlock' xlink:label='us-gaap_InventoryDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_InventoryDisclosureAbstract' xlink:to='us-gaap_InventoryDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials' xlink:label='us-gaap_InventoryRawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_InventoryDisclosureAbstract' xlink:to='us-gaap_InventoryRawMaterials' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryGross' xlink:label='us-gaap_InventoryGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_InventoryDisclosureAbstract' xlink:to='us-gaap_InventoryGross' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosurePROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosurePROPERTYANDEQUIPMENT"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosurePROPERTYANDEQUIPMENT">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract' xlink:label='us-gaap_PropertyPlantAndEquipmentAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_PropertyPlantAndEquipmentAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureINTANGIBLEASSETS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINTANGIBLEASSETS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:label='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock' xlink:label='us-gaap_IntangibleAssetsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract' xlink:to='us-gaap_IntangibleAssetsDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' xlink:label='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AdvancesForPurchasesOfIntangibleAssetsAbstract' xlink:to='fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureRELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureRELATEDPARTYTRANSACTIONS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureRELATEDPARTYTRANSACTIONS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract' xlink:label='us-gaap_RelatedPartyTransactionsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock' xlink:label='us-gaap_RelatedPartyTransactionsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RelatedPartyTransactionsAbstract' xlink:to='us-gaap_RelatedPartyTransactionsDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankerSAcceptanceNotesPayableAbstract' xlink:label='fil_BankerSAcceptanceNotesPayableAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankerSAcceptanceNotesPayableTextBlock' xlink:label='fil_BankerSAcceptanceNotesPayableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BankerSAcceptanceNotesPayableAbstract' xlink:to='fil_BankerSAcceptanceNotesPayableTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCONSTRUCTIONLOANFACILITY" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureCONSTRUCTIONLOANFACILITY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCONSTRUCTIONLOANFACILITY">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_DebtAbstract' xlink:label='fil_DebtAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermDebtTextBlock' xlink:label='us-gaap_LongTermDebtTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DebtAbstract' xlink:to='us-gaap_LongTermDebtTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINCOMETAXES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureINCOMETAXES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINCOMETAXES">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract' xlink:label='us-gaap_IncomeTaxDisclosureAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock' xlink:label='us-gaap_IncomeTaxDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_IncomeTaxDisclosureAbstract' xlink:to='us-gaap_IncomeTaxDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureFAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureFAIRVALUEMEASUREMENTS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureFAIRVALUEMEASUREMENTS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FairValueMeasurementsAbstract' xlink:label='fil_FairValueMeasurementsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock' xlink:label='us-gaap_FairValueMeasurementInputsDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FairValueMeasurementsAbstract' xlink:to='us-gaap_FairValueMeasurementInputsDisclosureTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureSTOCKHOLDERSEQUITY"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSTOCKHOLDERSEQUITY">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract' xlink:label='us-gaap_EquityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock' xlink:label='us-gaap_StockholdersEquityNoteDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_EquityAbstract' xlink:to='us-gaap_StockholdersEquityNoteDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureCOMMITMENTSANDCONTINGENCIES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CommitmentAndContingenciesAbstract' xlink:label='fil_CommitmentAndContingenciesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' xlink:label='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_CommitmentAndContingenciesAbstract' xlink:to='us-gaap_CommitmentsAndContingenciesDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCONCENTRATIONS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureCONCENTRATIONS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCONCENTRATIONS">
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract' xlink:label='us-gaap_RisksAndUncertaintiesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock' xlink:label='us-gaap_ConcentrationRiskDisclosureTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_RisksAndUncertaintiesAbstract' xlink:to='us-gaap_ConcentrationRiskDisclosureTextBlock' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureACCOUNTINGPOLICIESPOLICIES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AccountingPoliciesAbstract1' xlink:label='fil_AccountingPoliciesAbstract1'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations' xlink:label='us-gaap_NatureOfOperations'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_NatureOfOperations' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock' xlink:label='us-gaap_ConsolidationPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ConsolidationPolicyTextBlock' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates' xlink:label='us-gaap_UseOfEstimates'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_UseOfEstimates' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy' xlink:label='us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock' xlink:label='us-gaap_CashAndCashEquivalentsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_CashAndCashEquivalentsPolicyTextBlock' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_RestrictedCashTextBlock' xlink:label='fil_RestrictedCashTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='fil_RestrictedCashTextBlock' use='optional' order='6.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock' xlink:label='us-gaap_ReceivablesPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ReceivablesPolicyTextBlock' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' xlink:label='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock' xlink:label='us-gaap_InventoryPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_InventoryPolicyTextBlock' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' xlink:label='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_PropertyPlantAndEquipmentPolicyTextBlock' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_RevenueRecognitionPolicyTextBlock' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' xlink:label='us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy' xlink:label='us-gaap_ResearchAndDevelopmentExpensePolicy'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ResearchAndDevelopmentExpensePolicy' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock' xlink:label='us-gaap_EarningsPerSharePolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_EarningsPerSharePolicyTextBlock' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk' xlink:label='us-gaap_ConcentrationRiskCreditRisk'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_ConcentrationRiskCreditRisk' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InterestRateRiskPolicyTextBlock' xlink:label='fil_InterestRateRiskPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='fil_InterestRateRiskPolicyTextBlock' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' xlink:label='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AccountingPoliciesAbstract1' xlink:to='us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock' use='optional' order='18.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINVENTORYTABLES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureINVENTORYTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINVENTORYTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InventoryTablesAbstract' xlink:label='fil_InventoryTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock' xlink:label='us-gaap_ScheduleOfInventoryCurrentTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryTablesAbstract' xlink:to='us-gaap_ScheduleOfInventoryCurrentTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosurePROPERTYANDEQUIPMENTTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PropertyAndEquipmentTablesAbstract' xlink:label='fil_PropertyAndEquipmentTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock' xlink:label='us-gaap_PropertyPlantAndEquipmentTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='us-gaap_PropertyPlantAndEquipmentTextBlock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_UsefulLivesOfTheAssetsTableTextBlock' xlink:label='fil_UsefulLivesOfTheAssetsTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentTablesAbstract' xlink:to='fil_UsefulLivesOfTheAssetsTableTextBlock' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINTANGIBLEASSETSTABLES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureINTANGIBLEASSETSTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINTANGIBLEASSETSTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IntangibleAssetsTablesAbstract' xlink:label='fil_IntangibleAssetsTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IntangibleAssetsMedicalFormulasTablesTextBlock' xlink:label='fil_IntangibleAssetsMedicalFormulasTablesTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsTablesAbstract' xlink:to='fil_IntangibleAssetsMedicalFormulasTablesTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:label='fil_ScheduleOfLongTermDebtInstrumentsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock' xlink:label='us-gaap_ScheduleOfDebtInstrumentsTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ScheduleOfLongTermDebtInstrumentsAbstract' xlink:to='us-gaap_ScheduleOfDebtInstrumentsTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINCOMETAXESTABLES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureINCOMETAXESTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINCOMETAXESTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IncomeTaxesTablesAbstract' xlink:label='fil_IncomeTaxesTablesAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' xlink:label='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' xlink:label='us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesTablesAbstract' xlink:to='us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FairValueMeasuresAndDisclosuresAbstract' xlink:label='fil_FairValueMeasuresAndDisclosuresAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock' xlink:label='us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FairValueMeasuresAndDisclosuresAbstract' xlink:to='us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:label='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' xlink:label='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' xlink:label='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PercetageOfAcquiredByOnnyInHelpson' xlink:label='fil_PercetageOfAcquiredByOnnyInHelpson'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract' xlink:to='fil_PercetageOfAcquiredByOnnyInHelpson' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_TRADEACCOUNTSRECEIVABLEANDALLOWANCEFORDOUBTFULACCOUNTSDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_TRADEACCOUNTSRECEIVABLEANDALLOWANCEFORDOUBTFULACCOUNTSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_TRADEACCOUNTSRECEIVABLEANDALLOWANCEFORDOUBTFULACCOUNTSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:label='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BadDebtExpenseTotaled' xlink:label='fil_BadDebtExpenseTotaled'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:to='fil_BadDebtExpenseTotaled' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TradeAccountsReceivableBalances' xlink:label='fil_TradeAccountsReceivableBalances'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract' xlink:to='fil_TradeAccountsReceivableBalances' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_INVENTORYCONSISTEDOFTHEFOLLOWINGDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_INVENTORYCONSISTEDOFTHEFOLLOWINGDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_INVENTORYCONSISTEDOFTHEFOLLOWINGDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InventoryConsistedOfTheFollowingDetailsAbstract' xlink:label='fil_InventoryConsistedOfTheFollowingDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_RawMaterials' xlink:label='fil_RawMaterials'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryConsistedOfTheFollowingDetailsAbstract' xlink:to='fil_RawMaterials' use='optional' order='1.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_WorkInProcess' xlink:label='fil_WorkInProcess'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryConsistedOfTheFollowingDetailsAbstract' xlink:to='fil_WorkInProcess' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FinishedGoods' xlink:label='fil_FinishedGoods'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryConsistedOfTheFollowingDetailsAbstract' xlink:to='fil_FinishedGoods' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InventoryGross1' xlink:label='fil_InventoryGross1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryConsistedOfTheFollowingDetailsAbstract' xlink:to='fil_InventoryGross1' use='optional' order='4.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryValuationReserves' xlink:label='us-gaap_InventoryValuationReserves'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryConsistedOfTheFollowingDetailsAbstract' xlink:to='us-gaap_InventoryValuationReserves' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalInventory' xlink:label='fil_TotalInventory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_InventoryConsistedOfTheFollowingDetailsAbstract' xlink:to='fil_TotalInventory' use='optional' order='6.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' xlink:label='fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LandAndLandImprovements' xlink:label='us-gaap_LandAndLandImprovements'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' xlink:to='us-gaap_LandAndLandImprovements' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BuildingsAndImprovementsGross' xlink:label='us-gaap_BuildingsAndImprovementsGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' xlink:to='us-gaap_BuildingsAndImprovementsGross' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MachineryAndEquipmentGross' xlink:label='us-gaap_MachineryAndEquipmentGross'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' xlink:to='us-gaap_MachineryAndEquipmentGross' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_MotorVehicle' xlink:label='fil_MotorVehicle'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' xlink:to='fil_MotorVehicle' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_OfficeEquipment' xlink:label='fil_OfficeEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' xlink:to='fil_OfficeEquipment' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_Total' xlink:label='fil_Total'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' xlink:to='fil_Total' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_LessAccumulatedDepreciation' xlink:label='fil_LessAccumulatedDepreciation'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' xlink:to='fil_LessAccumulatedDepreciation' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PropertyAndEquipmentNet' xlink:label='fil_PropertyAndEquipmentNet'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract' xlink:to='fil_PropertyAndEquipmentNet' use='optional' order='8.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_PROPERTYANDEQUIPMENTASSETSLIFEDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_PROPERTYANDEQUIPMENTASSETSLIFEDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_PROPERTYANDEQUIPMENTASSETSLIFEDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:label='fil_PropertyAndEquipmentAssetsLifeAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PermitOfLandUseMinimumLife' xlink:label='fil_PermitOfLandUseMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:to='fil_PermitOfLandUseMinimumLife' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PermitOfLandUseMaximumLife' xlink:label='fil_PermitOfLandUseMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:to='fil_PermitOfLandUseMaximumLife' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BuildingMinimumLife' xlink:label='fil_BuildingMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:to='fil_BuildingMinimumLife' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BuildingMaximumLife' xlink:label='fil_BuildingMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:to='fil_BuildingMaximumLife' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PlantMachineryAndEquipmentMinimumLife' xlink:label='fil_PlantMachineryAndEquipmentMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:to='fil_PlantMachineryAndEquipmentMinimumLife' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PlantMachineryAndEquipmentMaximumLife' xlink:label='fil_PlantMachineryAndEquipmentMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:to='fil_PlantMachineryAndEquipmentMaximumLife' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_MotorVehicleMinimumLife' xlink:label='fil_MotorVehicleMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:to='fil_MotorVehicleMinimumLife' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_MotorVehicleMaximumLife' xlink:label='fil_MotorVehicleMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:to='fil_MotorVehicleMaximumLife' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_OfficeEquipmentMinimumLife' xlink:label='fil_OfficeEquipmentMinimumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:to='fil_OfficeEquipmentMinimumLife' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_OfficeEquipmentMaximumLife' xlink:label='fil_OfficeEquipmentMaximumLife'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PropertyAndEquipmentAssetsLifeAbstract' xlink:to='fil_OfficeEquipmentMaximumLife' use='optional' order='10.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_ASSETSDEPRECIATIONDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_ASSETSDEPRECIATIONDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_ASSETSDEPRECIATIONDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AssetsDepreciationDetailsAbstract' xlink:label='fil_AssetsDepreciationDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_DepreciationExpensePropertyAndEquipment' xlink:label='fil_DepreciationExpensePropertyAndEquipment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AssetsDepreciationDetailsAbstract' xlink:to='fil_DepreciationExpensePropertyAndEquipment' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract' xlink:label='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_GrossCarryingAmount' xlink:label='fil_GrossCarryingAmount'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract' xlink:to='fil_GrossCarryingAmount' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AccumulatedAmortization' xlink:label='fil_AccumulatedAmortization'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract' xlink:to='fil_AccumulatedAmortization' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_NetCarryingAmount' xlink:label='fil_NetCarryingAmount'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract' xlink:to='fil_NetCarryingAmount' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_AMORTIZATIONEXPENSEDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_AMORTIZATIONEXPENSEDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_AMORTIZATIONEXPENSEDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AmortizationExpenseAbstract' xlink:label='fil_AmortizationExpenseAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AmortizationExpensesRelatingToIntangibleAssets' xlink:label='fil_AmortizationExpensesRelatingToIntangibleAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AmortizationExpenseAbstract' xlink:to='fil_AmortizationExpensesRelatingToIntangibleAssets' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:label='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CompanyWasObligatedToPayLaboratories' xlink:label='fil_CompanyWasObligatedToPayLaboratories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:to='fil_CompanyWasObligatedToPayLaboratories' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories' xlink:label='fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract' xlink:to='fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_RELATEDPARTYTRANSACTIONSOWINGSDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_RELATEDPARTYTRANSACTIONSOWINGSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_RELATEDPARTYTRANSACTIONSOWINGSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_RelatedPartyTransactionsOwingsAbstract' xlink:label='fil_RelatedPartyTransactionsOwingsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AdavancesOwingToBoard' xlink:label='fil_AdavancesOwingToBoard'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_RelatedPartyTransactionsOwingsAbstract' xlink:to='fil_AdavancesOwingToBoard' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InterestRateOnAdvancesFromMemberOfBOD' xlink:label='fil_InterestRateOnAdvancesFromMemberOfBOD'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_RelatedPartyTransactionsOwingsAbstract' xlink:to='fil_InterestRateOnAdvancesFromMemberOfBOD' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_RELATEDPARTYTRANSACTIONSMEMBEROFBODDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_RELATEDPARTYTRANSACTIONSMEMBEROFBODDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_RELATEDPARTYTRANSACTIONSMEMBEROFBODDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_RelatedPartyTransactionsMemberOfBod1Abstract' xlink:label='fil_RelatedPartyTransactionsMemberOfBod1Abstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalInterestExpenseRecognizedForThePeriod' xlink:label='fil_TotalInterestExpenseRecognizedForThePeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_RelatedPartyTransactionsMemberOfBod1Abstract' xlink:to='fil_TotalInterestExpenseRecognizedForThePeriod' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_BANKERSACCEPTANCENOTESPAYABLEDetails" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_BANKERSACCEPTANCENOTESPAYABLEDetails"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_BANKERSACCEPTANCENOTESPAYABLEDetails">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankerSAcceptanceNotesPayableDetailsAbstract' xlink:label='fil_BankerSAcceptanceNotesPayableDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes' xlink:label='fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BankerSAcceptanceNotesPayableDetailsAbstract' xlink:to='fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank' xlink:label='fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BankerSAcceptanceNotesPayableDetailsAbstract' xlink:to='fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CompanyHadOutstandingBankerSAcceptanceNotes' xlink:label='fil_CompanyHadOutstandingBankerSAcceptanceNotes'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_BankerSAcceptanceNotesPayableDetailsAbstract' xlink:to='fil_CompanyHadOutstandingBankerSAcceptanceNotes' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONSTRUCTIONLOANFACILITYDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONSTRUCTIONLOANFACILITYDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONSTRUCTIONLOANFACILITYDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ConstructionLoanFacilityDetailsAbstract' xlink:label='fil_ConstructionLoanFacilityDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalLoanFacilityAmountRmb80000000' xlink:label='fil_TotalLoanFacilityAmountRmb80000000'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='fil_TotalLoanFacilityAmountRmb80000000' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CompanyMadeAPrincipalPayment' xlink:label='fil_CompanyMadeAPrincipalPayment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='fil_CompanyMadeAPrincipalPayment' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_RemainingAnnualPrincipalPayment' xlink:label='fil_RemainingAnnualPrincipalPayment'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConstructionLoanFacilityDetailsAbstract' xlink:to='fil_RemainingAnnualPrincipalPayment' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:label='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PrincipalPayments2017' xlink:label='fil_PrincipalPayments2017'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2017' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PrincipalPayments2018' xlink:label='fil_PrincipalPayments2018'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2018' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PrincipalPayments2019' xlink:label='fil_PrincipalPayments2019'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2019' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PrincipalPayments2020' xlink:label='fil_PrincipalPayments2020'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2020' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PrincipalPayments2021' xlink:label='fil_PrincipalPayments2021'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_PrincipalPayments2021' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalPrincipalPaymentsDue' xlink:label='fil_TotalPrincipalPaymentsDue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract' xlink:to='fil_TotalPrincipalPaymentsDue' use='optional' order='6.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_INCOMETAXESUNDISTRIBUTEDEARNINGSANDINCOMRTAXRATESDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_INCOMETAXESUNDISTRIBUTEDEARNINGSANDINCOMRTAXRATESDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_INCOMETAXESUNDISTRIBUTEDEARNINGSANDINCOMRTAXRATESDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IncomeTaxesUndistributedEarningsAbstract' xlink:label='fil_IncomeTaxesUndistributedEarningsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_UndistributedEarningsOfHelpson' xlink:label='fil_UndistributedEarningsOfHelpson'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesUndistributedEarningsAbstract' xlink:to='fil_UndistributedEarningsOfHelpson' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' xlink:label='fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesUndistributedEarningsAbstract' xlink:to='fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2016' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2016'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesUndistributedEarningsAbstract' xlink:to='fil_EnterpriseIncomeTaxRatesForTheYear2016' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_EnterpriseIncomeTaxRatesForTheYear2017' xlink:label='fil_EnterpriseIncomeTaxRatesForTheYear2017'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesUndistributedEarningsAbstract' xlink:to='fil_EnterpriseIncomeTaxRatesForTheYear2017' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_EnterpriseIncomeTaxRateThereafter' xlink:label='fil_EnterpriseIncomeTaxRateThereafter'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesUndistributedEarningsAbstract' xlink:to='fil_EnterpriseIncomeTaxRateThereafter' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1' xlink:label='fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesUndistributedEarningsAbstract' xlink:to='fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1' xlink:label='fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesUndistributedEarningsAbstract' xlink:to='fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1' use='optional' order='7.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_INCOMETAXESPROVISIONDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_INCOMETAXESPROVISIONDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_INCOMETAXESPROVISIONDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_IncomeTaxesProvisionAbstract' xlink:label='fil_IncomeTaxesProvisionAbstract'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit' xlink:label='us-gaap_CurrentFederalTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesProvisionAbstract' xlink:to='us-gaap_CurrentFederalTaxExpenseBenefit' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit' xlink:label='us-gaap_DeferredForeignIncomeTaxExpenseBenefit'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesProvisionAbstract' xlink:to='us-gaap_DeferredForeignIncomeTaxExpenseBenefit' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalIncomeTaxBenefitExpense' xlink:label='fil_TotalIncomeTaxBenefitExpense'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_IncomeTaxesProvisionAbstract' xlink:to='fil_TotalIncomeTaxBenefitExpense' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_DeferredIncomeTaxAssetsAndLiabilityAbstract' xlink:label='fil_DeferredIncomeTaxAssetsAndLiabilityAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ValuationAllowanceAgainstDeferredTaxAssets' xlink:label='fil_ValuationAllowanceAgainstDeferredTaxAssets'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_DeferredIncomeTaxAssetsAndLiabilityAbstract' xlink:to='fil_ValuationAllowanceAgainstDeferredTaxAssets' use='optional' order='1.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FairValueMeasurementsAtReportingDateUsingAbstract' xlink:label='fil_FairValueMeasurementsAtReportingDateUsingAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankersAcceptanceNotes' xlink:label='fil_BankersAcceptanceNotes'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FairValueMeasurementsAtReportingDateUsingAbstract' xlink:to='fil_BankersAcceptanceNotes' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_Total1' xlink:label='fil_Total1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FairValueMeasurementsAtReportingDateUsingAbstract' xlink:to='fil_Total1' use='optional' order='2.0' preferredLabel='http://www.xbrl.org/2003/role/terseLabel'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankersAcceptanceNotesLevel1' xlink:label='fil_BankersAcceptanceNotesLevel1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FairValueMeasurementsAtReportingDateUsingAbstract' xlink:to='fil_BankersAcceptanceNotesLevel1' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalLevel1' xlink:label='fil_TotalLevel1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FairValueMeasurementsAtReportingDateUsingAbstract' xlink:to='fil_TotalLevel1' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankersAcceptanceNotesLevel2' xlink:label='fil_BankersAcceptanceNotesLevel2'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FairValueMeasurementsAtReportingDateUsingAbstract' xlink:to='fil_BankersAcceptanceNotesLevel2' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalLevel2' xlink:label='fil_TotalLevel2'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FairValueMeasurementsAtReportingDateUsingAbstract' xlink:to='fil_TotalLevel2' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_BankersAcceptanceNotesLevel3' xlink:label='fil_BankersAcceptanceNotesLevel3'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FairValueMeasurementsAtReportingDateUsingAbstract' xlink:to='fil_BankersAcceptanceNotesLevel3' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_TotalLevel3' xlink:label='fil_TotalLevel3'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_FairValueMeasurementsAtReportingDateUsingAbstract' xlink:to='fil_TotalLevel3' use='optional' order='8.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_PREFERREDCOMMONSTOCKDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_PREFERREDCOMMONSTOCKDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_PREFERREDCOMMONSTOCKDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PreferredCommonStockAndWarrantsAbstract' xlink:label='fil_PreferredCommonStockAndWarrantsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_CommonSharesAuthorized' xlink:label='fil_CommonSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PreferredCommonStockAndWarrantsAbstract' xlink:to='fil_CommonSharesAuthorized' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PreferredSharesAuthorized' xlink:label='fil_PreferredSharesAuthorized'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PreferredCommonStockAndWarrantsAbstract' xlink:to='fil_PreferredSharesAuthorized' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_PreferredSharesParValue' xlink:label='fil_PreferredSharesParValue'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_PreferredCommonStockAndWarrantsAbstract' xlink:to='fil_PreferredSharesParValue' use='optional' order='3.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_STOCKOPTIONPLANDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_STOCKOPTIONPLANDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_STOCKOPTIONPLANDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_StockholdersEquity2010StockOptionPlanAbstract' xlink:label='fil_StockholdersEquity2010StockOptionPlanAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_NumberOfCommonShares' xlink:label='fil_NumberOfCommonShares'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StockholdersEquity2010StockOptionPlanAbstract' xlink:to='fil_NumberOfCommonShares' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' xlink:label='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_StockholdersEquity2010StockOptionPlanAbstract' xlink:to='fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan' use='optional' order='2.0'/>
	</link:presentationLink>
	<link:roleRef roleURI="http://www.chinapharmaholdings.com/20170331/role/idr_CONCENTRATIONSDETAILS" xlink:type="simple" xlink:href="cphi-20170331.xsd#idr_CONCENTRATIONSDETAILS"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://www.chinapharmaholdings.com/20170331/role/idr_CONCENTRATIONSDETAILS">
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ConcentrationsDetailsAbstract' xlink:label='fil_ConcentrationsDetailsAbstract'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FirstCustomerAccountedAccountsReceivable' xlink:label='fil_FirstCustomerAccountedAccountsReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_FirstCustomerAccountedAccountsReceivable' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_SecondCustomerAccountedAccountsReceivable' xlink:label='fil_SecondCustomerAccountedAccountsReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_SecondCustomerAccountedAccountsReceivable' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ThirdCustomerAccountedAccountsReceivable' xlink:label='fil_ThirdCustomerAccountedAccountsReceivable'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_ThirdCustomerAccountedAccountsReceivable' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FirstSupplierAccountedForRawMaterialPurchases' xlink:label='fil_FirstSupplierAccountedForRawMaterialPurchases'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_FirstSupplierAccountedForRawMaterialPurchases' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_SecondSupplierAccountedForRawMaterialPurchases' xlink:label='fil_SecondSupplierAccountedForRawMaterialPurchases'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_SecondSupplierAccountedForRawMaterialPurchases' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_ThirdSupplierAccountedForRawMaterialPurchases' xlink:label='fil_ThirdSupplierAccountedForRawMaterialPurchases'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_ThirdSupplierAccountedForRawMaterialPurchases' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='cphi-20170331.xsd#fil_FourthSupplierAccountedForRawMaterialPurchases' xlink:label='fil_FourthSupplierAccountedForRawMaterialPurchases'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='fil_ConcentrationsDetailsAbstract' xlink:to='fil_FourthSupplierAccountedForRawMaterialPurchases' use='optional' order='7.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815254704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>May 10, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CHINA PHARMA HOLDINGS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Entity Trading Symbol</a></td>
<td class="text">cphi<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001106644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815801024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,523,541<span></span>
</td>
<td class="nump">$ 2,665,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">1,718,823<span></span>
</td>
<td class="nump">1,088,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssetsCurrent', window );">Banker's acceptances</a></td>
<td class="nump">14,513<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1', window );">Trade accounts receivable, less allowance for doubtful accounts of $16,161,252 and $15,664,496, respectively</a></td>
<td class="nump">3,703,593<span></span>
</td>
<td class="nump">3,999,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other receivables, less allowance for doubtful accounts of $56,157 and $71,548, respectively</a></td>
<td class="nump">272,097<span></span>
</td>
<td class="nump">224,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesToSuppliers', window );">Advances to suppliers</a></td>
<td class="nump">2,036,758<span></span>
</td>
<td class="nump">2,003,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">6,985,965<span></span>
</td>
<td class="nump">7,310,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">205,293<span></span>
</td>
<td class="nump">226,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">17,460,583<span></span>
</td>
<td class="nump">17,519,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangibleAssets', window );">Advances for purchases of intangible assets</a></td>
<td class="nump">35,771,976<span></span>
</td>
<td class="nump">35,498,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">24,422,373<span></span>
</td>
<td class="nump">24,967,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">488,044<span></span>
</td>
<td class="nump">534,682<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">78,142,976<span></span>
</td>
<td class="nump">78,520,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">2,877,412<span></span>
</td>
<td class="nump">3,060,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">90,232<span></span>
</td>
<td class="nump">139,830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other payables</a></td>
<td class="nump">2,355,365<span></span>
</td>
<td class="nump">2,502,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerAdvancesCurrent', window );">Advances from customers</a></td>
<td class="nump">703,915<span></span>
</td>
<td class="nump">811,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Other payables - related parties</a></td>
<td class="nump">1,354,567<span></span>
</td>
<td class="nump">1,354,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermConstructionLoanCurrent', window );">Current portion of construction loan facility</a></td>
<td class="nump">1,440,154<span></span>
</td>
<td class="nump">1,440,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotesPayable', window );">Bankers' acceptance notes payable</a></td>
<td class="nump">1,718,823<span></span>
</td>
<td class="nump">1,088,879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">10,540,468<span></span>
</td>
<td class="nump">10,397,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent', window );">Construction loan facility</a></td>
<td class="nump">8,573,590<span></span>
</td>
<td class="nump">8,640,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">607,090<span></span>
</td>
<td class="nump">572,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">19,721,148<span></span>
</td>
<td class="nump">19,611,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively</a></td>
<td class="nump">43,580<span></span>
</td>
<td class="nump">43,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">23,590,204<span></span>
</td>
<td class="nump">23,590,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">23,790,476<span></span>
</td>
<td class="nump">24,757,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss', window );">Accumulated other comprehensive income</a></td>
<td class="nump">10,997,568<span></span>
</td>
<td class="nump">10,517,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">58,421,828<span></span>
</td>
<td class="nump">58,909,134<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 78,142,976<span></span>
</td>
<td class="nump">$ 78,520,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>AdvancesForPurchasesOfIntangibleAssets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchasesOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of advances to suppliers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers' acceptance notes payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankersAcceptanceNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade accounts receivable, less allowance for doubtful accounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TradeAccountsReceivableLessAllowanceForDoubtfulAccounts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerAdvancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of prepayments received from customers for goods or services to be provided in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerAdvancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermConstructionLoanCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current portion of a long-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermConstructionLoanCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConstructionLoanCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the current and noncurrent portions of a long-term real estate loan with an initial maturity beyond one year or beyond the normal operating cycle, if longer, to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConstructionLoanCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets that are pledged or subject to withdrawal restrictions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated other comprehensive Income or Loss at the balance sheet date before fresh-start adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=34712771&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815875504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS PARENTHETICALS - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockTransactionsParentheticalDisclosuresAbstract', window );"><strong>Parentheticals</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts on trade accounts receivable</a></td>
<td class="nump">$ 16,161,252<span></span>
</td>
<td class="nump">$ 15,664,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AllowanceForDoubtfulAccountsOnOtherReceivables', window );">Allowance for doubtful accounts on other receivables</a></td>
<td class="nump">$ 56,157<span></span>
</td>
<td class="nump">$ 71,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">95,000,000<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AllowanceForDoubtfulAccountsOnOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AllowanceForDoubtfulAccountsOnOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockTransactionsParentheticalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockTransactionsParentheticalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813626304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues {1}</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 3,285,203<span></span>
</td>
<td class="nump">$ 3,640,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">2,567,350<span></span>
</td>
<td class="nump">2,999,675<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">717,853<span></span>
</td>
<td class="nump">640,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">717,637<span></span>
</td>
<td class="nump">968,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">416,726<span></span>
</td>
<td class="nump">318,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">26,060<span></span>
</td>
<td class="nump">93,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense</a></td>
<td class="nump">360,063<span></span>
</td>
<td class="nump">581,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,520,486<span></span>
</td>
<td class="nump">1,962,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(802,633)<span></span>
</td>
<td class="num">(1,321,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">5,033<span></span>
</td>
<td class="nump">33,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(138,964)<span></span>
</td>
<td class="num">(242,309)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Net other expense</a></td>
<td class="num">(133,931)<span></span>
</td>
<td class="num">(208,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(936,564)<span></span>
</td>
<td class="num">(1,530,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxExpense1', window );">Income tax expense</a></td>
<td class="num">(30,334)<span></span>
</td>
<td class="num">(22,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(966,898)<span></span>
</td>
<td class="num">(1,552,896)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income - foreign currency translation adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">480,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (966,898)<span></span>
</td>
<td class="num">$ (1,072,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding</a></td>
<td class="nump">43,579,557<span></span>
</td>
<td class="nump">43,579,557<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxExpense1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited) For the Three Months ended March 31, 2017 For the Three Months ended March 31, 2016 Revenues Revenue 32,85,203 36,40,494 Cost of revenue 25,67,350 29,99,675 Gross profit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IncomeTaxExpense1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815713152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (966,898)<span></span>
</td>
<td class="num">$ (1,552,896)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">815,394<span></span>
</td>
<td class="nump">857,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BadDebtExpense', window );">Bad debt expense</a></td>
<td class="nump">360,063<span></span>
</td>
<td class="nump">581,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="nump">30,334<span></span>
</td>
<td class="nump">22,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade accounts and other receivables</a></td>
<td class="num">(261,377)<span></span>
</td>
<td class="num">(61,069)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDepositOtherAssets', window );">Advances to suppliers</a></td>
<td class="num">(17,509)<span></span>
</td>
<td class="num">(92,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">549,500<span></span>
</td>
<td class="nump">215,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payable</a></td>
<td class="num">(206,599)<span></span>
</td>
<td class="nump">888,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Accrued taxes payable</a></td>
<td class="num">(71,575)<span></span>
</td>
<td class="num">(53,955)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Other payables and accrued expenses</a></td>
<td class="num">(130,772)<span></span>
</td>
<td class="nump">25,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCustomerAdvances', window );">Advances from customers</a></td>
<td class="num">(113,615)<span></span>
</td>
<td class="nump">328,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">22,818<span></span>
</td>
<td class="nump">144,262<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">9,764<span></span>
</td>
<td class="nump">1,303,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(26,628)<span></span>
</td>
<td class="num">(39,248)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(26,628)<span></span>
</td>
<td class="num">(39,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConstructionLoansPayable', window );">Payments of construction term loan</a></td>
<td class="num">(145,176)<span></span>
</td>
<td class="num">(305,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used in Financing Activity</a></td>
<td class="num">(145,176)<span></span>
</td>
<td class="num">(305,835)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of Exchange Rate Changes on Cash</a></td>
<td class="nump">19,779<span></span>
</td>
<td class="nump">54,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (Decrease) Increase in Cash and Cash Equivalents</a></td>
<td class="num">(142,261)<span></span>
</td>
<td class="nump">1,013,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashAndCashEquivalentsAtBeginningOfPeriod', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">2,665,802<span></span>
</td>
<td class="nump">6,248,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CashAndCashEquivalentsAtEndOfPeriod', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">2,523,541<span></span>
</td>
<td class="nump">7,261,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">138,964<span></span>
</td>
<td class="nump">242,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Noncash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IssuanceOfBankerSAcceptances', window );">Issuance of banker's acceptances</a></td>
<td class="nump">621,753<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccountsReceivableCollectedWithBankerSAcceptances', window );">Accounts receivable collected with banker's acceptances</a></td>
<td class="nump">182,499<span></span>
</td>
<td class="nump">517,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryPurchasedWithBankerSAcceptances', window );">Inventory purchased with banker's acceptances</a></td>
<td class="nump">$ 167,981<span></span>
</td>
<td class="nump">$ 403,081<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccountsReceivableCollectedWithBankerSAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable collected with banker's acceptances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AccountsReceivableCollectedWithBankerSAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BadDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BadDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashAndCashEquivalentsAtBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashAndCashEquivalentsAtBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CashAndCashEquivalentsAtEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CashAndCashEquivalentsAtEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryPurchasedWithBankerSAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory purchased with banker's acceptances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InventoryPurchasedWithBankerSAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IssuanceOfBankerSAcceptances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of banker's acceptances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IssuanceOfBankerSAcceptances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCustomerAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of prepayments by customers for goods or services to be provided at a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInCustomerAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDepositOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDepositOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConstructionLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings to finance the cost of construction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConstructionLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6619674576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1', window );"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><!--egx--><p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">NOTE 1 &#150; ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</font></b></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Organization and Nature of Operations &#150; </font></i></b><font lang="EN-US">China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US" style='background:white'>On December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&nbsp;&nbsp;The reincorporation merger was approved by stockholders holding the majority of the Company&#146;s outstanding shares of common stock on December 21, 2012.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US" style='background:white'>The Foreign Investment Industrial Catalogue<i>&nbsp;</i>(the &#147;Catalogue&#148;) jointly issued by China&#146;s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &#147;FIE&#148;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company&#146;s business.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US" style='background:white'>Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&#146;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson&#146;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Consolidation and Basis of Presentation </font></i></b><font lang="EN-US">&#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Helpson&#146;s functional currency is the Chinese Renminbi. Helpson&#146;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&#146;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&#146; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Accounting Estimates </font></i></b><b><font lang="EN-US">- </font></b><font lang="EN-US">The methodology used to prepare for the Company&#146;s financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company (&#147;Management&#148;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Cash and Cash Equivalents </font></i></b><font lang="EN-US">&#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&#146;s acceptances purchased with maturities of three months or less.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Restricted Cash</font></i></b><b><font lang="EN-US">&nbsp;</font></b><font lang="EN-US">&#150;<b>&nbsp;</b>Restricted cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker's acceptance notes issued by the Company as discussed in Note 7.</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Trade Accounts Receivable and Allowance for Doubtful Accounts &#150; </font></i></b><font lang="EN-US">Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $360,063 and $581,300 for the three months ended March 31, 2017 and 2016, respectively.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectable trade accounts receivable balances in the amount of $0 against the allowance for both the three months ended March 31, 2017 and 2016, respectively. It is common practice in the pharmaceutical industry in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Advances to Suppliers and Advances from Customers</font></i></b><font lang="EN-US"> &#150; Common practice in the pharmaceutical industry in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier's credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected. The Company recognized no bad debt expense for the three months ended March 31, 2017 and 2016, respectively.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">&nbsp;</font></i></b></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Inventories&nbsp;&#150;</font></i></b><font lang="EN-US"> Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or market. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated portion of the Company&#146;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value. Market for raw materials is based on replacement cost. Provisions for inventory write-downs are included in cost of revenues in the consolidated statements of operations. Once written down, inventories are carried at this lower cost basis until sold or scrapped.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Valuation of Long-Lived Assets </font></i></b><font lang="EN-US">&#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. There was no impairment adjustment required for the three months ended March 31, 2017 and 2016.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Property and Equipment</font></i></b><font lang="EN-US"> &#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Revenue Recognition</font></i></b><font lang="EN-US"> &#150; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved. Revenue is deferred when collectability is not considered to be reasonably assured.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Cost of Revenues</font></i></b><font lang="EN-US"> &#150; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery of products.</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Research and Development</font></i></b><font lang="EN-US"> &#150; Research and development expenditures are recorded as expenses in the period in which they occur.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Basic and Diluted Loss per Common Share </font></i></b><b><font lang="EN-US">- </font></b><font lang="EN-US">Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares. There were no potential dilutive common shares outstanding during the three months ended March 31, 2017 and 2016, respectively.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Credit Risk</font></i></b><font lang="EN-US"> &#150; The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimates.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&#146; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&#146;s deposits may be at a higher risk of loss.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Interest Rate Risk</font></i></b><font lang="EN-US"> &#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Recent Accounting Pronouncements</font></i></b></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In May 2014, the FASB issued ASU 2014-09,&nbsp;<i>"Revenue from Contracts with Customers"</i>&nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. &nbsp;In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In February 2016, the FASB issued ASU No. 2016-02,&nbsp;<i>Leases</i>, a new standard on accounting for leases. The ASU introduces a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB's new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The pronouncement is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, using a modified retrospective approach. Early adoption is permitted. The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In June 2016, the FASB issued Accounting Standards Update 2016-13,&nbsp;<i>Financial Instruments &#150; Credit Losses (Topic 326)</i>, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial assets with credit deterioration since their origination.&nbsp;The pronouncement will be effective for Public business entities that are SEC filers in fiscal years beginning after&nbsp;December 15, 2019, including interim periods within those fiscal years.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Early application of the guidance will be permitted for all entities for fiscal years beginning after&nbsp;December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and related disclosures.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In August 2016, the FASB issued ASU No. 2016-15,&nbsp;<i>Classification of Certain Cash Receipts and Cash Payments</i>. The standard addresses the classification and presentation of eight specific cash flow issues that currently result in diverse practices. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The amendments in this ASU should be applied using a retrospective approach.&nbsp; The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures, but does not expect the impact to be material.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In November 2016, the FASB issued ASU 2016-18,&nbsp;<i>Statement of Cash Flows (Topic 230): Restricted Cash (&#147;ASU 2016-18&#148;)</i>. The ASU requires an entity to explain the changes in the total of cash, cash equivalents, restricted cash, and restricted cash equivalents on the statement of cash flows and to provide a reconciliation of the totals in that statement to the related captions in the balance sheet when the cash, cash equivalents, restricted cash, and restricted cash equivalents are presented in more than one line item on the balance sheet. This ASU is effective for annual and interim periods beginning after December 15, 2017, and is required to be adopted using a retrospective approach, with early adoption permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-18 may have on its consolidated financial statements.&nbsp;</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company&#146;s financial position, result of operations or cash flows.&nbsp;&nbsp;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6615587360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><!--egx--><p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">NOTE 2 &#150; INVENTORY</font></b></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Inventory consisted of the following:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">March 31,</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">December 31,</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2017</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2016</font></b></p></td></tr> <tr> <td valign="bottom" width="56%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Raw materials</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">10,796,239</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">11,562,388</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Work in process</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">692,827</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">360,550</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Finished goods</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">1,397,514</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">1,530,641</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">12,886,580</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">13,453,579</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Obsolescence reserve</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">(5,900,615</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">)</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">(6,142,640</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">)</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:9pt;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">Total Inventory</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">6,985,965</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">7,310,939</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr></table> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;&nbsp;</font></b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806367360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><!--egx--><p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">NOTE 3 - PROPERTY AND EQUIPMENT</font></b></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Property and equipment consisted of the following:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">March 31,</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">December 31,</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2017</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2016</font></b></p></td></tr> <tr> <td valign="bottom" width="56%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Permit of land use</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">408,775</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">405,645</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Building</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">9,492,387</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">9,419,700</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Plant, machinery and equipment</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">26,379,439</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">26,151,029</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Motor vehicle</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">312,167</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">309,777</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Office equipment</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">184,128</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">182,718</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:9pt;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">Total</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">36,776,896</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">36,468,869</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Less: accumulated depreciation</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">(12,354,523</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">)</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">(11,501,421</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">)</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">Property and Equipment, net</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">24,422,373</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">24,967,448</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr></table> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;&nbsp;</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" width="71%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:71%;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">Asset</font></p></td> <td valign="bottom" width="2%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:2%;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="27%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:27%;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;Life - years&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Permit of land use</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">40 - 70</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Building</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">20 - 49</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Plant, machinery and equipment</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">5 - 10</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Motor vehicle</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">5 - 10</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Office equipment</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">3-5</font></p></td></tr></table> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. For the three months ended March 31, 2017 and 2016, depreciation expense was $764,614 and $790,254, respectively.&nbsp;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620952256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><font lang="EN-US">NOTE 4 - INTANGIBLE ASSETS</font></b></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Intangible assets represent the cost of medical formulas approved for production by the China Food and Drug Administration (&#147;CFDA&#148;). The Company did not obtain CFDA production approval for any medical formula during the three months ended March 31, 2017 and 2016 and no costs were reclassified from advances to intangible assets during the three months ended March 31, 2017 and 2016, respectively.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.&nbsp;&nbsp;It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $50,780 and $66,941 for the three months ended March 31, 2017 and 2016, respectively, and was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period.&nbsp;</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Company&#146;s evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company&#146;s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the three months ended March 31, 2017 and 2016.&nbsp;</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Intangible assets consisted solely of CFDA approved medical formulas as follows:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">March 31,</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">December 31,</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2017</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2016</font></b></p></td></tr> <tr> <td valign="bottom" width="56%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Gross carrying amount</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">4,899,281</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">4,861,766</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Accumulated amortization</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">(4,411,237</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">)</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">(4,327,084</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">)</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Net carrying amount</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">488,044</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">534,682</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr></table> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806360016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract', window );"><strong>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock', window );">ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</a></td>
<td class="text"><!--egx--><p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">NOTE 5 &#150; ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS</font></b></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In order to expand the number of medicines the Company manufactured and marketed, it has entered into contracts with independent laboratories and others for the purchase of medical formulas. Although CFDA approval had not been obtained for these medical formulas at the dates of the respective contracts, the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. The Company received the titles to two patents that relate to medical formulas currently in the CFDA approval process for the year end December 31, 2013. These patents have not expired.</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Prior to entering into contracts with the Company, laboratories typically are required to complete all&nbsp;research and development to determine the content of the medical formula and the method to produce the generic medicine. The application to the CFDA for production approval must be made by the production facility that will produce the related product. As a result, a contract typically provides that the Company buys the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the CFDA.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">A typical CFDA approval process for the production of a generic medical product involves a number of steps that generally require three to five years to complete. If the medical formula is purchased at the point when the generic medical product receives the CFDA&#146;s approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take from one and a half to three years to complete. After completing the clinical study, the results are submitted to the CFDA and a production approval application is filed with the CFDA. In most cases, it will take between eight to eighteen months to prepare and submit the production approval application and obtain CFDA approval. Upon approving the generic medical product, the CFDA issues a production certificate and the Company can commence the production and sales of the generic medical product. As a result of this process, CFDA approval is expected to be received in approximately two to five years from the date&nbsp;the Company signs the medical formula contracts.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is required under the contract to provide a refund to the Company of the full amount of the payments made to the laboratory for that formula, or the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets. During the fiscal year of 2016, with CFDA's new regulations on scrutiny procedures in connection with its review of production applications and based on the Company's monitoring and assessment process, the Company determined five advanced payments to five independent laboratories were impaired. As a result, the Company recognized an impairment loss for the advances made to these laboratories in the amount of $3,962,141.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">As of March 31, 2017, the Company was obligated to pay laboratories and others approximately $4,400,000 upon the completion of various phases of contracts to obtain CFDA production approval of medical formulas.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangibleAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchasesOfIntangibleAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of advances for purchases of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6623712080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><font lang="EN-US">NOTE 6 &#150; RELATED PARTY TRANSACTIONS</font></b></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">A member of the Company&#146;s board of directors (the &#147;Board&#148;) had previously advanced the Company an aggregate amount of $1,354,567 as of March 31, 2017 and December 31, 2016 which are recorded as Other payables &#150; related parties on the accompanying consolidated balance sheets. The advances bear interest at a rate of 1.0% per year.&nbsp;&nbsp;Total interest expense of $3,386 was recognized for each of the three months ended March 31, 2017 and 2016.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806357408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BANKER'S ACCEPTANCE NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankerSAcceptanceNotesPayableAbstract', window );"><strong>BANKER'S ACCEPTANCE NOTES PAYABLE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankerSAcceptanceNotesPayableTextBlock', window );">BANKER'S ACCEPTANCE NOTES PAYABLE</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><font lang="EN-US">NOTE 7 &#150; BANKER'S ACCEPTANCE NOTES PAYABLE</font></b></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In April 2016, the Company entered into a Banker's Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company can issue banker's acceptance notes (the "Banker's Notes") to any third party as payment of amounts owing to that third party. The Company is required to deposit with the bank an amount equal to the amounts represented by the Banker's Notes issued to the third parties. The amount of these deposited balances is shown as "Restricted cash" on the accompanying balance sheets as of March 31, 2017 and December 31, 2016. The maximum amount that the Company can issue under this agreement is limited to the lesser of RMB30,000,000 (approximately $4.5 million) or the amount of cash available to deposit against the Banker's Notes. In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank. At March 31, 2017 and December 31 2016, the Company had outstanding Banker's Acceptance Notes in the amount of $1,718,823 and $1,088,879, respectively.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankerSAcceptanceNotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankerSAcceptanceNotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankerSAcceptanceNotesPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure is about the bankers' acceptance notes payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankerSAcceptanceNotesPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806331312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSTRUCTION LOAN FACILITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DebtAbstract', window );"><strong>CONSTRUCTION LOAN FACILITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">CONSTRUCTION LOAN FACILITY</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><font lang="EN-US">NOTE 8 &#150; CONSTRUCTION LOAN FACILITY</font></b></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The Company obtained a construction loan facility in the amount of RMB 80,000,000 (approximately $13 million) from a construction loan facility dated June 21, 2013. The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date and is from the same bank that currently provides the line of credit as discussed in Note 7.&nbsp;&nbsp;The proceeds of the loan were used for and are collateralized by the construction of the Company&#146;s new production facility and the included production line equipment and machinery. The loan currently bears weighted interest at 5.73%, based upon 110% of the PRC government&#146;s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. On July 10, 2015 the interest rate was adjusted to 5.94% and on July 10, 2016 the rate was further adjusted to 5.39%. &nbsp;The loan required interest only payments for the first two years. Beginning July 11, 2015, the balance of the principal is due in at least two (2) annual installments with the first annual payment being due within the six-month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2022 on the identical terms as described above for 2015. During the first quarter of 2017, the Company made a principal payment in the amount of approximately $145,000 (RMB1,000,000) with the remaining annual principal payment of approximately $1,306,000 (9,000,000 RMB) being due in July 2017. As of March 31, 2017, the Company had no additional amounts available to it under this facility.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Principal payments required for the next five years as of March 31, 2017 are as follows:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Year</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Amount</font></b></p></td></tr> <tr> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="43%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:43%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">2017</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="43%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:43%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">1,306,140</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">2018</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">2,176,901</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">2019</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">2,176,901</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">2020</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">2,176,901</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">2021</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">2,176,901</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">$10,013,744</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr></table> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Fair Value of Construction Loan Facility</font></i></b><font lang="EN-US"> &#150; Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of the construction loan facility outstanding as of March 31, 2017 and December 31, 2016 approximated its fair value because the underlying instrument bears an interest rate that approximated current market rates.&nbsp;&nbsp;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6614482784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><!--egx--><p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">NOTE 9 - INCOME TAXES</font></b></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates is recognized in income in the period that includes the enactment date.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Undistributed earnings of Helpson, the Company&#146;s foreign subsidiary, since its acquisition, amounted to approximately $30.5 million as of March 31, 2017. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practical because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Liabilities are established for uncertain tax positions expected to be taken in income tax return when such positions are judged to meet the &#147;more-likely-than-not&#148; threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through March 31, 2017, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2013 through December 31, 2016 and the Chinese income tax return for the year ended December 31, 2016 are open for possible examination.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">On March 16, 2007, the National People&#146;s Congress of China passed the Enterprise Income Tax Law (EIT Law) and on December 6, 2007, the State Council of China issued the Implementation Regulations for the EIT Law which took effect on January&nbsp;1, 2008. The EIT Law and Implementation Regulations Rules impose a unified EIT of 25% on all domestic-invested enterprises and Foreign Invested Entities, or FIEs, unless they qualify under certain limited exceptions.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The Company is located in a special region, which had a 15% corporate income tax rate before the new EIT Law. The new EIT Law abolished the preferential corporate income tax rate in the special region. The Company transitioned to the new 25% tax rate over a five year period which began on January 1, 2008. During 2010, the Company applied for and received a favorable tax rate of 15% for fiscal 2011 through 2013 due to its status in the PRC as a high technology enterprise. In 2013, the Company again applied for and received the same favorable tax rate for 2014 to 2016.&nbsp;The recent&nbsp;net losses put the Company in an unfavorable position for the potential renewal of&nbsp;"National High-Tech Enterprise" status for 2017. After evaluating the feasibility of the renewal in 2016, the Company has decided not to renew this status.&nbsp;&nbsp;Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" width="39%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:39%;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10%;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" rowspan="2" width="51%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:51%;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Enterprise Income</font></b></p> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Tax Rate</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Year</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">2016</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">15%</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">2017</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">25%</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">Thereafter</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">25%</font></p></td></tr></table> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The provision for income taxes consisted of the following:</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="7" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Three Months Ended March 31,</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2017</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2016</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Current</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&#151;&nbsp;&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&#151;&nbsp;&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" width="56%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Deferred</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">30,334</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">22,828</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">Total income tax expense</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">30,334</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">22,828</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr></table> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">As of March 31, 2017, the Company had net operating loss carryforwards for PRC tax purposes of approximately $52.2 million which are available to offset any future taxable income through 2022. These carryforwards begin to expire in 2018. The Company also has net operating losses for United States federal income tax purposes of approximately $4.6 million which are available to offset future taxable income, if any, through 2037.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.&nbsp;&nbsp;The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.&nbsp;&nbsp;Management considers projected future taxable income and tax planning strategies in making this assessment.&nbsp;&nbsp;Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of March 31, 2017 and December 31, 2016.&nbsp;&nbsp;Therefore, the Company provided for a valuation allowance against its deferred tax assets of $21,963,335 and $21,452,802 as of March 31, 2017 and December 31, 2016, respectively.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.<b>&nbsp;</b></font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806364896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueMeasurementsAbstract', window );"><strong>FAIR VALUE MEASUREMENTS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><!--egx--><p style='background:white;margin:0cm 0cm 0pt;line-height:10.25pt'><b><font lang="EN-US">NOTE 10 &#150; FAIR VALUE MEASUREMENTS</font></b></p> <p style='background:white;margin:0cm 0cm 0pt;line-height:10.25pt'><font lang="EN-US">&nbsp;</font></p> <p style='background:white;text-align:justify;margin:0cm 0cm 0pt;line-height:10.25pt'><font lang="EN-US">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 &#150; Quoted prices in active markets for identical assets or liabilities. Level 2 &#150; Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 &#150; Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.&nbsp;</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The Company uses fair value to measure the derivative warrant liability on a recurring basis because fair value is the primary measure for accounting. The Company also uses fair value to measure the value of the banker's acceptance notes it holds.&nbsp;&nbsp;The Company values its derivative warrants using a valuation method explained above.&nbsp;&nbsp;The banker's acceptance notes are recorded at cost which approximates fair value.&nbsp;&nbsp;As of December 31, 2016, the Company had no banker's acceptance notes to be recorded at fair value.&nbsp; The Company held the following assets and liabilities recorded at fair value as of March 31, 2017:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="11" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Fair Value Measurements at</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="10" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Reporting Date Using</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">Description</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">March 31, 2017</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><b><font lang="EN-US">Level 1</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><b><font lang="EN-US">Level 2</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><b><font lang="EN-US">Level 3</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td></tr> <tr> <td valign="bottom" width="40%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:40%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Banker's acceptance notes</font></p></td> <td valign="bottom" width="3%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">14,513</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="3%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&#151;&nbsp;&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="3%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">14,513</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="3%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&#151;&nbsp;&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Total</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">14,513</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&#151;&nbsp;&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">14,513</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&#151;&nbsp;&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr></table> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620701728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><!--egx--><p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">NOTE 11 - STOCKHOLDERS' EQUITY</font></b></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The Company is authorized to issue 95,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company&#146;s Board.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><u><font lang="EN-US">Employee Stock Options</font></u></b></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><i><font lang="EN-US">2010 Incentive Plan</font></i></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">On November 12, 2010, the Company&#146;s Board adopted the Company&#146;s 2010 Incentive Plan (the &#147;Plan&#148;), which was then approved by stockholders on December 22, 2010. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through March 31, 2017, there were 175,000 shares of restricted stock granted and outstanding under the Plan.&nbsp; No options were outstanding as of March 31, 2017 under the Plan.</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;There were no securities issued from the Plan during each of the three months ended March 31, 2017 and 2016.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The Company recognized no compensation expense related to the awards of common shares and the grants and modifications of stock options during each of the three months ended March 31, 2017 and 2016.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model. Expected volatility is based on the historical volatility of the Company&#146;s common stock prices. The Company uses historical data to estimate employee termination rates. The expected term of options granted is determined by the simplified method, which is one-half of the original contractual term. The simplified method is used due to the lack of historical share option exercise data to provide a reasonable basis upon which to estimate expected term. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">As of March 31, 2017, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6624597120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommitmentAndContingenciesAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><font lang="EN-US">NOTE 12 &#150; COMMITMENTS AND CONTINGENCIES</font></b></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Economic environment </font></i></b><b><font lang="EN-US">- </font></b><font lang="EN-US">Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company&#146;s operations.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommitmentAndContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CommitmentAndContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620297248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>CONCENTRATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><font lang="EN-US">NOTE 13 &#150; CONCENTRATIONS</font></b></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">For the three months ended March 31, 2017, no customer accounted for more than 10% of sales and two customers accounted for 46.2% and 15% of accounts receivable.&nbsp;Four suppliers accounted for 23.7%, 17.3%, 13.6% and 12.7% of raw material purchases.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">For the three months ended March 31, 2016, no customer accounted for more than 10% of sales and&nbsp;three customers accounted for 28.5%, 11.4% and 11.0%&nbsp;of accounts receivable, respectively.&nbsp;No supplier accounted for greater than 10% of raw material purchases.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6327-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815519904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTING POLICIES (POLICIES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccountingPoliciesAbstract1', window );"><strong>Accounting Policies:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Nature of Operations</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Organization and Nature of Operations &#150; </font></i></b><font lang="EN-US">China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, which owns 100% of Hainan Helpson Medical &amp; Biotechnology Co., Ltd (Helpson), a company organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US" style='background:white'>On December 31, 2012, China Pharma Holdings, Inc. consummated a reincorporation merger for the purpose of changing its state of incorporation from Delaware to Nevada pursuant to the terms and conditions of an Agreement and Plan of Merger dated December 27, 2012.&nbsp;&nbsp;The reincorporation merger was approved by stockholders holding the majority of the Company&#146;s outstanding shares of common stock on December 21, 2012.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US" style='background:white'>The Foreign Investment Industrial Catalogue<i>&nbsp;</i>(the &#147;Catalogue&#148;) jointly issued by China&#146;s Ministry of Commerce and the National Development and Reform Commission (the latest version is the 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the &#147;FIE&#148;) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case for the Company&#146;s business.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US" style='background:white'>Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson&#146;s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson on May 25, 2005 by entering into an Equity Transfer Agreement with Helpson&#146;s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The Company has acquired and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation and Basis of Presentation</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Consolidation and Basis of Presentation </font></i></b><font lang="EN-US">&#150; The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in the consolidation.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Helpson&#146;s functional currency is the Chinese Renminbi. Helpson&#146;s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson&#146;s financial statements are included in accumulated other comprehensive income, which is a component of stockholders&#146; equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Accounting Estimates </font></i></b><b><font lang="EN-US">- </font></b><font lang="EN-US">The methodology used to prepare for the Company&#146;s financial statements is in conformity with the accounting principles generally accepted in the United States of America, which requires the management of the Company (&#147;Management&#148;) to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Therefore, actual results could differ from those estimates.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Cash and Cash Equivalents </font></i></b><font lang="EN-US">&#150; Cash and cash equivalents include interest bearing and non-interest bearing bank deposits, money market accounts, and short-term banker&#146;s acceptances purchased with maturities of three months or less.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RestrictedCashTextBlock', window );">Restricted Cash</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Restricted Cash</font></i></b><b><font lang="EN-US">&nbsp;</font></b><font lang="EN-US">&#150;<b>&nbsp;</b>Restricted cash includes cash that has been deposited with a bank to satisfy obligations outstanding under banker's acceptance notes issued by the Company as discussed in Note 7.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts, Policy</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Trade Accounts Receivable and Allowance for Doubtful Accounts &#150; </font></i></b><font lang="EN-US">Trade accounts receivables are carried at the original invoiced amounts less an allowance for doubtful accounts. The allowances for doubtful accounts are calculated based on a detailed review of certain individual customer accounts and an estimation of the overall economic conditions affecting the Company's customer base. The Company reviews a customer's credit history before extending credit to the customer. If the financial condition of its customers were to deteriorate, resulting in an impairment of their ability to make payments, additions to the allowance would be required. A provision is made against accounts receivable to the extent they are considered unlikely to be collected. Charges to bad debt expense totaled $360,063 and $581,300 for the three months ended March 31, 2017 and 2016, respectively.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Trade accounts receivable that have been fully allowed for and determined to be uncollectible are charged against the allowance in the period the determination is made. The Company charged off uncollectable trade accounts receivable balances in the amount of $0 against the allowance for both the three months ended March 31, 2017 and 2016, respectively. It is common practice in the pharmaceutical industry in the PRC for receivables to extend beyond one year. Customer balances outstanding for more than one year are allowed for at a greater rate when calculating the allowance for doubtful accounts.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock', window );">Advances to Suppliers and Advances from Customers</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Advances to Suppliers and Advances from Customers</font></i></b><font lang="EN-US"> &#150; Common practice in the pharmaceutical industry in the PRC is to make advances to suppliers for materials and to receive advances from customers for finished products. Advances to suppliers are applied to trade accounts payable when the materials are received. Advances received from customers are applied against trade accounts receivable when finished products are sold. The Company reviews a supplier's credit history and background information before advancing a payment. If the financial condition of its suppliers were to deteriorate, resulting in an impairment of their ability to deliver goods or provide services, the Company would recognize bad debt expense in the period they are considered unlikely to be collected. The Company recognized no bad debt expense for the three months ended March 31, 2017 and 2016, respectively.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Inventories&nbsp;&#150;</font></i></b><font lang="EN-US"> Inventories consist of raw materials, work in process and finished goods and are stated at the lower of cost or market. Cost is determined using a weighted average. For work in process and manufactured inventories, cost consists of raw materials, direct labor and an allocated portion of the Company&#146;s production overhead. The Company writes down excess and obsolete inventory to its estimated net realizable value based upon assumptions about future demand and market conditions. For finished goods and work in process, if the estimated net realizable value for an inventory item, which is the estimated selling price in the ordinary course of business, less reasonably predicable costs to completion and disposal, is lower than its cost, the specific inventory item is written down to its estimated net realizable value. Market for raw materials is based on replacement cost. Provisions for inventory write-downs are included in cost of revenues in the consolidated statements of operations. Once written down, inventories are carried at this lower cost basis until sold or scrapped.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Valuation of Long-Lived Assets </font></i></b><font lang="EN-US">&#150; The carrying values of long-lived assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying values may not be recoverable. When such an event occurs, the Company projects the undiscounted cash flows to be generated from the use of the asset and its eventual disposition over the remaining life of the asset. If projections indicate that the carrying value of an asset will not be recovered, it is reduced by the estimated excess of the carrying value over the projected discounted cash flows estimated to be generated by the asset. There was no impairment adjustment required for the three months ended March 31, 2017 and 2016.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Policy</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Property and Equipment</font></i></b><font lang="EN-US"> &#150; Property and equipment are stated at cost. Maintenance and repairs are charged to expenses as incurred and major improvements are capitalized. Gains or losses on sale, trade-in or retirement are included in operations during the period of disposition. Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Revenue Recognition</font></i></b><font lang="EN-US"> &#150; Revenue is considered earned when the Company obtains persuasive evidence of an arrangement with the customer, when delivery of the products has occurred, when the sales price is fixed or determinable, and when collectability is reasonably assured. Delivery does not occur until products have been shipped to the customer, the risk of loss has transferred to the customer and customer acceptance has been obtained, customer acceptance provisions have lapsed, or the Company obtains objective evidence that the criteria specified in the customer acceptance provisions have been satisfied. The sales price is not considered to be fixed or determinable until all contingencies related to the sale have been resolved. Revenue is deferred when collectability is not considered to be reasonably assured.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock', window );">Cost of Revenues</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Cost of Revenues</font></i></b><font lang="EN-US"> &#150; Cost of revenues includes wages, materials, depreciation, handling charges, and other expenses associated with the manufacture and delivery of products.</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Research and Development</font></i></b><font lang="EN-US"> &#150; Research and development expenditures are recorded as expenses in the period in which they occur.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted (Loss) Earnings per Common Share</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Basic and Diluted Loss per Common Share </font></i></b><b><font lang="EN-US">- </font></b><font lang="EN-US">Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to potentially issuable dilutive common shares. There were no potential dilutive common shares outstanding during the three months ended March 31, 2017 and 2016, respectively.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Credit Risk</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Credit Risk</font></i></b><font lang="EN-US"> &#150; The carrying amount of accounts receivable included in the balance sheet represents the Company's exposure to credit risk in relation to its financial assets. No other financial asset carries a significant exposure to credit risk. The Company performs ongoing credit evaluations of each customer's financial condition. The Company maintains allowances for doubtful accounts and such allowances in the aggregate have not exceeded Management's estimates.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The Company has its cash in bank deposits primarily at state owned banks located in the PRC. Historically, deposits in PRC banks have been secured due to the state policy of protecting depositors&#146; interests. The PRC promulgated a new Bankruptcy Law in August 2006, effective June&nbsp;1, 2007, which contains provisions for the implementation of measures for the bankruptcy of PRC banks. In the event that bankruptcy laws are enacted for banks in the PRC, the Company&#146;s deposits may be at a higher risk of loss.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InterestRateRiskPolicyTextBlock', window );">Interest Rate Risk</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Interest Rate Risk</font></i></b><font lang="EN-US"> &#150; The Company is exposed to the risk arising from changing interest rates, which may affect the ability of repayment of existing debts and viability of securing future debt instruments within the PRC.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><b><i><font lang="EN-US">Recent Accounting Pronouncements</font></i></b></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In May 2014, the FASB issued ASU 2014-09,&nbsp;<i>"Revenue from Contracts with Customers"</i>&nbsp;(ASU 2014-09), which contains new accounting literature relating to how and when a company recognizes revenue. Under ASU 2014-09, a company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. &nbsp;In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities.&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. We have not yet determined our method of transition and are evaluating the impact that this guidance will have on our financial statements.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In February 2016, the FASB issued ASU No. 2016-02,&nbsp;<i>Leases</i>, a new standard on accounting for leases. The ASU introduces a lessee model that brings most leases on the balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in the current accounting guidance as well as the FASB's new revenue recognition standard. However, the ASU eliminates the use of bright-line tests in determining lease classification as required in the current guidance. The ASU also requires additional qualitative disclosures along with specific quantitative disclosures to better enable users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. The pronouncement is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, using a modified retrospective approach. Early adoption is permitted. The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In June 2016, the FASB issued Accounting Standards Update 2016-13,&nbsp;<i>Financial Instruments &#150; Credit Losses (Topic 326)</i>, which introduces new guidance for the accounting for credit losses on instruments within its scope. The new guidance introduces an approach based on expected losses to estimate credit losses on certain types of financial instruments. It also modifies the impairment model for available-for-sale (AFS) debt securities and provides for a simplified accounting model for purchased financial assets with credit deterioration since their origination.&nbsp;The pronouncement will be effective for Public business entities that are SEC filers in fiscal years beginning after&nbsp;December 15, 2019, including interim periods within those fiscal years.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Early application of the guidance will be permitted for all entities for fiscal years beginning after&nbsp;December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the pending adoption of the new standard on its consolidated financial statements and related disclosures.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In August 2016, the FASB issued ASU No. 2016-15,&nbsp;<i>Classification of Certain Cash Receipts and Cash Payments</i>. The standard addresses the classification and presentation of eight specific cash flow issues that currently result in diverse practices. This pronouncement is effective for annual reporting periods beginning after December 15, 2017. The amendments in this ASU should be applied using a retrospective approach.&nbsp; The Company has not completed an evaluation of the impact the pronouncement will have on its consolidated financial statements and related disclosures, but does not expect the impact to be material.</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">In November 2016, the FASB issued ASU 2016-18,&nbsp;<i>Statement of Cash Flows (Topic 230): Restricted Cash (&#147;ASU 2016-18&#148;)</i>. The ASU requires an entity to explain the changes in the total of cash, cash equivalents, restricted cash, and restricted cash equivalents on the statement of cash flows and to provide a reconciliation of the totals in that statement to the related captions in the balance sheet when the cash, cash equivalents, restricted cash, and restricted cash equivalents are presented in more than one line item on the balance sheet. This ASU is effective for annual and interim periods beginning after December 15, 2017, and is required to be adopted using a retrospective approach, with early adoption permitted. The Company is currently evaluating the potential impact that the adoption of ASU 2016-18 may have on its consolidated financial statements.&nbsp;</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Other accounting standards that have been issued by the FASB or other standards-setting bodies are not expected to have a material effect on the Company&#146;s financial position, result of operations or cash flows.&nbsp;&nbsp;</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccountingPoliciesAbstract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AccountingPoliciesAbstract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure for accounting policy of advances to Suppliers and Advances from Customers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesToSuppliersAndAdvancesFromCustomersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InterestRateRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure for accounting policy on interest rate risk</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InterestRateRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RestrictedCashTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RestrictedCashTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e4975-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the accounting policy for determining revenue earned from providing cargo and freight related services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionCargoAndFreightPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6615550496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryTablesAbstract', window );"><strong>INVENTORY (TABLES)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory consists</a></td>
<td class="text"><!--egx--><p style='margin:0cm 0cm 0pt'><font lang="EN-US">Inventory consisted of the following:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">March 31,</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">December 31,</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2017</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2016</font></b></p></td></tr> <tr> <td valign="bottom" width="56%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Raw materials</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">10,796,239</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">11,562,388</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Work in process</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">692,827</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">360,550</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Finished goods</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">1,397,514</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">1,530,641</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">12,886,580</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">13,453,579</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Obsolescence reserve</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">(5,900,615</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">)</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">(6,142,640</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">)</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:9pt;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">Total Inventory</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">6,985,965</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">7,310,939</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InventoryTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6611209696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentTablesAbstract', window );"><strong>PROPERTY AND EQUIPMENT (Tables)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and equipment consists</a></td>
<td class="text"><!--egx--><p style='margin:0cm 0cm 0pt'><font lang="EN-US">Property and equipment consisted of the following:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">March 31,</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">December 31,</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2017</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2016</font></b></p></td></tr> <tr> <td valign="bottom" width="56%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Permit of land use</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">408,775</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">405,645</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Building</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">9,492,387</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">9,419,700</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Plant, machinery and equipment</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">26,379,439</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">26,151,029</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Motor vehicle</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">312,167</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">309,777</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Office equipment</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">184,128</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">182,718</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:9pt;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">Total</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">36,776,896</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">36,468,869</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Less: accumulated depreciation</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">(12,354,523</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">)</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">(11,501,421</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">)</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">Property and Equipment, net</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">24,422,373</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">24,967,448</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_UsefulLivesOfTheAssetsTableTextBlock', window );">Useful lives of the assets</a></td>
<td class="text"><!--egx--><p style='margin:0cm 0cm 0pt'><font lang="EN-US">Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" width="71%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:71%;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">Asset</font></p></td> <td valign="bottom" width="2%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:2%;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="27%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:27%;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;Life - years&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Permit of land use</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">40 - 70</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Building</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">20 - 49</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Plant, machinery and equipment</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">5 - 10</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Motor vehicle</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">5 - 10</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Office equipment</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">3-5</font></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PropertyAndEquipmentTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_UsefulLivesOfTheAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of useful lives of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_UsefulLivesOfTheAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617652064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsTablesAbstract', window );"><strong>Intangible Assets (Tables)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsMedicalFormulasTablesTextBlock', window );">Intangible Assets Medical Formulas</a></td>
<td class="text"><!--egx--><p style='margin:0cm 0cm 0pt'><font lang="EN-US">Intangible assets consisted solely of CFDA approved medical formulas as follows:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">March 31,</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">December 31,</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2017</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2016</font></b></p></td></tr> <tr> <td valign="bottom" width="56%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Gross carrying amount</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">4,899,281</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">4,861,766</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Accumulated amortization</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">(4,411,237</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">)</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">(4,327,084</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">)</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Net carrying amount</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">488,044</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">534,682</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsMedicalFormulasTablesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabluar disclosure of Intangible Assets Medical Formulas</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssetsMedicalFormulasTablesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssetsTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6618165440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF CONSTRUCTION LOAN FACILITY (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ScheduleOfLongTermDebtInstrumentsAbstract', window );"><strong>Schedule of Construction Loan Facility:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Principal payments required for the next five years as of December 31, 2015</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">Principal payments required for the next five years as of March 31, 2017 are as follows:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Year</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Amount</font></b></p></td></tr> <tr> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="43%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:43%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">2017</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="43%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:43%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">1,306,140</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">2018</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">2,176,901</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">2019</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">2,176,901</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">2020</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">2,176,901</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">2021</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">2,176,901</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">$10,013,744</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfLongTermDebtInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleOfLongTermDebtInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813645872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxesTablesAbstract', window );"><strong>INCOME TAXES (Tables)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock', window );">Schedule of Enterprise Income Tax Rates</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The Company has decided not to renew this status.&nbsp;&nbsp;Under the current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" width="39%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:39%;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10%;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" rowspan="2" width="51%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:51%;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Enterprise Income</font></b></p> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Tax Rate</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Year</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">2016</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">15%</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">2017</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">25%</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">Thereafter</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><font lang="EN-US">25%</font></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for income taxes</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The provision for income taxes consisted of the following:</font></p> <p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="7" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Three Months Ended March 31,</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2017</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">2016</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Current</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&#151;&nbsp;&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&#151;&nbsp;&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" width="56%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:56%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Deferred</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">30,334</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="8%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:8%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="12%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:12%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">22,828</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">Total income tax expense</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">30,334</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">22,828</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxesTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IncomeTaxesTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure is about the Enterprise Income Tax Rates under the current tax law in the PRC, the Company is and will be subject to.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ScheduleOfEnterpriseIncomeTaxRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620833184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE MEASUREMENTS (TABLES)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueMeasuresAndDisclosuresAbstract', window );"><strong>SCHEDULE OF FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Company held the following assets and liabilities recorded at fair value as of December 31, 2016</a></td>
<td class="text"><!--egx--><p style='text-align:justify;margin:0cm 0cm 0pt'><font lang="EN-US">The banker's acceptance notes to be recorded at fair value.&nbsp; The Company held the following assets and liabilities recorded at fair value as of March 31, 2017:</font></p> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p> <table cellspacing="0" cellpadding="0" width="100%" border="0" style='width:100%;border-collapse:collapse'> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" colspan="3" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="11" style='border-top:#f0f0f0;border-right:#f0f0f0;border-bottom:#f0f0f0;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm;background-color:transparent'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Fair Value Measurements at</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" colspan="10" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">Reporting Date Using</font></b></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">Description</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="center" style='text-align:center;margin:0cm 0cm 0pt'><b><font lang="EN-US">March 31, 2017</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><b><font lang="EN-US">Level 1</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><b><font lang="EN-US">Level 2</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><b><font lang="EN-US">Level 3</font></b></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p></td></tr> <tr> <td valign="bottom" width="40%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:40%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Banker's acceptance notes</font></p></td> <td valign="bottom" width="3%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">14,513</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="3%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&#151;&nbsp;&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="3%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">14,513</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="3%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:3%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" width="10%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:10%;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&#151;&nbsp;&nbsp;</font></p></td> <td valign="bottom" width="1%" style='border-top:#f0f0f0;border-right:#f0f0f0;width:1%;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr> <tr> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">Total</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">14,513</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&#151;&nbsp;&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">14,513</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">$</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:black 1pt solid;padding-bottom:0cm;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p align="right" style='text-align:right;margin:0cm 0cm 0pt'><font lang="EN-US">&#151;&nbsp;&nbsp;</font></p></td> <td valign="bottom" style='border-top:#f0f0f0;border-right:#f0f0f0;background:white;border-bottom:#f0f0f0;padding-bottom:1pt;padding-top:0cm;padding-left:0cm;border-left:#f0f0f0;padding-right:0cm'> <p style='margin:0cm 0cm 0pt'><font lang="EN-US">&nbsp;</font></p></td></tr></table> <p style='margin:0cm 0cm 0pt'><b><font lang="EN-US">&nbsp;</font></b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueMeasuresAndDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_FairValueMeasuresAndDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=SL7498348-110258<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6626514640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract', window );"><strong>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited', window );">Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1', window );">Percentage of share owned by China Pharma Holdings Inc of Helpson Medical &amp; Biotechnology Co., Ltd.</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PercetageOfAcquiredByOnnyInHelpson', window );">Percetage of acquired by Onny in Helpson</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OrganizationAndSignificantAccountingPoliciesDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PercetageOfAcquiredByOnnyInHelpson">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percetage of acquired by Onny in Helpson</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PercetageOfAcquiredByOnnyInHelpson</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6603895024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS (DETAILS) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract', window );"><strong>TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BadDebtExpenseTotaled', window );">Bad debt expense totaled</a></td>
<td class="nump">$ 360,063<span></span>
</td>
<td class="nump">$ 581,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TradeAccountsReceivableBalances', window );">Trade accounts receivable balances</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BadDebtExpenseTotaled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bad debt expense totaled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BadDebtExpenseTotaled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TradeAccountsReceivableAndAllowanceForDoubtfulAccountsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TradeAccountsReceivableBalances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade accounts receivable balances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TradeAccountsReceivableBalances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6731421280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY CONSISTED OF THE FOLLOWING (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryConsistedOfTheFollowingDetailsAbstract', window );"><strong>INVENTORY CONSISTED OF THE FOLLOWING (DETAILS)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 10,796,239<span></span>
</td>
<td class="nump">$ 11,562,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_WorkInProcess', window );">Work in process</a></td>
<td class="nump">692,827<span></span>
</td>
<td class="nump">360,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,397,514<span></span>
</td>
<td class="nump">1,530,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InventoryGross1', window );">Inventory Gross</a></td>
<td class="nump">12,886,580<span></span>
</td>
<td class="nump">13,453,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Obsolescence reserve</a></td>
<td class="num">(5,900,615)<span></span>
</td>
<td class="num">(6,142,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalInventory', window );">Total Inventory</a></td>
<td class="nump">$ 6,985,965<span></span>
</td>
<td class="nump">$ 7,310,939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_FinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryConsistedOfTheFollowingDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InventoryConsistedOfTheFollowingDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InventoryGross1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InventoryGross1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_WorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_WorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760526448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract', window );"><strong>PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandAndLandImprovements', window );">Permit of land use</a></td>
<td class="nump">$ 408,775<span></span>
</td>
<td class="nump">$ 405,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Building</a></td>
<td class="nump">9,492,387<span></span>
</td>
<td class="nump">9,419,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Plant, machinery and equipment</a></td>
<td class="nump">26,379,439<span></span>
</td>
<td class="nump">26,151,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MotorVehicle', window );">Motor vehicle</a></td>
<td class="nump">312,167<span></span>
</td>
<td class="nump">309,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OfficeEquipment', window );">Office equipment</a></td>
<td class="nump">184,128<span></span>
</td>
<td class="nump">182,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Total', window );">Total</a></td>
<td class="nump">36,776,896<span></span>
</td>
<td class="nump">36,468,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_LessAccumulatedDepreciation', window );">Less: accumulated depreciation</a></td>
<td class="num">(12,354,523)<span></span>
</td>
<td class="num">(11,501,421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="nump">$ 24,422,373<span></span>
</td>
<td class="nump">$ 24,967,448<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_LessAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Less: accumulated depreciation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_LessAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MotorVehicle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Motor vehicle</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_MotorVehicle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OfficeEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Office equipment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OfficeEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PropertyAndEquipmentConsistedOfTheFollowingDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PropertyAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Total">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_Total</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandAndLandImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated deprecation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandAndLandImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760720000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT ASSETS LIFE (DETAILS)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PropertyAndEquipmentAssetsLifeAbstract', window );"><strong>PROPERTY AND EQUIPMENT Assets Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PermitOfLandUseMinimumLife', window );">Permit of land use minimum life</a></td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PermitOfLandUseMaximumLife', window );">Permit of land use maximum life</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BuildingMinimumLife', window );">Building minimum life</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BuildingMaximumLife', window );">Building maximum life</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlantMachineryAndEquipmentMinimumLife', window );">Plant, machinery and equipment minimum life</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PlantMachineryAndEquipmentMaximumLife', window );">Plant, machinery and equipment maximum life</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MotorVehicleMinimumLife', window );">Motor vehicle minimum life</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MotorVehicleMaximumLife', window );">Motor vehicle maximum life</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OfficeEquipmentMinimumLife', window );">Office equipment minimum life</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_OfficeEquipmentMaximumLife', window );">Office equipment maximum life</a></td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BuildingMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BuildingMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BuildingMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BuildingMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MotorVehicleMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_MotorVehicleMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MotorVehicleMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_MotorVehicleMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OfficeEquipmentMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OfficeEquipmentMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_OfficeEquipmentMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_OfficeEquipmentMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PermitOfLandUseMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PermitOfLandUseMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PermitOfLandUseMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PermitOfLandUseMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlantMachineryAndEquipmentMaximumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PlantMachineryAndEquipmentMaximumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PlantMachineryAndEquipmentMinimumLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Plant, machinery and equipment minimum life</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PlantMachineryAndEquipmentMinimumLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PropertyAndEquipmentAssetsLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PropertyAndEquipmentAssetsLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806255776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSETS DEPRECIATION (DETAILS) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AssetsDepreciationDetailsAbstract', window );"><strong>Assets Depreciation Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DepreciationExpensePropertyAndEquipment', window );">Depreciation Expense property and equipment</a></td>
<td class="nump">$ 764,614<span></span>
</td>
<td class="nump">$ 790,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AssetsDepreciationDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AssetsDepreciationDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DepreciationExpensePropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DepreciationExpensePropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759223520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract', window );"><strong>INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_GrossCarryingAmount', window );">Gross carrying amount</a></td>
<td class="nump">$ 4,899,281<span></span>
</td>
<td class="nump">$ 4,861,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(4,411,237)<span></span>
</td>
<td class="num">(4,327,084)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetCarryingAmount', window );">Net carrying amount</a></td>
<td class="nump">$ 488,044<span></span>
</td>
<td class="nump">$ 534,682<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization on long-term land leases capitalized as part of real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_GrossCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_GrossCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IntangibleAssetsCfdaApprovedMedicalFormulasDetails1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net carrying amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6623649856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>AMORTIZATION EXPENSE (DETAILS) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmortizationExpenseAbstract', window );"><strong>AMORTIZATION EXPENSE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AmortizationExpensesRelatingToIntangibleAssets', window );">Amortization expenses relating to intangible assets</a></td>
<td class="nump">$ 50,780<span></span>
</td>
<td class="nump">$ 66,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AmortizationExpensesRelatingToIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets. As a noncash expense, this element is added back to net income when calculating cash provided by (used in) operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AmortizationExpensesRelatingToIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620350256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (DETAILS)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract', window );"><strong>Advances for purchase of intangible assets details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyWasObligatedToPayLaboratories', window );">Company was obligated to pay laboratories</a></td>
<td class="nump">$ 4,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories', window );">Company recognized an impairment loss for the advances made to these laboratories</a></td>
<td class="nump">$ 3,962,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdvancesForPurchaseOfIntangibleAssetsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company recognized an impairment loss for the advances made to these laboratories</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CompanyRecognizedAnImpairmentLossForTheAdvancesMadeToTheseLaboratories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyWasObligatedToPayLaboratories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company was obligated to pay laboratories</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CompanyWasObligatedToPayLaboratories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6626523584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS OWINGS (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RelatedPartyTransactionsOwingsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS OWINGS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AdavancesOwingToBoard', window );">Adavances owing to board</a></td>
<td class="nump">$ 1,354,567<span></span>
</td>
<td class="nump">$ 1,354,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InterestRateOnAdvancesFromMemberOfBOD', window );">Interest rate on advances from Member of BOD</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AdavancesOwingToBoard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adavances owing to board</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AdavancesOwingToBoard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InterestRateOnAdvancesFromMemberOfBOD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate on advances from Member of BOD</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InterestRateOnAdvancesFromMemberOfBOD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RelatedPartyTransactionsOwingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RelatedPartyTransactionsOwingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6619743344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS MEMBER OF BOD (DETAILS) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RelatedPartyTransactionsMemberOfBod1Abstract', window );"><strong>RELATED PARTY TRANSACTIONS Member Of BOD</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalInterestExpenseRecognizedForThePeriod', window );">Total interest expense recognized for the period</a></td>
<td class="nump">$ 3,386<span></span>
</td>
<td class="nump">$ 3,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RelatedPartyTransactionsMemberOfBod1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adavances owing to board</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RelatedPartyTransactionsMemberOfBod1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalInterestExpenseRecognizedForThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total interest expense recognized for the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalInterestExpenseRecognizedForThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756921168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BANKER'S ACCEPTANCE NOTES PAYABLE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankerSAcceptanceNotesPayableDetailsAbstract', window );"><strong>BANKER'S ACCEPTANCE NOTES PAYABLE Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes', window );">Maximum amount that the Company can issue under this agreement against the Banker's Notes</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank', window );">Agreement calls for the payment of fees equal to the note amount to the bank</a></td>
<td class="nump">0.05%<span></span>
</td>
<td class="nump">0.05%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyHadOutstandingBankerSAcceptanceNotes', window );">Company had outstanding Banker's Acceptance Notes</a></td>
<td class="nump">$ 1,718,823<span></span>
</td>
<td class="nump">$ 1,088,879<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement calls for the payment of fees equal to the note amount to the bank</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_AgreementCallsForThePaymentOfFeesEqualToTheNoteAmountToTheBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankerSAcceptanceNotesPayableDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankerSAcceptanceNotesPayableDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyHadOutstandingBankerSAcceptanceNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company had outstanding Banker's Acceptance Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CompanyHadOutstandingBankerSAcceptanceNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount that the Company can issue under this agreement against the Banker's Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_MaximumAmountThatTheCompanyCanIssueUnderThisAgreementAgainstTheBankerSNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617084752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSTRUCTION LOAN FACILITY (DETAILS)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConstructionLoanFacilityDetailsAbstract', window );"><strong>Construction loan facility details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalLoanFacilityAmountRmb80000000', window );">Total Loan facility amount (RMB 80,000,000)</a></td>
<td class="nump">$ 13,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CompanyMadeAPrincipalPayment', window );">Company made a principal payment</a></td>
<td class="nump">145,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_RemainingAnnualPrincipalPayment', window );">Remaining annual principal payment</a></td>
<td class="nump">$ 1,306,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CompanyMadeAPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company made a principal payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CompanyMadeAPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConstructionLoanFacilityDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ConstructionLoanFacilityDetailsAbstract [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ConstructionLoanFacilityDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_RemainingAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining annual principal payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_RemainingAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalLoanFacilityAmountRmb80000000">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loan facility amount (RMB 80,000,000)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalLoanFacilityAmountRmb80000000</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6617652064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PRINCIPAL PAYMENTS REQUIRED FOR THE NEXT FIVE YEARS ARE AS FOLLOWS: (DETAILS)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract', window );"><strong>Principal payments required for the next five years are as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2017', window );">Principal Payments 2017</a></td>
<td class="nump">$ 1,306,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2018', window );">Principal Payments 2018</a></td>
<td class="nump">2,176,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2019', window );">Principal Payments 2019</a></td>
<td class="nump">2,176,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2020', window );">Principal Payments 2020</a></td>
<td class="nump">2,176,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PrincipalPayments2021', window );">Principal Payments 2021</a></td>
<td class="nump">2,176,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalPrincipalPaymentsDue', window );">Total principal payments due</a></td>
<td class="nump">$ 10,013,744<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2018">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2018</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal amount paid by the company in 2019</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2020">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2020</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPayments2021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPayments2021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PrincipalPaymentsRequiredForTheNextFiveYearsAreAsFollowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalPrincipalPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Principal amount due by the company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalPrincipalPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6596712560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES UNDISTRIBUTED EARNINGS AND INCOMR TAX RATES (DETAILS)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxesUndistributedEarningsAbstract', window );"><strong>Income Taxes Undistributed Earnings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_UndistributedEarningsOfHelpson', window );">Undistributed earnings of Helpson</a></td>
<td class="nump">$ 30,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany', window );">Investment in Helpson, a foreign subsidiary for the company</a></td>
<td class="nump">$ 23,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRatesForTheYear2016', window );">Enterprise Income Tax Rates for the year 2016</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRatesForTheYear2017', window );">Enterprise Income Tax Rates for the year 2017</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_EnterpriseIncomeTaxRateThereafter', window );">Enterprise Income Tax Rates There after</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1', window );">Net operating loss carryforwards for PRC tax purposes</a></td>
<td class="nump">$ 52,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1', window );">Net operating losses for United States federal income tax purposes</a></td>
<td class="nump">$ 4,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRateThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Enterprise Income Tax Rate Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRateThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRatesForTheYear2016">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Enterprise Income Tax Rates for the year 2016</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRatesForTheYear2016</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_EnterpriseIncomeTaxRatesForTheYear2017">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Enterprise Income Tax Rates for the year 2017</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_EnterpriseIncomeTaxRatesForTheYear2017</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxesUndistributedEarningsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IncomeTaxesUndistributedEarningsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Helpson, a foreign subsidiary for the company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryforwards for PRC tax purposes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetOperatingLossCarryforwardsForPrcTaxPurposes1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating losses for United States federal income tax purposes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NetOperatingLossesForUnitedStatesFederalIncomeTaxPurposes1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_UndistributedEarningsOfHelpson">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Undistributed earnings of Helpson</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_UndistributedEarningsOfHelpson</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756620704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES PROVISION (DETAILS) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_IncomeTaxesProvisionAbstract', window );"><strong>Income Taxes Provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred tax provision</a></td>
<td class="nump">30,334<span></span>
</td>
<td class="nump">$ 22,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalIncomeTaxBenefitExpense', window );">Total income tax (benefit) expense</a></td>
<td class="nump">$ 30,334<span></span>
</td>
<td class="nump">$ 22,828<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_IncomeTaxesProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_IncomeTaxesProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalIncomeTaxBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalIncomeTaxBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6620207376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEFERRED INCOME TAX ASSETS AND LIABILITY (DETAILS) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_DeferredIncomeTaxAssetsAndLiabilityAbstract', window );"><strong>Deferred Income Tax Assets And Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ValuationAllowanceAgainstDeferredTaxAssets', window );">Valuation allowance against deferred tax assets</a></td>
<td class="nump">$ 21,963,335<span></span>
</td>
<td class="nump">$ 21,452,802<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_DeferredIncomeTaxAssetsAndLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_DeferredIncomeTaxAssetsAndLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ValuationAllowanceAgainstDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation allowance against deferred tax assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ValuationAllowanceAgainstDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760576640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS AT REPORTING DATE USING (DETAILS)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FairValueMeasurementsAtReportingDateUsingAbstract', window );"><strong>FAIR VALUE MEASUREMENTS AT REPORTING DATE USING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotes', window );">Bankers acceptance notes</a></td>
<td class="nump">$ 14,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_Total1', window );">Total</a></td>
<td class="nump">14,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotesLevel1', window );">Bankers acceptance notes Level 1</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalLevel1', window );">Total Level 1</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotesLevel2', window );">Bankers acceptance notes Level 2</a></td>
<td class="nump">14,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalLevel2', window );">Total Level 2</a></td>
<td class="nump">14,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_BankersAcceptanceNotesLevel3', window );">Bankers acceptance notes Level 3</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_TotalLevel3', window );">Total Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers acceptance notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankersAcceptanceNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotesLevel1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers acceptance notes Level 1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankersAcceptanceNotesLevel1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotesLevel2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers acceptance notes Level 2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankersAcceptanceNotesLevel2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_BankersAcceptanceNotesLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bankers acceptance notes Level 3</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_BankersAcceptanceNotesLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FairValueMeasurementsAtReportingDateUsingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_FairValueMeasurementsAtReportingDateUsingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_Total1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_Total1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalLevel1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Level 1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalLevel1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalLevel2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Level 2</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalLevel2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_TotalLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Level 3</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_TotalLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6597928592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREFERRED COMMON STOCK (DETAILS)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PreferredCommonStockAndWarrantsAbstract', window );"><strong>Preferred Common Stock And Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_CommonSharesAuthorized', window );">Common shares authorized</a></td>
<td class="nump">95,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PreferredSharesAuthorized', window );">Preferred shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_PreferredSharesParValue', window );">Preferred shares par value | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_CommonSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_CommonSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PreferredCommonStockAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PreferredCommonStockAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PreferredSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PreferredSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_PreferredSharesParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_PreferredSharesParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806297488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>2010 STOCK OPTION PLAN (DETAILS) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Nov. 12, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_StockholdersEquity2010StockOptionPlanAbstract', window );"><strong>Stockholders Equity 2010 Stock Option Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_NumberOfCommonShares', window );">Number of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan', window );">Shares of restricted stock granted and outstanding under the 2010 Incentive Plan</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_NumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_NumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>shares of restricted stock granted and outstanding under the 2010 Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThe2010IncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_StockholdersEquity2010StockOptionPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_StockholdersEquity2010StockOptionPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815853344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS (DETAILS)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ConcentrationsDetailsAbstract', window );"><strong>Concentrations Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FirstCustomerAccountedAccountsReceivable', window );">First Customer accounted accounts receivable</a></td>
<td class="nump">46.20%<span></span>
</td>
<td class="nump">28.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SecondCustomerAccountedAccountsReceivable', window );">Second Customer accounted accounts receivable</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">11.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ThirdCustomerAccountedAccountsReceivable', window );">Third Customer accounted accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FirstSupplierAccountedForRawMaterialPurchases', window );">First Supplier accounted for raw material purchases</a></td>
<td class="nump">23.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_SecondSupplierAccountedForRawMaterialPurchases', window );">Second Supplier accounted for raw material purchases</a></td>
<td class="nump">17.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_ThirdSupplierAccountedForRawMaterialPurchases', window );">Third Supplier accounted for raw material purchases</a></td>
<td class="nump">13.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fil_FourthSupplierAccountedForRawMaterialPurchases', window );">Fourth Supplier accounted for raw material purchases</a></td>
<td class="nump">12.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ConcentrationsDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company made payments as per Construction agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ConcentrationsDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FirstCustomerAccountedAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>First Customer accounted accounts receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_FirstCustomerAccountedAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FirstSupplierAccountedForRawMaterialPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>First Supplier accounted for raw material purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_FirstSupplierAccountedForRawMaterialPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_FourthSupplierAccountedForRawMaterialPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fourth Supplier accounted for raw material purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_FourthSupplierAccountedForRawMaterialPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SecondCustomerAccountedAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Second Customer accounted accounts receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_SecondCustomerAccountedAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_SecondSupplierAccountedForRawMaterialPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Second Supplier accounted for raw material purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_SecondSupplierAccountedForRawMaterialPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ThirdCustomerAccountedAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Third Customer accounted accounts receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ThirdCustomerAccountedAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fil_ThirdSupplierAccountedForRawMaterialPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Third Supplier accounted for raw material purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fil_ThirdSupplierAccountedForRawMaterialPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fil_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"[";O>V(/]Q\970=G"K[N07U!+ P04    " !SB*M*F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    ( '.(JTJN+%"@A@(  $<)   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL?5;;CILP%/P5Q <LV%RS(DA)JJJ56BG:JNVSDS@!+6!J.V'[
M][4-2ZE]Z OX,G/&QYS!+@;&7T5%J?3>VJ836[^2LG\. G&N:$O$$^MIIV:N
MC+=$JBZ_!:+GE%P,J6T"'(9IT)*Z\\O"C!UY6;"[;.J.'KDG[FU+^.\];=BP
M]9'_/O!2WRJI!X*RZ,F-?J/R>W_DJA?,42YU2SM1L\[C]+KU=^CY@#)-,(@?
M-1W$HNWI5$Z,O>K.Y\O6#_6*:$//4H<@ZO6@!]HT.I):QZ\IJ#]K:N*R_1[]
MHTE>)7,B@AY8\[.^R&KKY[YWH5=R;^0+&S[1*:'$]Z;LO] ';11<KT1IG%DC
MS-,[WX5D[11%+:4E;^.[[LQ[&&=B--%@ IX(>";@_+^$:")$,P%%)OEQ92;5
M#T22LN!L\/CXM7JBBP(]1VHSSWK0[)V94]D*-?HHPR)XZ# 38C\B\ *!9D2@
M8L\"&!+88X>._Q4XN(@(%HC #")#CQ;T&*;'(#TV]'A!3ZP-<!$I+)"  HE#
MSRP!%Y'# BDHD#KTC27@(E (*V2@0N;RD24!0# LD8,2N<N/+ D LO*E-Z#$
MQN7;GWJ$) ;238F&:1JOZ* 0]E3H*J6VJP!,MJ*RXESD1L@M:TV894)QE&2;
M)%G3 DV\0]C5LHL,P."5*D.PDU'D1K#K#,*L%!J"#8]</V.[U"#,6@W KD>N
MJ;%=;1!F306V/G*=C9U*2YT:P.%JK<$_ .3:&]M_L0F3+C'V?RQ8'$LMY3=S
M@@OOS.Z=N3XL1N=;P@Z;8^TO?+QB?"7\5G?".S&I#D=SA%T9DU0M)7Q2R5;J
M5C-W&GJ5NIFI-A^/]K$C63]=6X+Y[E3^ 5!+ P04    " !SB*M*@S,5X)4$
M  #-%0  &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;(V8[6[J1A"&;P5Q
M <<[L]\102I452NU4G2JGOYV@A/0,9C:3CB]^ZZ-@V!F-LV?8#OO[C[KM1^&
M79R:]GNWK:I^]F-?'[K[^;;OCW=%T3UMJWW9?6F.U2']Y[EI]V6?3MN7HCNV
M5;D9&^WK I5RQ;[<'>;+Q7CMH5TNFM>^WAVJAW;6O>[W9?OOJJJ;T_T<YN\7
MONY>MOUPH5@NCN5+]6?5_W5\:--9<>EEL]M7AV[7'&9M]7P__PGNUMH-#<;$
MMUUUZJZ.9\-4'IOF^W#RV^9^K@:BJJZ>^J&+,GV\5>NJKH>>$L<_4Z?SRYA#
MP^OC]]Y_&2>?)O-8=M6ZJ?_>;?KM_3S,9YOJN7RM^Z_-Z==JFI"=SZ;9_UZ]
M576*#R1IC*>F[L:_LZ?7KF_V4R\)95_^.'_N#N/G:>K_O9G< *<&>&D YL,&
M>FJ@28/B3#9.]>>R+Y>+MCG-VO-J'<OAH8 [G6[FTW!QO'?C_])LNW3U;8EQ
M4;P-_4R1U3F"UY';Q)HGM+I$BC3^!0)%"!S;Z^OV(+?78GL]MC?7[0GBZASQ
M8^1PGH1%;0V0J0@YYVQ0*/,8D<=P'DUXSA%[-0YX" %);BWD5 C!1YG'BCR6
M\QC"8_DXQ@*EX:G,.CN1PW$.2S@<&T%[I6VD)$(NQAA4YKYXD<=S'D=X/!L'
M/:KH"8X00Z.]EFF"2!,X#1EF%?@P2CMO \&1<DK[F'F*H\@3.0\99Q79."X&
M&QU9U37/>0TJZLQJ@9)=I3@1DY42IFZ1/3]2#IVV/D.4L2<P(J,H$0BONG'*
M!L8D)2W$:#,V!%FG@)P**!7R%\AZ#]$[2B4E37K5;&[U9$D#M[2AEIXR-ZMB
M#.+UFS112<GHO#$A0R6K&KBK#74U< F;$)0QE(GGK#8N9-XZD&4-W-9TI!5P
M$?L !H75DY(6%9B,N4%6-SCV'6ULI@=9ML!M:ZAM0?!H\-X JSAX4"N7%&<R
M3+)R@3O74.<"EVE42 N,M1 #'4.N$ +9N<"E:ZAT@=LT53)6,^M*0:O0Q<Q-
M0EF[R+5KJ':1ZS1];4>@2$(N %S?S5LB6;O(M6NI=E&0:?*6=?2K^Q/!6Z9,
M#<NE:ZETD:L4C%%@J4D^$;QEDI6+7+F6*A>Y2.5*5 I^5(JB+%SDPK54N"A5
MO=:HY%(*)25U]#[[ T26+EJFM^R]E@6)O+BUM+A%7K4&ZU-UJ^BTA* S*F+N
MF925BURYEBH7N4F=\HHC\9SUJ$UN]67A(A>NI<)%P:31(P UX5I,.@"E7(9*
MMBY&OOJ9,D++CM3<D98Z4G/WT9O\8>260S:CYF9TU(R:"\_H]!.7LOQ?[)9'
MMJ+F5G34BIK+#H=W A75XF>2MU29_0+N1<<V#(0",_V"4H:56%+2^/1>YXH1
M+9M1<S,Z:D8M^2Y&;YD9Q:0%?UTBWE+)9M2\''6T'-6\R+3!( 1D5%(RJ@@Z
M=Z]DVVIN6UK^K*;,]5Y.ID@6DV*17%SMJPT;G7^4[<ONT,T>F[YO]N-&VG/3
M]%7J57U)L]Q6Y>9R4E?/_7#HTW%[WF \G_3-<=H\+2X[N,O_ %!+ P04
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MV( OF_K?6!L I>QN<(0Z_&"+H: )\?@.SVX:L\D(MI]_$%N^<?D;4$L#!!0
M   ( '.(JTIH;41=LP$  -(#   8    >&PO=V]R:W-H965T<R]S:&5E=#DN
M>&UL?5/;;MP@$/T5Q >$7=9)5RO;4C95E4JMM$K5YIFUQS8*%Q?P.OW[ B:.
MD[IY 6:8<^;,,.2C-D^V W#H60IE"]PYUQ\(L54'DMDKW8/R-XTVDCEOFI;8
MW@"K(T@*0C>;&R(95[C,H^]DREP/3G %)X/L("4S?XX@]%C@+7YQ//"V<\%!
MRKQG+?P ][,_&6^1F:7F$I3E6B$#38%OMX=C%N)CP"\.HUV<4:CDK/53,+[6
M!=X$02"@<H&!^>T"=R!$(/(R?B=./*<,P.7YA?U+K-W7<F86[K1XY+7K"KS'
MJ(:&#<(]Z/$>4CW7&*7BO\$%A \/2GR.2@L;5U0-UFF96+P4R9ZGG:NXC^EF
MGV#K )H = ;L8QXR)8K*/S/'RMSH$9FI]ST+3[P]4-^;*CAC*^*=%V^]]U)N
M=UE.+H$HQ1RG&+J,F2.(9Y]3T+441_H/G*[#=ZL*=Q&^^X_"-P39*D$6";(/
M2UR+N7Z7A"QZ*L&T<9HLJO2@XB0OO// WM+X)J_AT[1_9Z;ERJ*S=OYE8_\;
MK1UX*9LK/T*=_V"S(:!QX?C)G\TT9I/A=)]^$)F_<?D74$L#!!0    ( '.(
MJTHGTB>7M0$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;'U3
MVV[;, S]%4$?4"6.VP:!;:!I473 !@0MMCTK-FT+U<65Y+C[^U*RZWF;L1=)
MI'@.#RDJ&XQ]=2V )^]*:I?3UOONP)@K6U#<79D.--[4QBKNT;0-<YT%7D60
MDBS9;&Z8XD+3(HN^DRTRTWLI-)PL<;U2W/XZ@C1#3K?TT_$LFM8'!RNRCC?P
M OY[=[)HL9FE$@JT$T83"W5.[[:'8QKB8\ / 8-;G$FHY&S,:S"^5#G=!$$@
MH?2!@>-V@7N0,A"AC+>)D\XI W!Y_F1_C+5C+6?NX-[(GZ+R;4[WE%10\U[Z
M9S,\P53/-253\5_A A+#@Q+,41KIXDK*WGFC)A:4HOC[N L=]V&\2:\GV#H@
MF0#)#-C'/&Q,%)4_<,^+S)J!V+'W'0]/O#TDV)LR.&,KXAV*=^B]%-O=3<8N
M@6B*.8XQR3)FCF#(/J=(UE(<DW_@R3I\MZIP%^&[/Q3>KA.DJP1I)$C_6^):
MS/ZO)&S14P6VB=/D2&EZ'2=YX9T']BZ);_([?)SV;]PV0CMR-AY?-O:_-L8#
M2ME<X0BU^,%F0T+MP_$6SW8<L]'PIIM^$)N_<?$!4$L#!!0    ( '.(JTIY
M]7*BM $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;'U386_<
M( S]*X@?4')<UG:G)%*O4]5)FW3JM.TSES@)*H04R*7[]S,DS;(MVQ? QN_Y
MV9AL-/;9M0">O&K5N9RVWO<'QES9@A;NRO30X4UMK!8>3=LPUUL0501IQ7B2
M7#,M9$>++/I.MLC,X)7LX&2)&[06]L<1E!ESNJ-OCB?9M#XX6)'UHH$OX+_V
M)XL66U@JJ:%STG3$0IW3N]WAF(;X&/!-PNA69Q(J.1OS'(R/54Z3( @4E#XP
M"-PN< ]*!2*4\3)STB5E *[/;^P/L7:LY2P<W!OU75:^S>DM)1748E#^R8R/
M,-?SCI*Y^$]P 87A00GF*(UR<27EX+S1,PM*T>)UVF47]W&ZX3<S;!O 9P!?
M +<Q#YL21>4?A!=%9LU([-3[7H0GWATX]J8,SMB*>(?B'7HOQ6[_/F.70#3'
M'*<8OHY9(ABR+RGX5HHC_PO.M^'[387["-__0^%O!.DF01H)TO^6N!&3)G\D
M8:N>:K!-G"9'2C-T<9)7WF5@[WA\DU_AT[1_%K:1G2-GX_%E8_]K8SR@E.0*
M1ZC%#[88"FH?CC=XMM.8388W_?R#V/*-BY]02P,$%     @ <XBK2E%LO^:R
M 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL?5-A;]P@#/TK
MB!]0+KELJTY)I%ZG:956Z=1IVV<N<1)4P"F02_OO!R3-LBWM%\#&[_G9F'Q$
M\V@[ $>>E=2VH)US_8$Q6W6@N+W"'K2_:= H[KQI6F9[ [R.("59NMM]9(H+
M3<L\^DZFS'%P4F@X&6('I;AY.8+$L: )?74\B+9SP<'*O.<M? ?WHS\9;[&%
MI18*M!6HB8&FH#?)X9B%^!CP4\!H5V<2*CDC/@;CKB[H+@@""94+#-QO%[@%
M*0.1E_$T<](E90"NSZ_L7V+MOI8SMW"+\I>H75?0:TIJ:/@@W0..7V&NYP,E
M<_'?X +2AP<E/D>%TL:55(-UJ&86+T7QYVD7.N[C=+//9M@V()T!Z0*XCGG8
ME"@J_\P=+W.#(S%3[WL>GC@YI+XW57#&5L0[+]YZ[Z5,LB1GET TQQRGF'0=
MLT0PS[ZD2+=2'-/_X.DV?+^I<!_A^S<4_D60;1)DD2![M\2MF']5LE5/%9@V
M3I,E%0XZ3O+*NPSL31K?Y$_X-.WWW+1"6W)&YU\V]K]!=."E[*[\"'7^@RV&
MA,:%XR=_-M.838;#?OY!;/G&Y6]02P,$%     @ <XBK2HK$%[2S 0  T@,
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MSG8:L\GPV,\_B"W?N/P)4$L#!!0    ( '.(JTJ>+3_'LP$  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;'U388_4(!#]*X0?<.RRO?.R:9O<
MGC&::+(YHWYFVVE+#I@*='O^>X'V:M7J%V"&>6_>#$,^HGUV'8 G+UH95]#.
M^_[(F*LZT,+=8 \FW#1HM?#!M"USO051)Y!6C.]V=TP+:6B9)]_9ECD.7DD#
M9TO<H+6P/TZ@<"SHGKXZGF3;^>A@9=Z+%CZ#_]*?;;#8PE)+#<9)-,1"4]"'
M_?&4Q?@4\%7"Z%9G$BNY(#Y'XT-=T%T4! HJ'QE$V*[P"$I%HB#C^\Q)EY01
MN#Z_LK]+M8=:+L+!(ZIOLO9=0>\IJ:$1@_)/.+Z'N9Y;2N;B/\(55 B/2D*.
M"I5+*ZD&YU'/+$&*%B_3+DW:Q_GF,,.V 7P&\ 5PG_*P*5%2_E9X4>861V*G
MWO<B/O'^R$-OJNA,K4AW0;P+WFNYSVYS=HU$<\QIBN'KF"6"!?8E!=]*<>)_
MP?DV_+"I\)#@AW\H_(T@VR3($D'VWQ*W8N[^2,)6/=5@VS1-CE0XF#3)*^\R
ML \\O<FO\&G:/PG;2N/(!7UXV=3_!M%#D+*["2/4A0^V& H:'X]OPME.8S89
M'OOY!['E&Y<_ 5!+ P04    " !SB*M*2?=G[K0!  #2 P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-2YX;6Q]4V%OVR 0_2N('U 2XJY99%MJ.DVKU$I1
MIVV?B7VV4<'G 8[;?S_ KN>UUKX =]Q[]^XXT@'-LVT ''G1JK49;9SK#HS9
MH@$M[!5VT/J;"HT6SINF9K8S(,H(THKQS>83TT*V-$^C[V3R%'NG9 LG0VRO
MM3"O1U X9'1+WQQ/LFY<<+ \[40-W\']Z$[&6VQF*:6&UDILB8$JH[?;PS$)
M\3'@IX3!+LXD5')&? [&?9G131 $"@H7&(3?+G '2@4B+^/WQ$GGE &X/+^Q
M?XVU^UK.PL(=JE^R=$U&]Y244(E>N2<<OL%4SS4E4_$/< 'EPX,2GZ- 9>-*
MBMXZU!.+EZ+%R[C+-N[#>,.O)]@Z@$\ /@/V,0\;$T7E7X03>6IP(&;L?2?"
M$V\/W/>F",[8BGCGQ5OOO>3;Y"9EET TQ1S'&+Z,F2.89Y]3\+441_X!SM?A
MNU6%NPC?_:-POTZ0K!(DD2#Y;XEK,9_?)6&+GFHP=9PF2PKLVSC)"^\\L+<\
MOLG?\'':'X6I96O)&9U_V=C_"M&!E[*Y\B/4^ \V&PHJ%XXW_FS&,1L-A]WT
M@]C\C?,_4$L#!!0    ( '.(JTH9#9B7L@$  -(#   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;'U386_<( S]*X@?4!+NVE6G)%*OT]1*FW3JM/4S
MES@)*H04R*7[]S,DS;(MVQ? QN_YV9AL-/;%M0">O&G5N9RVWO<'QES9@A;N
MRO30X4UMK!8>3=LPUUL0501IQ7B2W# M9$>++/I.MLC,X)7LX&2)&[06]L<1
ME!ESFM)WQY-L6A\<K,AZT<!7\-_ZDT6++2R5U- Y:3IBH<[I77HX[D-\#/@N
M872K,PF5G(UY"<9CE=,D" (%I0\, K<+W(-2@0AEO,Z<=$D9@.OS._NG6#O6
M<A8.[HUZEI5O<WI+206U&)1_,N,#S/5<4S(7_QDNH# \*,$<I5$NKJ0<G#=Z
M9D$I6KQ-N^SB/DXW/)UAVP ^ _@"N(UYV)0H*O\HO"@R:T9BI][W(CQQ>N#8
MFS(X8ROB'8IWZ+T4Z762L4L@FF..4PQ?QRP1#-F7%'PKQ9'_!>?;\-VFPEV$
M[_ZA\#>"_2;!/A+L_UOB5LR?1;)53S78)DZ3(Z49NCC)*^\RL'<\OLFO\&G:
MOPC;R,Z1L_'XLK'_M3$>4$IRA2/4X@=;# 6U#\</>+;3F$V&-_W\@]CRC8N?
M4$L#!!0    ( '.(JTKROV-BLP$  -(#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;'U3VV[;, S]%4$?4"5RVA6!;:#I,'3 !@0=MCXK-GU!=?$D
M.>[^?I3LN&[G]442*9[#0XI*!V.?70/@R8N2VF6T\;[;,^:*!I1P5Z8#C3>5
ML4IX-&W-7&=!E!&D)..;S0U3HM4T3Z/O://4]%ZV&HZ6N%XI8?\<0)HAHUMZ
M<3RV=>.#@^5I)VKX ?YG=[1HL9FE;!5HUQI-+%09O=ON#[L0'P-^M3"XQ9F$
M2D[&/ ?C:YG131 $$@H?& 1N9[@'*0,1RO@]<=(Y90 NSQ?V+[%VK.4D'-P;
M^=26OLGH+24E5**7_M$,#S#5<TW)5/PW.(/$\* $<Q1&NKB2HG?>J(D%I2CQ
M,NZMCOLPWB07V#J 3P ^ VXC@(V)HO+/PHL\M68@=NQ])\(3;_<<>U,$9VQ%
MO$/Q#KWG?'O-4W8.1%/,88SARY@Y@B'[G(*OI3CP?^!\'9ZL*DPB//F/PC<$
MNU6"7238?5CB6DSR+@E;]%2!K>,T.5*87L=)7GCG@;WC\4U>P\=I_RYLW6I'
M3L;CR\;^5\9X0"F;*QRA!C_8;$BH?#A^PK,=QVPTO.FF'\3F;YS_!5!+ P04
M    " !SB*M*%3P5$;,!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q]4]MNW" 0_17$!X1=UIM&*]M2-E652JVT2M7FF;7'-@H7%_ Z_?L"
M)HZ3NGD!9IASYLPPY*,V3[8#<.A9"F4+W#G7'PBQ50>2V2O=@_(WC3:2.6^:
MEMC> *LC2 I"-YMK(AE7N,RC[V3*7 ].< 4G@^P@)3-_CB#T6. M?G$\\+9S
MP4'*O&<M_ #WLS\9;Y&9I>82E.5:(0--@6^WAV,6XF/ +PZC79Q1J.2L]5,P
MOM8%W@1!(*!R@8'Y[0)W($0@\C)^)TX\IPS Y?F%_4NLW==R9A;NM'CDM>L*
M?(-1#0T;A'O0XSVD>O88I>*_P06$#P]*?(Y*"QM75 W6:9E8O!3)GJ>=J[B/
MZ6:?8.L F@!T!MS$/&1*%)5_9HZ5N=$C,E/O>Q:>>'N@OC=5<,96Q#LOWGKO
MI=SNLYQ< E&*.4XQ=!DS1Q#//J>@:RF.]!\X78?O5A7N(GSW'X5O"+)5@BP2
M9!^6N!:S?Y>$+'HJP;1QFBRJ]*#B)"^\\\#>TO@FK^'3M']GIN7*HK-V_F5C
M_QNM'7@IFRL_0IW_8+,AH''A^,F?S31FD^%TGWX0F;]Q^1=02P,$%     @
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M"4D: =(E5=5*K11=U?:W \N'SL;4-N'Z]K4-X0A!]P?;ZYG96>-UW OYJBH
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MN@_9;G'F7#'M&3_I FM]?\R+EIV5F:9Z+L8N.BX4'Z8+(IIOJ?(?4$L#!!0
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M<OP<QT*+?GIIT/S<E?\ 4$L#!!0    ( '.(JTJ_@,?CWP$  &8$   9
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M->?V ;"!9./\MJ'E@2W_ 5!+ P04    " !SB*M*'WNS)O8!  #+!0  &0
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MH[;3I9E+_]3]0HM^[&)H:J75/U!+ P04    " !SB*M*_OQ\:;@!  #: P
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MMGYZZ^9ZO&YC854?7Q*9GG/Q 5!+ P04    " !SB*M*HJU53?\!   A!@
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M;L;3.@9.]]-%)//?H/H'4$L#!!0    ( '.(JTIGJGYN+P(  .@&   9
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MQ'F2X6&7P5E4UKY54/ZW?_F7)H!-8(XES7.^CNZK?UU%ZZ(VHYSQ%#[*HS6
M=QE_"?X2/]? MLMSFC@I%C#NCSC*6W=Y>-CK'PYZ;4MEFPW@TJS,%I_#8$8(
M%5SORJ*$:P8XMWQVGJSC/#B%Y>ZSO+:]V29:X]]OXVV6EWA;L,PV2FL#=1-R
M'#M^5D;EKH;9?]2176;X/5O#^XERV5EMV%76\N&G>+T^_)QF3P"#."JR-%X&
M%T6QB_-6K'"!?@[_6%NL.E+0J''L7VL7<WI]=3:]FDW/ OAI=GUY<3:Y@U_>
M32XG5Z?38/9^.KV;P>/_.#L+#MZ\K2T>+\S['K7AS:0HXK+XN?;GJ'B@Y[W
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MG7%:I)*OD>RP[AY,S4[^ M-167S9K4NNI,&@=4 G8=&%#:(P]0-VST4C'(S
M;6[CV<#&^2=BA_9.4'\H_!62U)K[-:^$GZGQ9S<I.[H\ A+S=>0P+V"J&]&[
MPCP'][YL,09*"5L_DC/6DC]@8EL!D4V]E-,)DX0CKI 6L '!04(CA53AF+A9
M= +\;9:@8J^A0FV;E(=>&#B8%#U/)0P6:X#E@H2[W?+9D2$HU$(!5R%53-W\
M3_GLPIH9\78%ZT\E)EUP";J48SDB>.SK%>,[@J8!)!-R FB K]QV=;="?BF=
MDJ+N=G/Q-[A/B5=LPA3W\5&@U=J-0&'T <ZWH3CRB*PCB;PJ.M0\+I\H61UM
M342H*#HC3E4B<K)]V0F.^VM%7'<[%M5]M.T$'[?F&X5+"Q:$%@9D52]\,"R<
M$A05L1E.FU)X1JR<QMTOGH3"GM3OT[R\1UUX;%+8,/.:(NX:[^<VXT6H0)Y]
M(1$6$0K]D=YK\E5\]R 8+]%,I0P; 9":@B5<[J;*KD.?=-FB/R]1+TNLVJPR
MC>I[A8+90 C$*PH@4.\G5>(03:UZ0+*$YO$]_)R+#31QQ#B4P5&V?XC+!U,L
MJ7)""1YA3QB<EN%OZ[LX,+Q FEFCE1Q[5JNE L<**=!*(O3T+VAZ<6J#81IL
MBJHGT( 20P]1]UU5^<@\Q^,+K=,=A=51+K>I'T"8-24 (=!6N]02$0TP%%/_
M#@OUF-@A>ASJ9".N+)\Y:_-%$WT47:TB^^%SL]PBKCM7L\)9A:K?L'&V>N>&
M>%'U%[N%AK<8ZS%S)%I^)#L&^J]+?6_"A#A[O*Z;V>=.)5!@&%I>?)AL590C
M5ZMSQ4WOPL&26FA>]/KJ[IW@S"JJCE,8![.MB ,@8)D?"_+L\F,12TF*V0T[
MX#W/3+.6%!G#51C26 H%D9I"%F'-TO8/I+=82%J<6$4<6,/2\J@U.Y\?)CUW
M0RS=RW'4^Y63G+CT$&3%53E:%"@RVK*63RF%KA3H+N6&5=3M&4J_S)TXZ%]4
MJ$D]MW80GHSZ8>^H1^MCY3#/<%!)OT.M9[Y.[C4P$<[:JA/ZW.(-:.]2I)RR
MI_C9F\0A6/@Q NP$0KHUN&15#'2KO&!<;](X:_5_IY=4@?5F@C[&N]O)U6QR
M2F65&W7TD8E?;?T.Y-I-K.)G@\5KGE&(PDJRW)!G4)$[]BB\P[^J<Q[5X"UB
M,  !E27%)_<"\.&;6#WG%GOLUQN-I3Q-@_6GJOF-1,JL/NU*.56!0*7-@+Z>
M]BI'7J"F%F)0#,5B%S;0BPSMN5@[>YWNGR@4EA.FV=N95(H:"^8.CD=5HQ@^
M!F+#<AU?81FK502>7/UE>OOC#&L^3F_NJ.X[H@66??]C\NYRVH@S8X78BY]3
MV E0Y+43"&+,T*X])@I,:Y.)#8N_R@!@E5IK$<7W@<K>6#Y07:OZ35AC?B2?
M-M7AE+8/A+H_F-W@%HH?WFI).O2R+*643U0$3EB>J=[R),X'#=72\;4 (5>H
MDW!$RU4IO!2? C\ E(C6IFC$1F.(;9R;<#)_WQKBHB RFTDTNM63+HI8]V&1
MFVP\Q0.F*<)Y?ZCTI_FA\9'X[^(KGBOO:1,!1=UM=&\U:X"]196NT-%EL 1S
M":5@J,I'6,R,J-?MAW>#KNDD<5 EWYUAL &5"VCN6Y6;+(#(<FW] \ZEN94;
M_ L@I4Z+?H0^:F+\^]HQ"EA46L7HF]$;[W:Z0U/!$''4 "8SF *,K7P!P@TO
M$*FQ&PO?]@2;>&H/ S7"X[X4 ^F%W6/X=7Q2<9TVE N?W=U^),827%Y/KH+S
MR2DVKOB*,*9C$SC8.IGWU(RY-=K3%Z9^1,"5X+@=67H#BROLA]XW.S,,IXRA
M6"6KFR@TVYGT^\-G=:7:*&O6E)=<%1$VTI/I^&HU!G691T^4VLMZ*B5X.MH>
MR>Q$8NAU64NK8X.#O:$U$C&? S2C@GPZ.ZT,2-1YS,<@\1$]5H*G="R2_:@6
MF9K4N$[!&OELSLF$2K@\V#7+&2@W-QD@U:)@/*_.(#J"DS!)C@&)CG$NP )@
M3EJ^J0G@,O!A9SSX4^BFQ_=ZMK8HAJS?HQ,MU1IEY WTKY%% !M(;Z@G9]UZ
MEQ;ZY5 Q$]G)-G4<G^XN5G <,F)Y)0'INLOG;<Q1[51XA1=.4ZIUB4'!UK+1
M@#M2B1@@*7G1YK,EITI<*SIRD\.AW(@3Y\ZU3ND 3)J'G9.C/[$T[7\\8IU1
MOUGM<I+7_&\')W]R+M#P4K-DEB(ZJYZBD%@E.1+JITS#)&QY=/<U#4,AK6O5
M'MDR157OV(:$L0UH+]( "YSSH/]6;PH9 M!W&W'O+"]#E.+/8TY$BMW(_"+Y
M<D@BG8:T<ZRR#V/%_ )+;2W;Y_6!2T%AY'#74$)15M4#G,9?2L^"S.5]70CU
M^XI"'+."*HD4<$:OL-;G!;7ID=$0]UM1DQ$4P.3R,E9%N:**<<$K!^QZLAJM
MKM+FHR'3;*#A/:7@;^TUV$QV!5EMB89)PT%WQ-.>&*X "[QU )T((N-97J-L
MLEO02 C1VLAVGJ !Q-<1=93PD=O*W[8C5"K&5R^S61K+8\_?32T8)PQ>&L"'
M[QUU*4 ^ &UZ/ I/NB15G'B_]KO^KSWGUS> @\BJQD='P3F&&?RN809>$[1+
M?-'G2MY5UW M&J"-YXRYE$'3&,!1L:EI9A#1"WF2!<B):R'-6N)%BP>*Z\%W
MN;L&VS96[TI47Z&I.MC&]-:)PYC'BP@#/W%E0@1V5-FD'F%;5"7%);D<X>7.
MK!WI)#@E9^I=CVP\O?XP#>XF__$U[05.**C1?ADTM%EI+9N9QYH4IJ5Y-*<+
MO^)K=NWVY*ZC2XZ^:!HEKB&T@9'=YM'&&ZP!C_R*RF#&7!68BQU7? %<?X**
MCL1EN5;/MHWJ7[I]^%K.0S9E)[(.._91@X!<SN*'Z%"Q17?_IKI35-H4:/P#
M087N'#DO>10PHBR94TRR=J'#]:7Z;F/ZF[8@,K64GT'<H,+BB'I4-5N3$QCS
M#=!=DCCH6HVI$=<1<E1I5+85NO7G64)PZXJ;DNPUXML?=(R\'5;+7?'-H0D2
MBP[1!UCW'V?F8)!0:F:+P1@H[L?.K -ZUI)"\[)<<BG=;D!>\6WIH(-B2(R)
M7>09,W#W;.?F!N0BT5#'QC'R0' %,#(?/B5%W%3Z:QZ[DI^W4W*(U;=Z@)%5
M4B7"UB.AQ">Y9\0_%N.+MQRJ"/3/-#IP6P\IW:34P#.O#J(:5PS;W:5NK):^
M"MJQ\^)-ITIUTDA1/;2_"V$S5!6-I5^$(E12]1$Q'YZW"#K^V!0#S-)?@H?L
M":OSA/Z>&HYO$CY=1L%%9E#6\$MQT5&\,W3<SII,0+2&OC!=S)OD1"G\4)-\
M:DY'=.NFSKLG*A<#]TG9YTYIS/9K7.EONZ54;]E@9KBUL6)!Q4,N^7:(=:@.
M <IL<B7C8($7[;L$J-,)01%K,EN^9A;LF +3KA*$72"  *W+2OF(MC-[A5^B
M6JUNOS@#$@L6-/>+3(Q$&BM-+_RY=0=,0#D"C$#>J>$G0]T/)%)#:BV6R C#
M#1Q</=M2!;Y^L=50I88%1@0S;'//?B>-U8Z_1/H.2=EB$*%%AY.P<=JK2(1(
M;C^CM!YDJ_M< C\Y$V ;D0Z/W]A^"X%TN[N#_6+Z]\'TX@Y_>*LJFMFJMRBE
M[\$:< ')VBZAED<8<>%G?]\ZKB\%B"RES#K+/COL]M^CE+)6.>'\F+FQ?H%[
MV[/ [0X-_,F&&M9$@"6,,?@UJAQH6*-*?,$2C@X(OS@T?"-V>F'@*GXKC)A:
M58BD"*<XOY@62'RHF%R)53O0?I>LU(>MV*FF28S%W<I+J]B%G6(!4CZ&:GG?
M.UV-4&^(@AYL7YO;^.B&OTL)3-8!GA1@O)KS#ZBC"?5B'3<F\:CD@@QMDZN6
MZNW./XG-:;:66%P7@6[F(9TSLOJ)RCU\S'E\S[:*&@J((@D/INN3!RU'JA8G
M$]L!BT2/6<X4WRR_(B Z*<(P8\^\<7KPDL2@'8YV;FD!IFE8-B!P>D=9S"'[
MK[7.F4VBP;A]J\9DT[!CT:6/<$O69)YS"K_6<*&BZ/4 MQ1PT4YI"KP9"[2I
MFP+W'S^QO_$'0U3>PRD/[^"4#LWX04$BVQIK.%4EY7D%DGUB2Q2P#LYK)&FC
M91JM" L2NI#8$XM&Y"$%F-=T@VE4JQ$QNZWX V7$D/##6>..F,6BFMI#[ U6
M,1^4XV:22=4A2&\F*HYHQ>'A\,,=RHULP)%?G<K>7)31D>;VI7S>D:_O _OZ
MIDV^/EI=VY._(>VY]XO]P:AD@VXX&!P%?4S /38^R&J_4_A0!K[1H:^T:J!$
M:KI-KDUT/)SVB9*Q\=CX@HA=<T>QHD'P'_8[?:-B6&^N)[UEJQ57,7S63(.*
M3FC?<[^OP<#^;J@F@(2<)R2TD*'#IVC1NLA8_J@=3L)$_)87*K4[8-USTJ/.
MZ)4';3PD55.5D$D][6#,#B@*\["M([BPJ'F-#>ILZ$:"J:9E([BX,B.5\=9"
MPUC]E%XJREL%'M>(TER/07"Y27?VZS]JD4&$O(8&Z:95-F^:A=)1- ;%Q%](
M/4?YKAD]:E6K7,,!*76NT0!T%OHH)A\#3H/T$PF/0?+ X!5>(2B(<J1&H-H*
ME<V[([$246<=L:&:\L< 7]DOMXD^\^:3PHGGZ8B]C*OXIFZDCWIH,/P<?WDP
M=8B:5G:+>A*;;-RC+;<I\,N< F;-]I*\"D)TZ\XMM#P4- WD$A/I)XC7D-L@
M*$18-X?K7SGZ3>-6OLX_K4U6W%6-A8!CG6V"FBU0KTYB:C#6L MTJO9[X<EH
M .263?OX^]$0J&ZW_Q6;K'57J%(P4^Y3HY&DI1$RGY"[+24%N=&TIE5FRR7K
M,#),'D;+9;S4?]KE<XKE=1OL\E_PGAD>!<714:<)&T8%0@-I<-05UAC N=>E
M=%Y5NV\MLB!J:I]<-VB>3RYN@]\GEQ^GP8?I9/;QEIM3OW)8M:WLOA:K7358
MM\S%AF^VZW)!1?9-BW5/^W!QG4?.K;"=0;0,/_N(N6(;:HD(N#(SI3$!!:W1
MY0"]R5^2DJ=\:PR,QG= '1E0N\?0I1*>'.+$QA:;)IN/+N48<XBP4)#O^MEK
M:*7!ZC('!9S@4F0_EY8#;.IU[)AWF?ZC8_D.2;H& @Y8\VRK>+HFETHO*3RL
M]-W*.)($20$9SMG.E,WQNH1X@90L=O\DK8W<I;6Q^)K@TNR6=D6L_1Z)H$I\
M*,U;VA.1%.?E5;:9P1TGS"51:-.S]Z^[C!-J$JEJ%[$/6;N DAQIG'%*57)W
M^H[,:0K!7-> X;0WT_5M,:2_>UO !=6#TKA<6/D U5^J3N]M/+15=^IWP^$)
MS!D6Z/2A.$P.&W!&.\FZ>L:!GO%C_1JIP0,WW8)Y8+,ELZ TLVVHN,NW]MV0
MQ&2OC!I)!LY#KG06P$/C?RG?F'H U.M/.UW;U)!@?5)HH?O[+O:-YNX.5E26
MW'+9BJW603CS/-RBCD[+-;0LLG"0.PV=?-Y!J.[,64%O3*5^Y+SV)RI57#JT
M0A($D.]P@!BF"*CQ=^411*%-&U3W#4'(W(I.#2SMA;UYV<SMH7]H)LS6RXI%
M1BJV,]^NGK$P;20LSY>D/- DUA)WA%YPGK1]<3]&E:MYJQY@%07WE.I@;I
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MAM(5H3H5910BO)Q*V0CZBJF+J]#+;<9?XGR!]GP]OYN@*76SM+@?6=343^D
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MT(P>)$,@XY"?A+#F:RV :^%[+0!LX8LM@&SAFRT ;>&K+8!MX;LM &[ARRV
M;N';+0!OX>NM0&_EZZU ;WW 61L=MOEZ*]!;^7HKT%OY>BO06_EZ*]!;^7HK
MT%OY>BO06_EZ*]!;^7H;T-OX>AO0V_AZ&]#;'G!7@BY+^'H;T-OX>AO0V_AZ
M&]#;^'H;T-OX>AO0V_AZ&]#;^'I[H+?GZ^V!WIZOMP=Z>[[>'NCM'W#7C2Z[
M^7I[H+?GZ^V!WIZOM^_H'8N\":N/U&S+3;QWR<7PFS4=N&,Z[</],\Y3;^[O
M*)W:+<&=GW=7YSSU-\)=_'_X^@-02P,$%     @ <XBK2K1F&&*[ 0  9!P
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MXUJ5S5])/K5>'N:S[L_%V3=02P$"% ,4    " !SB*M*'R// \     3 @
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M2P$"% ,4    " !SB*M*8%!WF&P"  #6"   &               @ %^$
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ <XBK2K#NKMJ^
M P  ;P\  !@              ( !(!,  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( '.(JTK'0-3N700  &P3   8              "
M 107  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !SB*M*
MF-TW7;0!  #2 P  &               @ &G&P  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ <XBK2B=L<7*P 0  T@,  !@
M     ( !D1T  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M '.(JTK!1X;=LP$  -(#   8              "  7<?  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " !SB*M*:&U$7;,!  #2 P  &
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M970Q,RYX;6Q02P$"% ,4    " !SB*M*GBT_Q[,!  #2 P  &0
M    @ 'S*@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M '.(JTI)]V?NM $  -(#   9              "  =TL  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ <XBK2AD-F)>R 0  T@,  !D
M             ( !R"X  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " !SB*M*\K]C8K,!  #2 P  &0              @ &Q,   >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( '.(JTH5/!41LP$
M -(#   9              "  9LR  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ <XBK2OTFDYJ+ @  1 H  !D              ( !
MA30  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !SB*M*
MYK6C:+4!  #2 P  &0              @ %'-P  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( '.(JTHYI?\5Q@$  #<$   9
M      "  3,Y  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ <XBK2MJ)*K>V 0  T@,  !D              ( !,#L  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !SB*M*#S&*0[,!  #2 P
M&0              @ $=/0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( '.(JTK>ZK;_PP$  #<$   9              "  0<_  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ <XBK2B<-ID>S
M 0  T@,  !D              ( ! 4$  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " !SB*M*3.1K(:\!   B!   &0
M@ 'K0@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( '.(
MJTK71]XO\P$  .T$   9              "  =%$  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ <XBK2B0VQO5" @  L08  !D
M         ( !^T8  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " !SB*M*D>^7AW0"  #8!P  &0              @ %T20  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( '.(JTI?0X_0&0(  .$&
M   9              "  1],  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ <XBK2NPZT,_A 0  : 0  !D              ( !;TX
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !SB*M*75,M
M?>\!  #Z!   &0              @ &'4   >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( '.(JTJ_@,?CWP$  &8$   9
M  "  :U2  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M<XBK2E7</ FP 0  QP,  !D              ( !PU0  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " !SB*M*S8?$1\4!  !A!   &0
M            @ &J5@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( '.(JTHZ$TW_W $  &0$   9              "  :98  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ <XBK2A72;:#> 0
M\@0  !D              ( !N5H  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " !SB*M*,3[GI\ !   P!   &0              @ '.
M7   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( '.(JTH(
MR/GS[P$  &P%   9              "  <5>  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ <XBK2A][LR;V 0  RP4  !D
M     ( !ZV   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '.(JTHM"/;8O@$  !D$   9              "
M 7!K  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ <XBK
M2F>J?FXO @  Z 8  !D              ( !96T  'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " !SB*M*<&:-T$!*   ]!0$ %
M        @ '+;P  >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    " !S
MB*M*JCY1$#H"  !_"@  #0              @ $]N@  >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( '.(JTJT\3K(.@0  #T>   /              "  :*\
M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !SB*M*)1HY/,0!  !/'
M&@              @ $)P0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !SB*M*M&888KL!  !D'   $P              @ $%PP
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     -P W /,.  #QQ      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>6</ContextCount>
  <ElementCount>219</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>000020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>000030 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS PARENTHETICALS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETSPARENTHETICALS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS PARENTHETICALS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>000040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>000050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>000060 - Disclosure - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>000070 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>000080 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosurePROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>000090 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINTANGIBLEASSETS</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>000100 - Disclosure - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS</Role>
      <ShortName>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>000110 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureRELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>000120 - Disclosure - BANKER'S ACCEPTANCE NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureBANKERSACCEPTANCENOTESPAYABLE</Role>
      <ShortName>BANKER'S ACCEPTANCE NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>000130 - Disclosure - CONSTRUCTION LOAN FACILITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCONSTRUCTIONLOANFACILITY</Role>
      <ShortName>CONSTRUCTION LOAN FACILITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>000140 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>000150 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureFAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>000160 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSTOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>000170 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCOMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>000180 - Disclosure - CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureCONCENTRATIONS</Role>
      <ShortName>CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>000190 - Disclosure - ACCOUNTING POLICIES (POLICIES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureACCOUNTINGPOLICIESPOLICIES</Role>
      <ShortName>ACCOUNTING POLICIES (POLICIES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>000200 - Disclosure - INVENTORY (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINVENTORYTABLES</Role>
      <ShortName>INVENTORY (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>000210 - Disclosure - PROPERTY AND EQUIPMENT (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosurePROPERTYANDEQUIPMENTTABLES</Role>
      <ShortName>PROPERTY AND EQUIPMENT (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>000220 - Disclosure - INTANGIBLE ASSETS (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINTANGIBLEASSETSTABLES</Role>
      <ShortName>INTANGIBLE ASSETS (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>000230 - Disclosure - SCHEDULE OF CONSTRUCTION LOAN FACILITY (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSCHEDULEOFCONSTRUCTIONLOANFACILITYTABLES</Role>
      <ShortName>SCHEDULE OF CONSTRUCTION LOAN FACILITY (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>000240 - Disclosure - INCOME TAXES (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureINCOMETAXESTABLES</Role>
      <ShortName>INCOME TAXES (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>000250 - Disclosure - SCHEDULE OF FAIR VALUE MEASUREMENTS (TABLES)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureSCHEDULEOFFAIRVALUEMEASUREMENTSTABLES</Role>
      <ShortName>SCHEDULE OF FAIR VALUE MEASUREMENTS (TABLES)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>000260 - Statement - ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_ORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.chinapharmaholdings.com/20170331/role/idr_DisclosureORGANIZATIONANDSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>000270 - Statement - TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_TRADEACCOUNTSRECEIVABLEANDALLOWANCEFORDOUBTFULACCOUNTSDETAILS</Role>
      <ShortName>TRADE ACCOUNTS RECEIVABLE AND ALLOWANCE FOR DOUBTFUL ACCOUNTS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>000280 - Statement - INVENTORY CONSISTED OF THE FOLLOWING (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_INVENTORYCONSISTEDOFTHEFOLLOWINGDETAILS</Role>
      <ShortName>INVENTORY CONSISTED OF THE FOLLOWING (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>000290 - Statement - PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_PROPERTYANDEQUIPMENTCONSISTEDOFTHEFOLLOWINGDETAILS</Role>
      <ShortName>PROPERTY AND EQUIPMENT CONSISTED OF THE FOLLOWING (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>000300 - Statement - PROPERTY AND EQUIPMENT ASSETS LIFE (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_PROPERTYANDEQUIPMENTASSETSLIFEDETAILS</Role>
      <ShortName>PROPERTY AND EQUIPMENT ASSETS LIFE (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>000310 - Statement - ASSETS DEPRECIATION (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_ASSETSDEPRECIATIONDETAILS</Role>
      <ShortName>ASSETS DEPRECIATION (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>000320 - Statement - INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_INTANGIBLEASSETSCFDAAPPROVEDMEDICALFORMULASDETAILS</Role>
      <ShortName>INTANGIBLE ASSETS CFDA APPROVED MEDICAL FORMULAS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>000330 - Statement - AMORTIZATION EXPENSE (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_AMORTIZATIONEXPENSEDETAILS</Role>
      <ShortName>AMORTIZATION EXPENSE (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>000340 - Statement - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_ADVANCESFORPURCHASESOFINTANGIBLEASSETSDETAILS</Role>
      <ShortName>ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>000350 - Statement - RELATED PARTY TRANSACTIONS OWINGS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_RELATEDPARTYTRANSACTIONSOWINGSDETAILS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS OWINGS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>000360 - Statement - RELATED PARTY TRANSACTIONS MEMBER OF BOD (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_RELATEDPARTYTRANSACTIONSMEMBEROFBODDETAILS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS MEMBER OF BOD (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>000370 - Statement - BANKER'S ACCEPTANCE NOTES PAYABLE (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_BANKERSACCEPTANCENOTESPAYABLEDetails</Role>
      <ShortName>BANKER'S ACCEPTANCE NOTES PAYABLE (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>000380 - Statement - CONSTRUCTION LOAN FACILITY (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_CONSTRUCTIONLOANFACILITYDETAILS</Role>
      <ShortName>CONSTRUCTION LOAN FACILITY (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>000390 - Statement - PRINCIPAL PAYMENTS REQUIRED FOR THE NEXT FIVE YEARS ARE AS FOLLOWS: (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_PRINCIPALPAYMENTSREQUIREDFORTHENEXTFIVEYEARSAREASFOLLOWSDETAILS</Role>
      <ShortName>PRINCIPAL PAYMENTS REQUIRED FOR THE NEXT FIVE YEARS ARE AS FOLLOWS: (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>000400 - Statement - INCOME TAXES UNDISTRIBUTED EARNINGS AND INCOMR TAX RATES (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_INCOMETAXESUNDISTRIBUTEDEARNINGSANDINCOMRTAXRATESDETAILS</Role>
      <ShortName>INCOME TAXES UNDISTRIBUTED EARNINGS AND INCOMR TAX RATES (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>000410 - Statement - INCOME TAXES PROVISION (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_INCOMETAXESPROVISIONDETAILS</Role>
      <ShortName>INCOME TAXES PROVISION (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>000420 - Statement - DEFERRED INCOME TAX ASSETS AND LIABILITY (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_DEFERREDINCOMETAXASSETSANDLIABILITYDETAILS</Role>
      <ShortName>DEFERRED INCOME TAX ASSETS AND LIABILITY (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>000430 - Statement - FAIR VALUE MEASUREMENTS AT REPORTING DATE USING (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_FAIRVALUEMEASUREMENTSATREPORTINGDATEUSINGDETAILS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS AT REPORTING DATE USING (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>000440 - Statement - PREFERRED COMMON STOCK (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_PREFERREDCOMMONSTOCKDETAILS</Role>
      <ShortName>PREFERRED COMMON STOCK (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>000450 - Statement - 2010 STOCK OPTION PLAN (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_STOCKOPTIONPLANDETAILS</Role>
      <ShortName>2010 STOCK OPTION PLAN (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cphi-20170331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>000450 - Statement - CONCENTRATIONS (DETAILS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.chinapharmaholdings.com/20170331/role/idr_CONCENTRATIONSDETAILS</Role>
      <ShortName>CONCENTRATIONS (DETAILS)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cphi-20170331.xml</File>
    <File>cphi-20170331.xsd</File>
    <File>cphi-20170331_cal.xml</File>
    <File>cphi-20170331_def.xml</File>
    <File>cphi-20170331_lab.xml</File>
    <File>cphi-20170331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001010549-17-000167-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001010549-17-000167-xbrl.zip
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M;/'-ETZSTW(BBOI==6]@;N\,MG?_^NO]9WJ(]2W <'>PO;7WO:LS8/\(-"L
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M5E<DAC;8K'*C&V _@L)4=:B2C3 3=QE%*<*)IW%DN@M:T']36*X#H-BEB>?
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MO>YU(VC1C57<*$:,'C)1*&!S]$F0?/1A*1W\(:F"V\T^$F 8G&O&L22YB-1
MB$XL(36IT!R5DK7-%KX>DIE=DV&33<V0^7A<3\B+OG$[-M*F9V3YASST4_^&
MM>$F1[GVUKZ;VH)C"B;H')!9@3$$9^,WG1'7!R2X#%>\ Z!9[@"\KW,,^V0B
MN ;;%9BJ%FUZMZY)@ /5![GF+4)2 Z]X,GU1"! _!4>9KB9  $:L&ZEZF\)X
M!KQU_]!'<LEH 1Q^JF:S5*+<)^O!_$)^I,&C6H:EX%H>A]]-A5)9]1(YNU!V
M%T1=2#/2G/G"S_H0L7Z%ME>K/$JZP#R:"1X[ZW/D7G#0.@,1*OU!8\_Q.B@]
M8G0B5@Z!V,50AB$?9SJ#VQ/.N46Y\UC)<*-@H?D6]D"#J#Q-;C(PS+9N,##H
M.-Z>Z@,B,'S$(E';'@Q2<F2-PK^+N5&#<QGF1B)2/.8++O(\(=^5# B E!+%
M)1 8Y^+8[;/- <#++S#;=%'S+ZB#>U@433CK*=#%7YSFQTV(3HF5;XF[%GGQ
MI&O%)("LI#RMN3Q-ZSC_L,!SYF#2442]1715"X40B+'X@@0')!NS$Y34?,P$
M;0X<*;YHG2E4E05'+7'@0L>&0/WBWU*Y5E&EF$.OA+R8T!A\),2Y;FU+<#)U
M$DH,TSL)>3J]']6RH02L^!@!,]+6F7;K.,^& INU^]02O]:RBQZ"54Y$-,=5
M5X7D0ZZK#,^AS(KS$0@ZV+)=[;7) 3"14.!"40(' 6W]AX3F)5Z>TNYA-4,'
MT0DOP_JK$@Q.2NY/Q)2W8E*6'#^/@=B"LSFXAB:M[9;UL%7K; .V.W4.KYI#
M*)&F.GA?:]*\ %,+4S,Q@9)3I4TB2\B^-LRJ\@QFO<8S!4RAP 4@;DG=X?$8
M -,<]B=2 ;M%:8CS,^&1]4:>([S#\A4E$YXOSRT=WT&<E1A(0J3="2T]E($(
M:#(\71+#\:Q+7XA9"B8#J09<28_SBA2A$%^MUT)TLY'0]87YLS/F(2<TOW#&
MC:"NSU.:YVO!*;FRSAY#EV<60R$6BC3OB%(I\! F)66-S*SB I0_*!1OP"ZN
M"R\]VBC,^SR[V'A/%I0^PGZ )!3$'N5O$&T2_E.<-Z5YS6$1&7AH6FD?QC%;
MHBRKZ#P-Y2W8:@+M%22VD@P6/DWG0SI9Q-54E<9/3#C?C1SALF4IT^B:L@XI
MAD+)R<A$O>!WM A5%4\H<'5)ME,<@SAH&D,@G#!9D<4*&'E2D7%IHL)CH%.E
MK1P^%+2IT_2"LN=@! 2;BD(38BR-18>T\EP?<$W!H,5-I'+<'(&L1[TH8N+;
M(*#O:/#TE&W=A(9(@!E)(<+'*JX#S;7\T5I$+V-^>+-HO2A!XK %2/5X\^#2
M$^K]T5$>I4N"4>B22((,0Q]-,.P[3$0O,%K6!3H!I'7)#@V>_]%-B&6[M8U9
MA)EESG1C)?4APO.^C (7^#0>ZTOM])FX$D583,X/G2!6A4F,I-1Z)!Y,MZV3
M8N*(DIW1XUA,M\&[/U$*WA5YD1L@:BBD4P*AV76Z.M')-W/.IK53!+SB<'8O
M>"O C !?C_B\$"9"@^F68S1,:G!<1:HQC4XU8%,QF?)UEH@NF)CMD_&34K!'
MY]$D[G3S(\XI<\\1K8>8G%EVQBXJPG'9[&"FD,KUG$54H$=BXR-&#^6CDN@5
MZ$M5$:5MZ51K*^&+ I5DG:_NGG&$/**.!-A<*AL(P:-,4G^D#^SLR!#*V,Z8
M._-5D/EEP[\C9!@RYBGZ:(*\''J0#3L:G0<ZP'AK%I'D@F\$T,S:PG.69*+:
MF,L_T^&DQIY(5TKUA>T-Q=LH=?I^L?@&YQXXIU?FH-6>Y#*8$09MC\UJVYE6
MET8SA<\VLXTLKG*ZY]! 5:VDT=H&>]UX!4[>Z!TF9K#0X;(T494Y7/%=+$M7
MK'-;$:@!C]+#9OC@[7R64S44<0)G^D* ,4ZQ.H>2$W-%^ 9Z:%U5"Y%XF=26
M9,YR6X/[ <+."TZ>3GFXBBY0R[A1#$?!A$ 464)>-NMFG7?#JLC1T2K'-TR6
MA$Z ,V$4?5)5RR<;:'[V*0UG0@FR9A%$SE75Y6LD9Y[$N1)+.$RDOI?&<?J\
M2,BUJQ'<# O#7QR2H?@P27C/U2WKPHLB?+'OK4PKY([WJ,D BN8<B(LDW0G9
MCY%[RPM.S2+-M7E:)!^ASBKMU5'&",H%C&#1&]K5,X'6#9-[GU5TU=ZYAJ_O
MY;OU;^:M[)X%F5U-O8PZOP64S 4I89T+FP>S'',A) 4<,+N*M&""8^%SC158
M?Q3_)W->O>'YFU;L\R >1B?R@=P9&('+EH:-N%:=B-!VNCA_S4 ?[ -)" K=
MSO@.6*-6BCE2!/%)&=845N;=D$DKC9^8VXAP?6#($;5><))K+3OWDPZGTA&F
M<ZOIAKF:YP? 1GB,B0[Q1>YD38E+$U:D4)"(@'CG$[!:CC2;@V-<BXWCV[/4
M,'67XG/UDR8MY.*B$!<8]")S%(U*C%$)YJHZ75Y#N,[T?DZ\=,^+I716P8FN
MS=QJY\(X^"ZZB@Q7)H#'ZBOB=1I"+_B-#L@Q32&]#NN1X!',4N#W'$=&Q'2.
MEE0V6XVGF6&=,&,,ECI94(^6-^XBV:()3&XX"[PRK=(+730G$U?!&YBWJ&8E
M#/D^NL+5'%07 $V\:[S3J-Q19:+&$E]&WC5'3.@CL2O>/$G!95.IXJF][@D+
MGX)O0V:3>614+P)OAQIP]()CAA^'HLE/=!ZE,D]TJS*+8E,(@^%8PSULRI?Z
MS- B (/AX'!1\M $5##F#CG^\_-BD.\X%==W$,Z0.!]*YQBFE%HWU XXH:IQ
MN:XN\&26AA%U6[ #T>W< #)^./EX.AN%1/E78%=FK9$6O)?2>9CXD^8TI[TC
MO"&KRJ+BV"KZ<P[[>]II\^%BA+9SK>YCD6?PF0]G[^;,KQ\<;^4XKMK1'VRQ
M<'MW\.F-N1!Q\.ESP)7\]\/F<AET-(J)37'&'LR&276ZY$6=P,<3UE"WH[UP
M)GFYH %0J3@7!%,,Z7&U0S?$/\FOZA!I7<W/9C_9>\R]X#/=!W$W]LT7>$A9
MVI@G*:6I5#;/ H_*=9(7&7TV?8X3Q[192]JF$./4GG2:&)VU/ZTO;Y>#?G]<
MFL-/NI6;LAE@;S^SSL/;=G76AUE.+ZBA?(QU/U+"\[:#9RQXFK#X2P">^EC2
M:FGWEB%B@MRNJ"#/T^3-OL8(1:03YL+%1TWYJ7I43B_!TV@^K*4B,=/%.X?P
M%E V'=)&8TS"M?7B!MOLT?6"HZA JRG)9WP0HR>SY:S"8%25Z%7"2C'=C[-&
MR!O$9<1X.0Z623O9P%QB@K+TENR")6L12LZ"MK:N<F8,J0L)XGUA[()2B++(
M:Q>;3A+1FYEA@N4"I@/MO7'@?/Y=YZ2%KM@[@08JM2AUF %35:]-,,"NULF
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M?;G(6SLT><[I'$J>F'/<_I[WP1]_='2]5_O/1>T/9F7G(;VNPFN4 L0"P$!
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M.\_;3T@:W2#0 T-GBQ0(.(FF>5'*_QB$(*R3J!1,))8R,*F*B ?3KG1VE2P
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M&T!?$DCB'J5JUH+%/A8R9_Y"EL"H31M/.!03-IFB+BD246VA/RN$(M5GT<2
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MW)07;JRNV8V"*O*1>*[;)."\2'5V'"H6'-5U58W+Q-L<B0LN-ZV9(; \H"L
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M.PVA0>*6L%1\10' N>,X<-D4YJ.!L>E1O>2!6;*G[MNI&W'X3O=7=B3J<9;
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M=D+**:@M3&OH\2ZT *LICV,F9!Z;FIWZLC'1JU0/9@;NZC(E,&QB2C2RGXJ
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M5&^.#.6Q>^$RPC .3,@#[47V.N\^5 NNZ\G1JH05YQ8-W4Y,=6R,]O6;0CH
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MU==33NJ,S^VK1J-IIX*URXN+1+:U%GA/?M5,I1W[G\>^#T,4 0M3!8G"K9[
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M<^,H3^#!.'U"<DJT^J)NLUM/__&^N_P!4$L#!!0    ( '.(JTK03QP-/P8
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MR -\UEU9*7)Y$;P6>GH"SM/Q/F_.C@3[RS01\2JVXD,9C=+B^!P>S7P@O>S
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M@YN'1QK%PD.34X/$9O>,'W:RL1R7%62:^,@6%'ZY$ ?DLQ\\^<EMAG#J3 '
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M:K1>:<I9>*9N-.<R+/?%$ WJ((L*S[16B.O7#3;B&;E$UIO4AZY6=6J*ZW"
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MX+'UB*U83#,B1M,A3V[,T$P"7_A!PV]!%L+/?K8]>D5<L7+2T"37KBIAYQ>
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M^89S<J)V59H3U0RF;K8=&PS^F6K4(V0M;V=,.(>1O+NIR6I.9T4@VMO-Y'=
MPWMBC2=T\#+>;GUTNM I*J4YSD+CNMF>K-\CIL$3-0&3%TJ[H.$7BFB..]^L
M;G8BZX.^(' +D&=^W\(@A'*WPR\[$!H$AG:SX]C2G%!E+C@4_)7BJ3K;C7)W
M3H.!14S<1Q#"T%I-*3C!&M&Q)55'XN%+!#5'O0H$'>TQ-O%)> M)]++P0;HX
M2&=+6[;F)QX8I"*:<Z5F=D?[D$V&ZV)#HEJ:WUT_9FN&'S'VGI%_?&"WDNA
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MUYZX<H/;2[+<$C6;+4"$K2%;9(S"+0Z!;ZW8B;,9>H)>>H=$D;8Z50V'TEI
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MEQJJQ.$EK\WSYOC')0:+[(FIXGQ+0\LFLS>-K9>G]Z\H,^1)F#E-(C!(?E6
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MJL)2\Y9&]@OVGP=:T3]_^']02P$"% ,4    " !SB*M*'5(A"M6$  #\508
M$0              @ $     8W!H:2TR,#$W,#,S,2YX;6Q02P$"% ,4
M" !SB*M*/(>P,DH3  #.R   $0              @ $$A0  8W!H:2TR,#$W
M,#,S,2YX<V102P$"% ,4    " !SB*M*0TAU5*T#  ":&   %0
M    @ %]F   8W!H:2TR,#$W,#,S,5]C86PN>&UL4$L! A0#%     @ <XBK
M2M!/' T_!@  #$<  !4              ( !79P  &-P:&DM,C Q-S S,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( '.(JTKRM"J8+4@   $I P 5
M  "  <^B  !C<&AI+3(P,3<P,S,Q7VQA8BYX;6Q02P$"% ,4    " !SB*M*
M,W_J-2@B   ']P$ %0              @ $OZP  8W!H:2TR,#$W,#,S,5]P
<<F4N>&UL4$L%!@     &  8 B@$  (H- 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
